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PVL: Panton Valentine Leukocidin 
SCC: Staphylococcal cassette chromosome 
ST: Sequence Type 
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TSST: Toxic Shock Syndrome Toxin 
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1 Staphylococcus aureus: The microorganism. 
Staphylococcus aureus belongs to, Phylum 2 of Bacteria, class Bacilli, of the order 
Bacillales, family Staphylococcaceae, genus Staphylococcus. The genus includes 46 
species, some of which are opportunistic pathogens for humans and animals 
(http://www.bacterio.cict.fr/s/staphylococcus.html). 
The term Staphylococcus comes from the Greek staphyle = a bunch of grapes and 
kokkus = grains, the name was originally given by Ogston around 1883 although both 
Koch and Pasteur had also observed.1 This are gram-positive cocci, non-spore former, 
low G+C content,2 of 0.5-1.5μm in diameter, and a feature presentation in irregular 
clusters similar to grapes because of their ability to divide in three planes (Figure 1a-b).  
The type specie, Staphylococcus aureus or "golden staphylococci" (Figure 1c), to produce 
carotenoids during growth, and have all the typical features of the genre. It is aerobes or 
facultative anaerobes, stationary, mesophilic and amino acids and vitamins are needed to 
grow. It is able to ferment glucose and mannitol with acid production, and tolerates 
highly variable environmental conditions. Thus, it can grow in any temperature between 
6-46ºC (optimum 30-37ºC), pH between the values of 4.0-9.8 (optimum setting to 
neutrality). It is also tolerant to salt concentrations resisting up to 20% NaCl, and this is a 
property used to create selective culture conditions for its isolation and propagation.3 
This characteristic allows it to grow in foods with very low water activity. It is also quite 
resistant to drying, freezing and heat, but not as much as the endospores of spore-
forming bacteria. 
 
 
 
S. aureus is the most virulent and pathogenic specie for human, due to its potential to 
cause a wide spectrum of infections and to be implicated in major outbreaks or hospital 
Figure 1. S. aureus morphology. (a) Gram stain of gram-positive coco grouped in clusters. (b) 
Scanning micrograph of S. aureus. (c) Growth in blood-agar-plate of S. aureus´s golden colonies. 
                            (a)                                            (b)                                            (c) 
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and community epidemics. However it can be also found colonizing the skin and mucous 
membranes.2 
1.1 Habitat and epidemiology. 
Staphylococcus is ubiquitous colonizers of the skin and mucosa of all animals including 
mammals and birds. Some species have their preferential ecological niche as indicated by 
their names, i.e., S. epidermidis and S. capitis are constantly colonizing the skin, and hair 
& scarp, respectively.2 
S. aureus is widespread among primates, but not restricted to them. In humans, the 
primary reservoir of S. aureus is the anterior nostrils, mainly in adults, though it can be 
isolated from multiple locations. Approximately 20% of healthy people are chronic nasal 
carriers of S. aureus, 30% intermittent carriers and 50% non-carriers. Colonization by S. 
aureus is more common in hospitals, especially in immunodeficient patients (undergoing 
dialysis, insulin-dependent diabetics, HIV seropositive), or intravenous drug users and 
patients with skin lesions.4  
Methicillin-resistant S. aureus (MRSA) colonization has been increasing during the last 
decade. Factors associated with MRSA carriage include, prolonged hospitalization, prior 
use of antibiotics, surgery, intensive care units (ICUs) stay, living-in a nurse-home and 
close coexistence with a carrier of MRSA or infected patient.5 Obviously, MRSA nasal 
carriers have an increased risk of infection with this microorganism, and have a higher 
morbidity and mortality compared with patients infected with methicillin sensible 
(MSSA).6 Hence, to determine the clonality of MRSA in these patients, it is important to 
differentiate sporadic cases of MRSA and epidemic situation by a single clone. In addition, 
though community acquire- (CA-)MRSA has increased, the prevalence rate of MRSA 
among people without risk factors is relatively low, and most colonization and infection 
by MRSA, still develops in hospitals and/or health-care associated settings and in close 
contact with carriers.2  
1.2 Microbiological diagnosis: Culture and Identification. 
S. aureus grows well on non-selective culture media such as trypticase-soy agar 
supplemented with 5-10% sheep-blood (blood-agar-plate) or poor liquid medium such 
as trypticase-soy broth. In cultures from clinical samples, which may have gram-negative 
bacteria, it is advisable to use a selective medium to isolate S. aureus. For diagnosis from 
normally sterile samples, besides solid-agar medium, enrichment and thioglycolate 
broths should be used.7 
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The selective media used in most clinical laboratories to isolate S. aureus is the mannitol-
salt agar medium (Chapman medium), which allows a presumptive identification based 
on the acquirement of a characteristic yellow coloration for colonies, due to mannitol 
fermentation with acid production, as a result the medium turns from pale pink to yellow 
(Figure 1.2.A).  
In recent years, it has been developed culture media incorporating a chromogenic 
substrate and so allowing direct identification of S. aureus, even MRSA. In the presence of 
specific enzymes and substrates, these chromogens are modified to colored colonies 
(Figure 1.2.B). Although the cost of these resources is high, they let you generate the 
isolation and identification of S. aureus and MRSA directly.8-10  
The identification of S. aureus can be performed by a few conventional biochemical tests. 
The workflow, from my point of view, could be, catalase detection to differentiate the 
genus Staphylococcus (catalase-positive) from the general Streptococcus and 
Enterococcus (catalase-negative), fermentation of glucose to differentiate among the 
genus Micrococcus (non-ferment anaerobically) and Staphylococcus (yes-ferment),7 and 
coagulase, which remains the most commonly test used for identification of S. aureus. 
The coagulase test differentiates S. aureus (coagulase-positive) from the rest of 
staphylococci (coagulase-negative, CoNS) and it is based on the ability of S. aureus to 
produce the extracellular enzyme, which coagulates the plasma.  
 
                         (a)                                       (b) 
  
In addition, small colony morphology variants (SCVs) of S. aureus have been described 
growing on blood-agar-plate as colonies approx. 1/10 of the usual size morphotype. 
These colonies are not pigmented and non-haemolytic, and require at least 48 hours of 
incubation to develop. They are mutants in the respiratory chain with low membrane 
potential, auxotrophic for haemin, use fewer carbohydrates and are resistant to 
aminoglycosides. In culture medium, these SCVs may occur alone or together with the 
Figure 2.1. Culture and 
identification. (a) S. aureus 
on mannitol-salt agar 
medium. (b) MRSA on 
selective-differential 
medium. 
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usual morphotype, giving the impression of a mixed culture. After subculturing, they may 
be stable or revert to the wild-morphotype, especially if the medium are supplemented 
with haemin or thymidine and incubated in a CO2 atmosphere.11,12 SCVs were recovered 
from the sputa of up to 20% of patients with cystic fibrosis carrying S. aureus or 
osteomyelitis infections, and were associated with prior treatment with trimethoprim-
sulfamethoxazole13 and aminoglycosides.  
Clinical laboratories generally have commercial phenotypic identification systems. These 
manual or automatic systems use various dried substrates which allow the identification 
of different staphylococci spp. with a reliability ranging from 70 to over 90% depending 
on the system.14 Currently some clinical laboratories have mass spectrometry technology, 
such as MALDI-TOF (Matrix Assisted Laser Desorption / Ionization- Time of Flight), 
allowing identification scores > 2. 
1.3 Molecular diagnosis. 
Although laborious and very costly, molecular diagnosis plays an increasing role in rapid 
detection of microbial pathogens and identification of drug-resistance determinants so 
that results can be obtained within a few hours. Identification techniques based on 
molecular probing15 fluorescent detection of 16S rRNA with a peptide nucleic acid 
probe (peptide nucleic acid fluorescence in situ hybridization, PNA-FISH). It identifies S. 
aureus in positive blood cultures in less than 3 hours with > 95% sensitivity and 
specificity.16 The method allowed rapid discrimination between S. aureus and potential 
contaminant coagulase-negative, thus improving therapeutic decision-making.17 Another 
technique developed to quantify organisms directly in clinical sample has been multiplex 
real-time PCR, which amplified simultaneously genes of species and resistance 
mechanism.18,19 A wealth of molecular techniques is being developed and proposed for 
routine use. Further high-throughput techniques, including RNomics and proteomics, 
might provide a comprehensive picture of the “good- coagulase-negative” and the “bad-
aureus” staphylococci and help to decide which of them must be considered for 
therapeutic intervention.  
1.3.1 Molecular Typing. 
Molecular typing systems are one of the great microbiological diffusion contributions in 
recent years. These systems consist of a variety of techniques, which are intended to 
compare the composition of the nucleic acids of two or more microorganisms, thereby 
can be recognized the relationship between epidemiologically linked isolates, and 
therefore a recent derived from a common precursor microorganism. In addition, 
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techniques must be able to differentiate unrelated isolates, irrespective of their 
belonging to the same microbial species or taxon.20,21 
The application of these techniques is essential in the study of nosocomial infections, 
especially in hospitals where there are available ICUs, neonatal units, burn units, 
hematology or oncology, wherever inpatients are more capable of acquiring nosocomial 
severe infections, particularly MRSA (59% for ICUs patients, 55% in non-ICU patients, 
and 48% in outpatients),22 which usually appears to be highly clonal.  
The main typing methods underlying this comprehension are briefly presented 
subsequently.  
1.3.1.1 Pulsed Field Gel Electrophoresis (PFGE). 
Pulsed field gel electrophoresis (PFGE) is a highly discriminative molecular typing 
technique that is used in epidemiological studies worldwide. Actually it is the most 
widely used method and is extremely useful for following given clones, although it does 
not provide accurate information on the genealogy of the organism.  
PFGE is a restriction-fragment length technique to separate large chromosomal 
fragments generated by digestion with the low-frequency cutting enzyme Sma1 for S. 
aureus. The generated fragments are separated, yielding banding patterns specific for 
particular clones. Banding comparison has allowed identification of the major epidemic 
clones, which represented 70% of more than 3000 MRSA isolates recovered 
worldwide.22 However, the length of chromosomal fragments, and thus the clone-
specific banding, may be modified with acquisition or loss of mobile DNA (MGEs) such 
as transposons, prophages, or pathogenicity islands. The new banding pattern may 
identify a different clone, which is in fact the same bacterium that has gained or lost 
MGEs. If the new organism has acquired properties important for successful spread, it 
may indeed behave as a new clone with its proper behaviour. Nevertheless, the 
phylogenetic relation between the new clone and the parent persists. 
1.3.1.2  Secuenciación: “Multilocus Sequence Typing” (MLST). 
Multilocus sequence typing (MLST) is a technique designed to track clones and/or clonal 
lines and is a good molecular marker of long-term epidemiology. However, its 
discriminatory power is lower than other techniques such as PFGE, and it is a 
demanding technique in terms of methodology and expensive. MLST is a sequence-
based method that allows the unambiguous assignment of the ancestral phylogeny of 
the staphylococcal population.39 The technique consists of sequencing a total of seven 
housekeeping genes: 
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 arcC: carbamate kinase. 
 aroE: shikimato dehydrogenase. 
 gmk: guanylate kinase. 
 pta: phosphate acetyltransferase 
 tpi: triosephosphate isomerase 
 yqiY: acetyl coenzyme A acetyltransferase. 
 glpF: glycerol kinase. 
and submitting the sequences to a central database (www.mls.net) where they are 
checked and matched. The classification is based on allelic profile diversity based on 
approximately 300-700-bp internal gene fragments. Thousands of sequences have 
been submitted, generating numerous sequence types (STs). Organisms that share all 
seven alleles are defined as clones, those that share five of seven identical alleles are 
defined as clonal complexes (CC), and those that share less than seven alleles are 
defined as unrelated.  
Since the implementation of this technique in S. aureus, over 2000 year, it has been 
found that MRSA strains have a clonal structure highly well conserved compared with 
MSSA, and that a small number of clones are able to spread.23,24 Also the data obtained 
by MLST, indicate that S. aureus has a low level of genetic recombination and clonal 
diversity is more frequently caused by point mutations than genetic exchange 
processes.  
1.3.1.3  “Spa typing” y “double locus spa-clfb typing”. 
Spa typing and double-locus spa-clfb typing, are sequencing-methods, based on PCR 
amplification of strain-specific regions of hypervariable segments of the spa (protein A) 
or clfB (clumping factor B) genes, respectively.25 The variable regions are made of 24 
nucleotides repeats in spa  (http://spa.ridom.de/) and serine-aspartate repeats in clfB, 
the length of which may vary from duplication or accidental loss of DNA material. 
Although less discriminative, these simpler methods generate unambiguous data sets 
that can be compared in multicenter studies. 
Typing has become an important part of the comprehension of the S. 
aureus epidemiology. However, no specific types can be attributed to disease producing 
versus colonizing strains, as yet.25 
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2 Staphylococcus aureus: Pathogenesis. 
S. aureus can cause a wide range of infections, from superficial skin infections to deep-
seated infections, from which it spread through the blood stream. The wide range of 
infections caused, is due to expression of several proteins, which may be surface-
associated or secreted. Many of these proteins are involved in colonization of host 
tissues, lysis of host cell membranes, promotion of bacterial spread within host tissues 
and survival in phagocytes. These accessory proteins are expressed coordinately during 
growth, and are controlled by several regulatory systems, such as two component 
regulatory systems (two-CS) (e.g., agr, arlRS, saeRS, srrAB, vraRS) and transcriptional 
regulatory systems (e.g., sarA family, sigB).26 
Currently, thirty-five complete S. aureus genomes are available in public databases. The 
S. aureus genome is circular and contains approximately 2.8 million bp that represents 
approximately 2700 coding sequences (2600 proteins),27 plus structural and regulatory 
RNAs. These belong either to, a core genome containing mostly housekeeping genes, 
which is quite conserved along various staphylococcal species and accounts for about 
80% of the whole DNA, or an accessory genome that carries mobile genetic elements 
(MGEs) that contains most S. aureus pathogenic and drug-resistance features, which may 
vary between different species and strains. Genome evolution is driven by random point 
mutations that lead to single nucleotide polymorphism (SNP), larger variations in core 
genes (e.g., deletions or duplication of repeat regions) that may differ between lineages, 
and MGEs that include insertion sequences (IS), transposons (Tn), viruses, and 
pathogenicity and genomic islands.2 
2.1 Pathogeneses: Regulation.  
At least three families of regulatory elements intertwine to adjust gene expression to 
specific environmental conditions: (1) two-component regulatory systems (two-CS); (2) 
DNA-binding proteins or transcriptional regulatory system, largely represented by the Sar 
family of proteins; and (3) small regulatory RNAs. 
2.1.1 Two-Component Regulatory System. 
Bacterial two-component systems (two-CS) are signaling pathways, which permit the 
creation of a communication bridge to the external environment, allowing the cell to 
translate an external stimulus into an intracellular change in gene expression. The 
defining components are a membrane-associated sensor histidine kinase and a 
cytoplasmic response regulator. After activation from an external signal, the histidine 
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kinase typically dimerizes and trans-autophosphorylates.28 This leads to 
phosphorylation of the response regulator, characteristically at a conserved aspartic 
acid residue, and this phosphorylation induces a conformational change allowing it to 
bind DNA at a specific consensus sequence in a manner that alters the transcription of 
the target gene.  
S. aureus has at least 16 two-component systems (two-CS).29 In addition to their role in 
pathogenesis, at least three of these systems have been shown to modulate resistance 
to antibacterial agents,30 thus further emphasizing their important role in pathogenesis 
of S. aureus infection. 
2.1.1.1 The Quorum Sensing and Agr Two Component Regulatory System. 
Quorum Sensing (‘QS’) is a system of stimulus and response, defined as the capacity to 
detect extracellular, small molecule signals and to alter gene expression in response to 
bacterial population densities.  Bacteria use ‘QS’ signals to coordinate their behavior via 
gene expression within their own kind. These sensing signals are used to either inhibit 
or activate transcriptional programs among competing bacterial strains and other 
species existing within the same microenvironment.31,32 These responses to 
environmental changes include adaptation to availability of nutrients and defence 
against other bacterias. ‘QS’ systems control biofilm formation,33-35 growth potential, 
sporulation, antibiotic resistance, DNA transfer, autolysis, oxidative stress tolerance, 
metabolic activity, motility, antibiotic synthesis by antibiotic-producing bacteria, sessile 
versus planktonic behavior, and most importantly, genetic determinants of virulence.45  
S. aureus has at least two ‘QS’ systems together with a large number of other sensing 
systems and transcriptional and post-transcriptional control mechanisms. In S. aureus 
the dominant ‘QS’ regulator is the cyclic peptide Agr (accessory gene regulator) system. 
This major human pathogen, and other staphylococcal species, could in the same way 
as other bacterias (i.e. Escherichia coli), use LuxS signals to regulate virulence and to 
initiate detachment from biofilms by expression of phenol-soluble modulins (PSMs) 
peptides.34  
The accessory gene regulator (agr) operon constitutes a global regulatory system that 
controls cell density-dependent virulence factor expression. Several studies have 
demonstrated that Agr activity is essential for skin and soft tissue infections, and there 
is considerable interest in developing inhibitors of this system as novel antivirulence 
drugs for therapeutic use.36,37  
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The agr operon consists of two divergent promoters, P2 and P3, where expression from 
P2 produces the components of a ‘quorum sensing’ system (AgrB, D, C, A) (Figure 
2.1.1), and expression from P3 produces the agr effector molecule RNAIII (Figure 2.1). 
The transmembrane P2 product AgrB is required for the processing of the propeptide 
AgrD to produce the quorum signal molecule, autoinducing peptides (AIP) types I–IV, 
each one functions as a specific ligand for the corresponding sensor kinase AgrC, but as 
an inhibitor of other AgrC variants. AgrC possesses an extracellular N-terminal domain 
and seven transmembrane domains (Figure 2.1.1).  
Figure 2.1.1 The Agr quorum-sensing accessory gene regulator system. Binding of AIP 
(heterologous autoinducing peptide) induces a conformational change within the cytoplasmic helix 
that links the sensor and kinase domains of specific AgrC, enabling autophosphorylation. However, 
binding of another AIP that expresses one of the three other different allelic variants of this agr, 
causes the helical linker to twist in the opposite direction, preventing autokinase activity. This 
specific binding AIP-AgrC is the target for the anti-’QS’ molecule solonamide B, which prevents AgrC 
activation in all allelic variants of agr, inhibiting ‘QS’ and subsequent virulence gene expression via 
agr activation. Activated AgrA dimmers bind to the agr intergenic region (agr-ir) between P2 and P3 
and up-regulate expression from these promoters. This interaction is the target of a recently 
identified small molecule, savirin (S. aureus virulence inhibitor), which inhibits agr-associated 
virulence gene expression by preventing AgrA binding to the agr-ir.  
Reprint from [38] with permission from Elsevier Limited. Copyright © 2014 Copyright Clearance 
Center, Inc. All rights reserved.  
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Numerous global regulators enable specific bacterial responses to specific 
environmental stimuli or collaborations, regulated by agr-operon. For example, the 
global regulator CodY [see below], a stronger repressor, prevents, indirectly, the 
inappropriate agr expression at low cell densities during exponential phase when 
conditions are nutrient replete.36,39 Or, the sarA family in the early phase of microbial 
invasion. Thus, when the population density is low, the agr expression is lower too, so 
that most virulence genes are turned off in favor of surface adherence structures and 
the immunoglobulin inhibitory molecule protein A. Once infection begins, the ‘quorum 
sensing’ is activated towards sequential gene activation rapidly with, exotoxin, protease 
and haemolysin production.33 Simultaneously, adhesin molecule expression is turned 
off, thereby facilitating dissemination to other regions in the host. In vivo, detection of 
agr expression, indicates this biphasic activation of the system, which occurs with early 
activation, secondary reduction, and then later reactivation of this ‘quorum sensing’ 
system during infection.40  
The loss of Agr activity creates phenotypes compatible with persistent infection and 
enhances staphylococcal survival in endothelial cells, as occurs during infective 
endocarditis.38 agr-defective strains are associated with a high mortality level in 
bacteremic infections. agr-negative strains have a fitness advantage over agr-positive 
strains in the presence of sublethal concentrations of some antibiotics, because the 
fitness defect of agr-positive cells is caused by antibiotic-mediated expression of the 
agr effector molecule RNAIII.41 
2.1.1.2 Staphylococcus exoprotein expression, SaeR/S-Two-Component System. 
The Staphylococcus exoprotein expression saeRS, is transcribed as a 4-gene operon 
(saePQRS), being SaeS and SaeR the sensor and response regulator respectively. The role 
for SaeP and SaeQ has not yet been determined, although they might be involved in 
stabilization of SaeS forming a protein complex together with the sensor kinase SaeS 
and activate the sensor kinase's phosphatase activity.42 Once phosphorylated, SaeR 
binds to a specific target sequence to activate transcription of saePQRS itself.43  
Several studies have demonstrated that sae also modulates the production of virulence 
factors, other than toxins, including surface proteins and capsule biosynthesis 
components.43 Actually, the loss or deletion of SaeR/S resulted in a decreased amount 
of more than 17 extracellular proteins and two cell surface-associated proteins, among 
them α-haemolysin (Hla), β-haemolysin (Hlb), ϒ-haemolysin subunit C (HlgC), 
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leukocidin F (LukF) and leukocidin M (LukM). These proteins are important virulence 
factors. 
"SaeR/S-mediated transcription is unique to and dependent on specific host stimuli. 
SaeR/S is strongly involved in a tight temporal control of virulence factor expression. 
SaeR/S is the major regulator of virulence factors in S. aureus."44 
Agr and SaeR/S each contribute independently to the remarkable virulence of USA300, 
likely by means of their effects on expression of secreted toxins.45 
2.1.1.3 Other Two Component Regulatory Systems. 
The staphylococcal respiratory response regulator srrAB, responds to oxygen stress by 
suppressing expression of agr and the genes encoding certain exotoxins.46 The activity 
of SrrA/B, and the production of multiple types of virulence factors linked to oxygen 
availability, provide an important example of the link between central metabolic 
processes and virulence in S. aureus. SrrA/B also positively regulates expression of the 
icaADBC operon and production of polysaccharides of cell wall, apparently by repressing 
transcription of the icaR-encoded repressor.47 One note, the repression of transcription 
of spa ergo the production of protein A, suggests that the impact of srrAB is not 
mediated directly via its regulation of agr. 
The haeme response regulator hssRS, is an iron-responsive-system, highly conserved 
among Gram-positive pathogens suggesting a conserved mechanism of iron acquisition 
among these organisms. Actually, S. aureus can acquire iron in the form of haeme, 
likely accessed via lysis of erythrocytes, using highly efficient transport systems that can 
move haeme into the bacterial cytoplasm. In addition, iron is an essential nutrient for 
many bacterial species during infection,48 though, a high level of haeme is toxic to the 
bacterial cell. To avoid this toxicity, S. aureus senses haeme by HssS resulting in HssR 
phosphorylation and binding to the promoter of hrtAB. HrtAB encodes an iron efflux 
pump that maintains intracellular haeme homeostasis,49 and whose mutant is more 
virulent than the wild-type,48 likely due to the stress response induced by increasing 
intracellular haeme. 
The arlRS, is a novel regulator of clumping and pathogenesis, which could be a key 
regulatory element that defines the “balance” between agr and sarA. Since, inactivation 
of arlRS results in increased autolysis and an enhanced capacity to form a biofilm.50 
Several studies have related this ArlR/S two-CS, with a production of additional 
virulence factors including, the exfoliative toxin and capsular polysaccharides, indirect 
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effect via positive regulation of MgrA,51 or with the control of agglutination by 
negatively regulating the expression of the Giant Staphylococcal Surface Protein.52 Thus, 
the ArlR/S system is essential for pathogenesis, at least in a rabbit model of sepsis and 
infective endocarditis.53 Like arlRS, the lytSR two-CS is a negative regulator of S. aureus 
autolysis and biofilm formation, in fact arlRS is an activator of lytSR transcription.54 
LytS/R two-CS has led to the identification of the two operons involved in affect 
stationary-phase survival, murein hydrolase activity, biofilm formation and antibiotic 
tolerance.54 On the other hand, recent studies have demonstrated that LytS could act 
like a staphylococcal “voltmeter sensor". Hence, the LytS/R two-CS plays an important 
role in an adaptive response, and could be directly involved in the control of 
programmed cell death and lysis.55 
Other less well-characterized sensor protein kinase-systems are, KdpDE system, which 
is up-regulated by the Agr/RNAIII system, and linked to the autoinducer peptide (AI)-
2/LuxS ‘quorum sensing’-system with capsule production,56 could be an important 
virulence regulator coordinating the external K+ sensing and Agr signalling, during 
pathogenesis.57 VraS/R, which are involved in the stress response to cell-wall inhibitors 
such as β-lactams and vancomycin.58 GraS/R (ApsS/R), which aid in resistance to 
oxidative and heat stress, probably due to their role in the modification of wall teichoic 
acids, and also vancomycin resistance by expression of vraFG ABC transporter.59 BceAB 
system, associated with altered susceptibility to bacitracin (Figure 2.1.1.3), and NsaR/S, 
involved in biofilm formation, as well as cell envelope stability in response to cell wall 
and membrane disruption.60 Another additional two-CS that stands out from the others, 
because it is the only one that is essential in S. aureus, is WalK/R (YycGF). WalK/R has 
been shown to be involved in peptidoglycan crosslinking and biofilm formation, and 
plays an important role in virulence and eliciting the host inflammatory response by 
controlling autolytic activity. Transcriptome analysis of the WalK/R regulon revealed 
positive regulation of major virulence genes involved in host matrix interactions (efb, 
emp, fnbA, and fnbB), cytolysis (hlgACB, hla, and hlb), and innate immune defence 
evasion (scn, chp, and sbi), via activation of the SaeS/R two-CS.61 
2.1.2 The DNA-binding proteins or Transcriptional regulatory system. 
DNA-binding transcription factors, play an important regulatory role by either 
repressing or activating genes, in response to environmental and physiological 
conditions. Generally, they simultaneously bind DNA and RNA polymerase, as well as 
other agents necessary for the transcription, and can be regulated through reversible 
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structural alterations such as, phosphorylation or inactivated through such mechanisms 
as proteolysis. 
2.1.2.1 Staphylococcal regulator Sar Family. 
The staphylococcal regulator specific Sar family proteins, are involved in the expression 
of numerous target genes involving oxidative stresses, biofilm formation, antibiotic 
resistance, virulence, autolysis and metabolic processes. Ten Sar-family proteins, SarA, 
SarR, SarS, SarT, SarU, SarV, SarX, SarZ, Rot, and MgrA, have been partially characterized 
in S. aureus, being sarA gene well-studied, although the exact mechanism of target 
gene regulation remains largely unknown. The Sar family proteins are homologous to 
each other, as well as homologous to the MarR family transcriptional regulators in 
Gram-negative bacteria. The Sar protein family members are able to regulate numerous 
target genes, either by binding directly to promoter regions or indirectly via other 
regulatory systems.62 (Figure 2.1.2.1). The most important is SarA. 
Figure 2.1.1.3. Resistance mechanism mediated by two-component systems. 
 
Reprint from [30] with permission from Taylor & Francis Group, LLC. Copyright © 2011 Landes 
Bioscience. All rights reserved. 
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Figure 2.1.2.1. Regulatory network of agr and sar family of DNA-binding proteins. Intertwining of 
activation (green arrows) and repression (red arrows) underlines complexity of system. gene 
expression is further modulated by additional factors (sigB, arls, sae and srrAB), which can act on agr 
promoters or directly on specific genes. Gene promoters are denominated P1, P2, and P3 and 
represented by dark blue arrows. Figure adapted from Mandell [2]. 
 
The sarA locus, is complex and includes three promoters, which drive the production of 
three transcripts (sarB, sarC and sarA). The sarA locus is known to up-regulate the 
synthesis of fibronectin and fibrinogen binding proteins, haemolysins, enterotoxins, 
TSST-1 (toxic shock syndrome toxin) and capsule biosynthesis genes, and to down-
regulate proteases, protein A and a collagen binding protein. SarA has been also shown 
to bind to several regulatory and target gene promoter regions (e.g., Agr, SarS, Rot, 
SarV, SarT, Hla, Fnb, Spa, Cna, Bap, IcaRA) to modulate gene transcription, thus 
implicating both agr-dependent and agr-independent pathways, as well as direct and 
indirect mode for SarA-mediated regulation.62 Interestingly, the inactivation of sarA has 
been consistently shown to result in a reduced capacity to form a biofilm, the opposite 
to that of agr,63 suggesting that the role of sarA in biofilm formation is independent to 
its regulation of agr. On the other hand, the impact of SarA on exotoxin production has 
been shown to be heavily influenced by SaeR/S, with an impact on α-haemolysin and 
PSMs.64 In addition, in the same way as agr, inactivation of sarA has been shown to 
Introduction: Staphylococcus aureus: Pathogenesis 
 
19 
attenuate virulence in multiple animal models of S. aureus infection, including septic 
arthritis, osteomyelitis, and endocarditis.65 This, together with the impact of SarA on 
expression of agr, provides direct indications of the interactive role of SarA in S. aureus 
regulatory circuits.  
SarR down-regulates the expression of SarA, and its maximum expression is in the 
exponential phase of growth. Inactivation of sarR has positive effects on the 
transcription of the agr locus and also on the maximal transcription of aureolysin and 
serine protease in S. aureus.62 SarS, repressed by Agr and SarA, and activated by SigB 
(σB), is an activator of protein A and a repressor of α-haemolysin.66 SarT, repressed by 
Agr, also represses hla (via sae),67 and induces expression of protein A (indirectly via 
sarS). SarU, repressed by SarT, whose inactivation results in a reduction of both RNAII 
and RNAIII expression, suggests a positive effect of SarU on agr, and a key role during 
biofilm-associated infections by modulating agr. SarV is involved in regulation of 
autolysis, which may be part of the common pathway through which SarA and MgrA 
control autolysis.68 SarX also acts as a repressor of the agr locus and can therefore 
regulate other genes via Agr. Its maximal expression is during the stationary phase of 
growth,69 and could be involved in a regulatory cascade that promotes polysaccharide-
intercellular-adhesion (PIA)-dependent biofilm formation in S. aureus.70 SarZ positively 
regulates the expression of agr and mgrA but negatively of sarA. Its expression is 
growth phase dependent, with maximum expression during early exponential phase, 
and affects surface proteins, toxins and biofilm by modulating the aforementioned 
global regulators, as well as direct activation on SspA protease.71 
2.1.2.2 Others Transcriptional Regulatory Systems. 
Sigma factors (Sig, σ), are other major mechanism of response to environmental stimuli. 
There are currently four identified sigma factors (Sig) in S. aureus: SigA, responsible for 
transcription of housekeeping genes; SigB (σB), responsible for the transcription of 
stress-response genes; SigS, controls expression of genes required for overall fitness 
and survival; and SigH, involved in competence and more recently, prophage integration 
and excision.72  
The alternative SigB σB operon contains: σB, anti-σB factor RsbW, anti-anti-σB factor 
RsbV, and RsbU, a Mn2+-dependent phosphatase that positively controls σB activity by 
dephosphorylating RsbV (Figure 2.1.3.2). This alternative transcriptional factor SigB σB 
is an essential part of the complex regulatory network controlling the expression of 
over 200 genes involved in virulence, cell wall metabolism, membrane transport 
processes, and microbial response to a variety of stress (temperature, energy 
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depletion,..) and chemical stimuli.2 It has been also demonstrated to aid in heat 
tolerance and resistance to cell wall active antibiotics,73 and contribute to pathogenesis 
in animal models of infections. More recently, it has been shown that inactivation of 
SigB has an indirect impact on the agr ‘quorum sensing’ system by enhancing RNAIII 
expression,74 as well as to regulate several extracellular virulence factors and capsule 
via SpoVG. Hence, it is demonstrating the role in virulence as a response to stress.75  
 
MgrA, member of the multiple antibiotic resistance regulator MarR and SarA family 
proteins, which positively regulates sarX gene expression, plays a key role in regulating 
the expression of major virulence factors in S. aureus, including capsule and sortase. 
Several studies have provided evidence that MgrA regulates hla and spa expression by 
agr-dependent and independent pathways, and plays an important role in 
S. aureus sepsis, even increasing mortality and accelerating the onset and development 
of sepsis.76 In addition, MgrA has been found to repress biofilm formation, in part, by 
agr-dependent pathway and DNA release, probably by affecting LytS/R and the 
antiholin-like protein LrgAB.77 
Figure 2.1.3.2 Post-transcriptional 
regulation of SigB. After stress-
induction, RsbU de-phosphorylates 
RsbV, which can then bind specifically 
to RsbW thereby removing RsbW from 
SigB. Phosphorylated RsbV is inactive 
and therefore cannot bind RsbW. RsbW 
also promotes phosphorylation of RsbV 
to maintain its inactivity. RsbW binds to 
SigB to inhibit transcription by 
preventing SigB from complexing with 
the RNA polymerase (RNAP). Once SigB 
is free from inhibition by RsbW, it can 
complex with RNAP forming the holo-
enzyme and activate transcription of 
target genes. Active proteins are 
highlighted with yellow. 
Figure adapted from [ Junecko ME et al., 
2012, World J Clin Infect Dis]. 
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lence
[157]
. Thus, CodY is able to regulate virulence via di-
rect binding of virulence gene promoters and viainhibi-
tion of metabolic regulatory pathways providing another 
regulatory link between metabolism and virulence
[70,156]
. 
CodY is repressed by the i tracellular chaperon  
ClpC[40], possibly via ClpC-induced proteolytic degrada-
tion in association with ClpP. Although CodY acts as a 
repressor of virulence genes, it can also be negatively 
regulated under various environmental conditions, elimi-
nating the repressive effect of CodY on virulence genes.
Sigma factors
Sigma factors are highly conserved among bacterial 
species. They provide promoter specificity to the RNA 
polymerase, and are highly regulated by anti-sigma fac-
tors via direct binding of the protein
[158]
. There are cur-
rently four identified Sigma factors in S. aureus: SigA, 
which is responsible for transcription of housekeeping 
genes; SigB, which is responsible for the transcription of 
stress-response genes; SigS, which controls expression 
of genes required for overall fitness and survival
[2]
; and 
SigH, which has a demonstrated involvement in compe-
tence and more recently, prophage integration and exci-
sion
[159,160]
.
The most thoroughly studied of these is SigB, which 
is transcribed from the four-gene operon rsbUVWsigB 
that encodes an anti-sigma factor (RsbW), anti-anti-sigma 
factor (RsbV) and RsbU, an anti-RsbV phosphatase
[95,161]
.
The regulation of SigB is very tightly controlled by 
RsbW, RsbV and RsbU (Figure 2). SigB controls expres-
sion of an array of genes responsible for the survival 
of hydrogen peroxide-induced stress and desiccation as 
well as production of the carotenoid staphyloxanthin and 
extracellular proteases
[161-164]
. SigB has also been demon-
strated to aid in heat tolerance and resistance to cell-wall 
active antibiotics
[165,166]
. The repressive effect of SigB on 
V8 proteases positively regulates biofilm formation[162] 
because the presence of extracellular proteases has 
been correlated with the inability to form a biofilm[164]. 
SigB regulates its target genes either by recognizing a 
conserved sequence or by downstream regulators. For 
example, SigB effect on sarA or agr expression has been 
reported
[95,167]
. More recently, SigB has been shown to 
regulate several extracellular virulence factors and capsule 
through SpoVG
[168,169]
, demonstrating a role for SigB in 
virulence as a response to stress.
CONCLUSION
In this review, we describe several regulators involved in 
virulence regulation. These represent only a fraction of 
all regulators encoded in the S. aureus genome. S. aureus 
is a pathogen that can cause a wide range of diseases and 
can infect almost every tissue. It is thus not surprising 
that a large number of regulators are needed to modulate 
the production of various virulence factors in different 
environmental conditions in the host. What is surpris-
ing is the high degree of complexity of the interactions 
among the regulators. Compounding the complexity is 
the finding that virulence genes in different strains of-
ten are regulated differently. The molecular mechanisms 
underlying some of the strain differences have been 
illustrated but most have not. Nonetheless, significant 
progress has been made toward understanding virulence 
gene regulation. However, most of the results have been 
obtained by in vitro studies. The big challenge that lies 
ahead would be to test the in vitro results in suitable ani-
mal models to better understand virulence gene regula-
tion in pathogenesis. With the rise of antibiotic resistance 
and the prevalence of multi-drug resistant isolates, fully 
understanding the virulence regulation in pathogenesis 
may provide sound rationale for identifying regulators as 
potential targets for anti-staphylococcal drug therapies. 
Targeting a cellular factor not absolutely required for sur-
vival, such as a virulence regulator, may lessen selective 
pressures, and therefore resistance, while still attenuating 
virulence of the organism
[170,171]
.
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Repressor of toxins Rot, is another global regulator that belongs to the Sar family, 
which mediates modulation of several genes involved in virulence (especially 
autolysins).78 Its transcription is growth-phase dependent,79 however its translation is 
regulated by the agr ‘quorum sensing’ system.80 Rot has also been shown to repress hla 
production by repressing the SaeR/S two-CS, and both, Rot and the Sae-two-CS, had 
been proposed to work in opposition of one another on their target genes. Otherwise 
now, it is known that both regulators work in concert to activate promoters.81  
Other similar transcriptional regulatory system, teicoplanin-associated locus regulator 
TcaR, belongs to MarR family, appeared to be a weak negative regulator of transcription 
of the ica (intercellular adhesion) locus, necessary for biofilm production, as well as a 
further activator of sarS, and a modulator of sasF expression. Obviously, the inactivation 
of the tcaRAB operon leads to teicoplanin resistance. And, AraC/XylS family, involves in 
biofilm formation82 and virulence in S. aureus.83 
Finally, the GTP-sensing transcriptional pleiotropic repressor CodY, well conserved 
within the low G+C Gram-positive, has been shown to be an important regulator of 
metabolism and virulence. CodY acts repressing toxin production during times of 
plentiful nutrition by directly and indirectly via agr. It functions by sensing intracellular 
levels of branched chain aminoacids and GTP during growth, and responds by 
repressing genes involved in starvation behaviors in nutrient-rich conditions (amino 
acid transport, sporulation…). When these levels decline (branched chain-aminoacids 
and GTP), CodY loses its affinity for DNA binding, bringing about de-repression of 
target genes, and as a result, a physiological transition from growth and division to 
amino acid metabolism and stress tolerance.84 Briefly, apart from direct regulation of 
virulence genes, CodY also affects metabolic regulation in S. aureus via carbon flow, 
nitrogen assimilation, amino acid synthesis and transport systems.85 Moreover, CodY is 
also repressed by the intracellular protease/chaperone ClpC, possibly via ClpC-induced 
proteolytic degradation in association with ClpP, eliminating the repressive effect of 
CodY on virulence genes.86 
“CodY is activated in nutrient replete environments, repressing virulence factors and 
metabolic synthesis genes”. 
2.1.3 Small regulatory RNAs systems (sRNA). 
S. aureus also uses, besides these signaling pathways, around 250 regulatory RNAs to 
coordinate the expression of the numerous virulence genes for growth and survival. 
Most S. aureus sRNAs are located within the core genome, but a few are expressed from 
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the pathogenicity islands and from plasmids. The sRNAs expressed from the core 
genome are probably involved in wider biological functions. Most of the few sRNAs, 
whose physiological roles have been determined, control the expression of genes 
involved in response to quorum sensing, in central metabolisms, and on virulence by 
pairing to target mRNAs to modulate their translational activities and stabilities. Several 
sRNAs encode and express small peptides that may play important roles in virulence or 
in bacterial growth control. Most of these well-characterized sRNAs act as fine-tuning 
regulators by repressing the translational level of only one gene, but it is probably that 
one gene is regulated by different sRNAs.74 
"Multiple sRNAs controlling the expression of a similar component from a regulatory 
network allows the sharp regulation of virulence genes. It is most probably that S. 
aureus expresses many other sRNAs that deeply interact with this network to influence 
bacterial virulence".74 
SbrA and SbrB, highly conserved among Staphylococci, encode putative basic peptides, 
which are potential virulence factors. Another SbrC, encodes for an ABC transporter 
dedicated in the uptake of manganese, crucial element for defense systems against 
oxidative stress and contributes to the virulence of S. aureus.74  
RsaA, RsaD, and RsaF, are differently transcribed in response to environmental stress, 
heat, cold, osmotic and oxidative stress, as well as acidic pH. Recently, RsaE, sRNA 
conserved in all S. aureus strains, has been shown to regulate several metabolic 
pathways, exactly down-regulates the synthesis of enzymes from the Krebs cycle 
(tricarboxylic cycle, TCA) and from the folate-dependent one-carbone metabolism. 
However its expression profile is a subject of controversy,87,88 because of some S. 
aureus strains. RsaE is expressed at late exponential phase and repressed at stationary 
phase, it could facilitate the transition of energy metabolisms, the purine biosynthesis, 
and amino acid transport in response to the nutrients’ availability. Moreover, the RsaE 
expression seems to be dependent on the agr ‘quorum sensing’ system and SigB 
activity (Figure 2.1), suggesting that it could modulate the metabolism profile according 
to stress responses and/or virulence.43  
Small stable RNAs (SSRs) are RNAs specifically produced and/or stabilized in response 
to various environmental conditions. For example, SSR42, expressed during the 
stationary phase, is involved in host erythrocyte lysis, resistance to human 
polymorphonuclear leukocyte killing, and pathogenesis in a murine model of bacterial 
infection.74,89 
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Figure 2.1. The agr system and its two main intracellular effectors AgrA and RNAIII. The agr system 
regulates the expression of multiple genes in an RNAIII-independent manner via AgrA and in an 
RNAIII-dependent manner. RNAIII-independent regulation: AgrA activates the synthesis of several 
peptides by binding to their promoter regions and represses metabolic enzymes by an unknown 
mechanism. RsaE regulates enzymes of the central metabolism. RNAIII-dependent regulation: RNAIII 
encodes hld (δ-haemolysin) and the secondary structure of RNAIII and three of the hairpin domains 
containing a redundant UCCC motif (gray color). The 3’ non-coding region of hld, which contains the 
three redundant hairpin loops, binds to the ribosome binding sites of coa mRNA encoding coagulase, 
rot mRNA encoding repressor of toxins rot, and spa mRNA encoding protein A. The 5’ non-coding 
region of hld binds to hla mRNA to facilitate ribosome binding, and to activate translation. Dashed 
bars and dashed arrows are for transcriptional regulation while black bars and arrows are for post-
transcriptional regulation. Bars are for repression and arrows for activation.90 
Reprint from [90] with permission from Taylor & Francis Group LLC. Copyright © 2012 Landes 
Bioscience. All Rights Reserved. 
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Small pathogenicity island rNA D9 (SprD), is expressed from the genome of a converting 
phage, a horizontally-acquired pathogenicity island, being the repository of 
superantigens, toxins, adherence, invasion factors, and secretion systems, playing 
important roles during host infection. SprD down-regulates, the expression of the 
immunoglobulin binding (Sbi) immune evasion molecule, located on the core genome.74 
Finally, RNAII encoding a ‘quorum sensing’-cassette and an agr-locus-two-CS [see 
above], and RNAIII encoding δ-haemolysin (Hld). (Figure 2.1) RNAIII is one fascinated 
regulator and structured mRNAs that regulates multiple targets involved in virulence 
and peptidoglycan metabolism.74,90 RNAIII is responsible for post-transcriptional 
regulation of multiple virulence factors, by  mediating a switch from expression of cell-
surface associated proteins, such as staphylococcal protein A and fibronectin-binding 
proteins A and B (FnbA and FnbB), to secreted toxins, such as α-haemolysin and δ-
haemolysin, PSMs, and leukocidins such as Panton–Valentine leukocidin (PVL).36,37,91  
Recently, a new sRNA, named ArtR (AgrA-repressed, toxin-regulating sRNA), has been 
reported to activate α-haemolysin (Hla) expression by binding to the sarT mRNA.92 
Although both, RNAIII and ArtR, similarly regulate hla expression, in contrast to RNAIII, 
ArtR transcription is repressed by agrA, suggesting that up-regulation of hla mediated 
by ArtR could be enhanced in agr-deficient strains.74 
2.2 Pathogenesis: Virulence determinants. 
S. aureus is  known due to its virulence, which is multifactorial and dependent on a series 
of toxins, adhesion proteins, another virulence determinants and immune system 
evasion; the same is true for MRSA strains. The molecular basis of infection by S. aureus, 
has been an active field of research for several decades. However, now such research has 
further intensified to become decisive, with the recent emergence of highly pathogenic 
CA-MRSA strains that combined antibiotics resistance, rapid ability for spreading and 
exceptional virulence.93 The last decade has been decisive for the identification of yet 
unrecognized S. aureus virulence factors such as the PSMs,94 as well as the 
characterization of the pathogenic role of long-known toxins such as the PVL.95,96 This 
virulence can be gained via acquisition of new toxin genes by horizontal transfer, such as 
the phage-borne pvl genes, or can be gained via overexpression of core genome-
encoded toxins, such as PSMs or α-haemolysin.94,97,98 Moreover, to this already intricate 
scheme of complexity, it has also been added, the observation that the acquisition of new 
genes, can be harbored by MGEs.99 (Figure 2.2) 
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Figure 2.2 Pathogenic factors of Staphylococcus aureus, with structural and secreted products, both 
playing roles as virulence factors. (a), surface and secreted proteins.(b) & (c), cross-sections of the 
cell envelope. Reprint from [100,101] with permission from Lowy, FD (author) and Oxford University 
Press. Copyright © 2008 Copyright Clearance Center, Inc. All rights reserved. 
 
2.2.1 Cell Surface Determinants Involved in Pathogenesis. 
Cell surface proteins are proteins embedded in cell membrane with a multiple important 
roles in S. aureus pathogenesis, such as key functions in bacterial cell wall metabolism. 
They bind to host tissue, facilitate internalization and immune evasion, and are involved 
in bacterial aggregation and biofilm formation. Most surface proteins are encoded on 
the core genome.102 
2.2.1.1 Teichoic, Lipoteichoic Acids and peptidoglycan. 
Teichoic acids are bacterial polysaccharides constituted of polyribitol-phosphate 
polymers cross-linked to N-acetylmuramic acid residues of the peptidoglycan, and 
decorated with D-alanine and N-acetylglucosamine residues. They represent up to 50% 
of the dry weight of purified staphylococcal walls, and play an important physiologic 
role in cell wall metabolism, probably to be a site of attachment of cell wall for active 
enzymes and other proteins. Teichoic acids have also been involved in adherence to 
nasal epithelia, nevertheless, their role in invasive infection and host inflammatory 
response is unclear.2,102 (Figure 2.2.1.1) 
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Figure 2.2.1.1. Cell wall organization 
 
Lipoteichoic acids are the major constituent of cell wall in gram-positive, with a plasma 
membrane-bound counterparts of teichoic acids. They have a similar general structure 
to teichoic acids, except that they contain polyglycerol-phosphates and are linked to a 
diacylglycerol-moiety, which serves as a plasma membrane anchor. Lipoteichoic acids 
can act like receptors, and have been implicated in inflammation via triggering the 
release of cytokines by macrophages and other players of the innate immune system. In 
particular, the stereochemistry of the D-alanine and the presence of the diacylglycerol 
lipid anchor, were shown to be determinants for host recognition and subsequent 
inflammation. Certainly, lipoteichoic acids may facilitate bacterial recognition by host 
innate immunity, but at the same time, they protect bacteria from killing by cationic 
antimicrobial peptides, which are produced by professional phagocytes. Native 
lipoteichoic acid is polyanionic (negative charge) and therefore, attracts cationic 
antimicrobial peptides. To circumvent the problem, lipoteichoic acids become decorated 
with D-alanyl residues (positive charge) by the dltABC gene products, which render the 
structure more positively charged, and thus repulse cationic antimicrobial peptides. 
Indeed, mutants impaired in dltABC are also less adherent to endothelial cells and less 
able than wild type to produce experimental endocarditis in rabbits. Hence, the 
microbial cover is not an amorphous scaffold that only ensures bacterial shape, it is also 
a sophisticated structure indispensable to mediate adherence, sensing, and growth in 
complex environments.2 (Figure 2.2.1.1). 
Peptidoglycan, also known as murein, is a critical cell structure highly conserved 
constituent of both the gram-positive and gram-negative, however in gram-positive 
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bacteria is a thick structure while in gram-negative is thin. It is constituted of glycan 
chains made of N-acetylglucosamine and N-acetylmuramic acid disaccharide subunits, 
in which the N-acetylmuramate moiety is linked to highly conserved pentapeptide or 
tetrapeptide stems (L-alanine–D-isoglutamine–L-lysine–D-alanine–[D-alanine]). In S. 
aureus, the peptidoglycan is cross-linked via a characteristic pentaglycine interpeptide 
bridge, piece that comprises 1 to 5 glycine residues. The addition of glycines to the wall 
precursors is driven by femABC and fmhB genes. These determinants are implicated in 
the plasticity of the wall and are indirectly implicated in staphylococcal resistance to 
methicillin and vancomycin (see subsequent Antibiotic Resistance section).2 
Peptidoglycan is the major scaffold for anchoring most MSCRAMMs (microbial surface 
component recognizing adhesive matrix molecule), thus it plays a key role in 
pathogenesis. However, peptidoglycan is recognized by the innate immune system and 
triggers cytokine release and inflammation, therefore it is made important for the 
microorganisms to be able to hide these structures (peptidoglycan and lipoteichoic 
acids) from host recognition. The objective is achieved by producing antiphagocytic 
components such as a capsule, or protein A. 
2
 
2.2.1.2 Capsule and biofilms. 
More than 90% of clinical isolates of S. aureus elaborate a polysaccharide capsule. 
Heretofore, 11 serotypes have been reported, of which capsule type 1 and 2 produce 
large quantities of polysaccharides and appear mucoid on culture plates, though they 
are rarely found in human clinical samples. Nevertheless, capsule type 5 and 8 are 
responsible for up to 75% of clinical infections, indeed antibodies against these capsular 
types are protective in animal models of sepsis, and naturally occurring antibodies are 
detected in normal human serum. This could be because of, both capsule type (type 5 
and 8) are antiphagocytic and can increase virulence in several animal models. Capsule 
type 5 and type 8 are made of various sugars, including mannose and fucose. Thus, the 
capsule is an antiphagocytic constituent that might be a promising target for 
vaccination. Actually, in patients for haemodialysis, a conjugate vaccine addressed 
against type 5 and 8 capsules has been shown temporally effective, however, no 
definitive human studies are available on this issue.2 
Biofilms are surface-attached bacterial agglomerations embedded in extracellular 
matrix. The production of a series of surface molecules that promote extracellular 
matrix formation, allow Staphylococci to be known as a very good biofilm formers.102 
Biofilm-formation evolves in two steps, starting with nonspecific adherence of 
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individual cells to the materials, followed by growth and biofilm formation. Biofilm-
formation is associated with the production of polysaccharide intercellular adhesion 
(PIA), which is synthesized by an operon called ica (intercellular adhesion) composed of 
a regulator (icaR) and biosynthetic (icaADBC) genes.2 Throughout this chapter, we will 
continue to explain the factors involved in biofilm formation, Figure 2.2.1.3 and Figure 
2.2.2. The strategy of colonizing or biofilm-formation of S. aureus, to remain in or on 
human epithelia in relative ‘stealth’, is opposed to an aggressive status of active toxin 
production during acute S. aureus disease. Moreover, biofilms enable the bacteria to 
remain attached to surfaces, and provide considerable protection from antibiotics and 
host defenses. Therefore, biofilms may contribute to prolonged colonization and 
infection, and the spread of MRSA in hospital and community settings. It is noteworthy 
in that regarding many colonizing S. aureus isolates were shown to be defective in the 
global virulence regulator agr.102 
2.2.1.3 Surface Adhesines. 
Surface adhesines-anchored are binding-proteins that are covalently attached to 
peptidoglycan,2,102,103 which are known as cell wall-anchored (CWA) proteins. These 
surface proteins are crucial to the success of the organism as a commensal bacterium 
and as a pathogen (Figure 2.2.1.3). The repertoire of CWA proteins on the surface varies 
among strains, and S. aureus can express up to 24 different CWA proteins. Moreover, 
the expression of CWA proteins can be altered by growth conditions; for example, some 
proteins are expressed only under iron-limited conditions, whereas others are found 
predominantly on cells in the exponential or stationary phases of growth. The most 
prevalent group is the microbial surface component recognizing adhesive matrix 
molecule (MSCRAMM) family, which is defined by tandemly linked IgG-like folded 
domains and likely play a role in nasal colonization, especially when the mucin layer is 
breached and matrix proteins are exposed.100 All these MSCRAMMs obey a relatively 
similar type of structure, a N-terminal signal sequence, which is followed by variable 
functional domains that carry the binding activity and are themselves followed by a 
series of repeated sequences, a LPXTG (Leu-Pro-any aminoacid-Thr-Gly) wall-
anchoring domain, and a membrane-spanning domain, which is cleaved off during wall 
anchoring by an enzyme called sortase.2 Secretory signal sequences are located at the 
amino-terminal, which direct the translated proteins to the secretory (sec) apparatus in 
the membrane, to cleave during secretion. Carboxyl-terminal has a characteristic 
sorting signal, which facilitates to each protein their covalent anchorage to 
peptidoglycan. Some examples of CWA is, the protein A, a multifunctional CWA protein 
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ubiquitous in S. aureus, which is often used in strain typing on the basis of spa-typing. 
Surface protein G (SasG), closely related to the accumulation-associated protein (Aap), 
which is needed for biofilm formation in S. epidermidis. And near iron transporter 
(NEAT) motif proteins, involved in haem capture from haemoglobin, which help bacteria 
to survive in the host, where iron is restricted. Haem is transported via several CWA 
proteins, called iron-regulated surface (Isd) proteins, to a membrane transporter and 
then to the cytoplasm, where haemoxygenases release free iron.103 Relevant CWA for 
pathogenesis are summarized in Table 2.2.1.3.103 
Figure 2.2.1.3 Functions of cell wall anchore (CWA) proteins of S. aureus. The CWA protein iron-
regulated surface determinant (isd) binds haemoglobin and extracts, and transports haem across the 
cell wall and membrane into the cytoplasm, where iron is released. Phagocytosis by neutrophils is 
inhibited by the binding of CWA proteins to IGg and other plasma proteins, by reducing the level of, 
or access by, neutrophil receptors to the complement opsonin C3b. CWA proteins promote adhesion 
to the extracellular matrix, to the surface of host cells and to biomaterial surfaces. Interactions 
between CWA proteins on adjacent cells contribute to the accumulation phase of biofilm formation. 
CWA proteins directly or indirectly interact with integrins and promote the invasion of non-
phagocytic host cells. Intracellular bacteria can cause host cell apoptosis or necrosis, or they can 
enter a non-disruptive semi-dormant state known as small colony variants. By binding to and 
activating tumour necrosis factor receptor 1 (TNRF1) on host epithelial cells, protein a triggers the 
synthesis of cytokines and causes disruptive inflammation, which contributes to pathogenesis. 
Reprint from [103] with permission from Nature Publishing Group. Copyright © 2013 Copyright 
Clearance Center, Inc. All rights reserved. 
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Table 2.2.1.3 The main groups of cell wall-anchored (CWA) proteins as virulence factors of Staphylococcus aureus. Role in the colonization. 
#ECM: extracellular adhesion; LPXTG: Leu-Pro-any aminoacid-Thr-Gly; Ct: carboxyl-terminal; Nt: amino-terminal; gp: glucoprotein; TNFR1: tumour necrosis factor 
receptor 1; VH3: variable heavy chain 3; SAg: superantigen.
103  
 
PROTEIN GROUP LIGAND AND BINDING MECHANISM FUNCTION ROLE 
MSCRAMMs (microbial surface component recognizing adhesive matrix molecule) 
ClfA Clumping factor A Fibrinogen γ-chain carboxyl-t Adhesion to immobilized fibrinogen; (thrombus) immune 
evasion by binding soluble fibrinogen 
Endocarditis 
Kidney abscess following 
survival in blood 
Septic arthritis 
Septic death; survival in blood 
Complement factor I Immune evasion; degradation of C3b. Reduce 
opsonophagocytosis 
ClfB Clumping factor B Fibrinogen a-chain repeat 5, keratin 10 and loricrin Adhesion to desquamated epithelial cells; nasal 
colonization. 
Adhesion to thrombus 
Nasal or skin colonization 
Endocarditis 
Kidney abscess following 
survival in blood 
SdrC Serine-aspartate repeat 
protein C 
β-neurexin Unknown  
Desquamated epithelial cells Nasal colonization?  
SdrD SdrD 
SdrE SdrE Complement factor H Immune evasion; degradation of C3b  
Bone sialoprotein-binding 
protein (isoform of SdrE) 
Fibrinogen α-chain 
Adhesion to ECM 
 
FnbA, 
FnbB 
Fibronectin-binding 
proteins A and B 
FnbA A domains binds the Ct of fibrinogen γ-chain and elastin 
FnbB A domain also binds fibronectin but not only 
Mastitis 
Foreign body infection 
Endocarditis Fibronectin (FnbA and FnbB Ct repeats b-zipper) Adhesion to ECM; invasion. Adhesion to thrombus; 
adhesion to intra-aortic patch. 
Cna Collagen adhesion  Collagen triple helix; collagen hug Adhesion to collagen-rich tissue. Adhesion to cartilage Ocular keratitis 
Septic arthritis Complement protein C1q Prevention of classical pathway of complement activation. 
Enhanced colonization and evasion 
Near Iron Transporter, NEAT mofit family 
IsdA Iron-regulated surface 
protein A 
Haem, fibrinogen, fibronectin, cytokeratin 10, locicrin (Nt 
NEAT-mofit region) 
Haem up-take and iron acquisition; adhesion to 
desquamated epithelial cells; resistance to lactoferrin 
Nasal colonization 
Kidney abscess following 
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Unknown ligand (Ct domain NEAT. Mofit region) Resistance to bacterial lipids and antimicrobial peptides; 
survival in neutrophils 
survival in blood 
IsdB IsdB Haemoglobin, haem (Nt NEAT-mofit region) Haem up-take and iron acquisition Kidney abscess following 
survival in blood β3-integrins (NEAT mofit regions) Invasion of non-phagocytic cells 
IsdH IsdH Haemoglobin, haem (Nt and/or Ct NEAT-mofit region) Haem up-take and iron acquisition Septic death; survival in blood 
Unknown ligand (Nt domain NEAT. Mofit region) Accelerated degradation of C3b 
Structurally uncharacterized proteins 
AdsA Adenosine synthase A Function not mediated by binding Promotion of survival in neutrophils by inhibiting the 
oxidative burst 
 
SasX S. aureus surface protein X Unknown ligand Biofilm formation; cell aggregation; and squamous cell 
adhesion 
Nasal or skin colonization 
Septic death; survival in blood 
SraP Serine-rich adhesion for 
platelets 
Salivary agglutinin gp340 and an unidentified ligand on 
platelets 
Endocarditis; and endovascular infection Endocarditis 
SasC SasC Unknown ligand Promotes primary attachment and accumulation phases 
of biofilm formation 
 
 SasB, SasD, SasF, SasJ, SasK 
and SasL 
Unknown ligand Putative LPXTG proteins identified from genome 
sequences. No knows structure or function 
 
Bap Biofilm –associated protein  gp96 Promotes biofilm formation; prevents invasion of 
mammary gland epithelial cells; and promotes 
aggregation on epithelial cell surfaces. Only found in 
bovine strains 
 
G5-E repeat family 
SasG S. aureus surface protein G 
(SasG) and plasmin-
sensitive surface protein 
(PIs) (a SasG homologue in 
MRSA) 
Unknown ligand (A domain) Adhesion to desquamated epithelial cells  
Unknown ligand (G5-E repeat) Biofilm formation  
Three-helical bundle 
Prot A Protein A IgG, IgM Fab VH3 subclass, TNFR1 Inhibition of opsonophagocytosis; B cell SAg; 
inflammation 
Pneumonia 
Septic death; survival in blood 
Septic arthritis vonWillebrand factor Endovascular infection; endocarditis 
Unknown ligand (region Xr) Biofilm formation 
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2.2.2 Secreted Enzymes and Haemolysins. 
S. aureus is known for producing a plethora of toxins, with a wide variety and common 
repertoire, because many toxins together with other virulence determinants are 
encoded on MGEs, whose presence varies considerably between strains. Such MGE-
encoded toxins include, superantigens such as TSST, some leukotoxins such as PVL, 
and exfoliative toxins. Whereas, α-haemolysin (Hla), ϒ-haemolysin (Hlg), other 
leukotoxins and PSMs are produced by most strains. Notwithstanding, differential 
expression of every core-genome encoded toxin genes, could cause considerable 
differences in the pathogenic potential between S. aureus strains, i.e., mutants agr-
defective, which controls the expression of many S. aureus toxin genes.102 (Table 2.2.2) 
Table 2.2.2 Main toxins of S. aureus.  
NAME 
 
FUNCTION 
β-haemolysin/toxin Hlb Sphingomyelinase with cytolytic activity 
α-haemolysin/toxin Hla Cytolytic pore-forming toxin 
Leukocidins D, E and M LukD/E/M Kill leukocytes; bicomponent pore-forming leukotoxins 
PSM peptides PSMs Pore-foring toxins or detergent activity 
Exfoliative toxins A, B and D ETA/B/D Exotoxins with superantigen activity: glutamate-specific 
serine protease that digest desmoglein1 
Enterotoxins SEs Gastroenteric toxicity; immunomodulation via superantigen 
activity 
SE-like proteins SEIs Unknown. Non gastroenteric toxicity; immunomodulation 
via superantigen activity 
Toxic shock syndrome toxin-1 TSST-1 Endothelial toxicity; superantigen activity 
Formylpeptides  fMLPs Ligands for formyl peptide receptor 
2.2.2.1 Haemolysins. 
S. aureus has a minimum of four haemolysins referred: α- (Hla), β- (Hlb), γ- (Hlg) 
and δ- (Hld, see in PSMs) toxins, which are present in most S. aureus isolates, encoded 
on the chromosome and subject to agr regulation. Also, they are able to lyse 
erythrocytes and other eukaryotic cells.2 
α-toxin/α-haemolysin Hla, the main and most characterized virulence factor, is a 
cytolysin produced by most S. aureus strains.104,105 The hla gene is not mobile, and its 
expression is regulated by at least three global regulatory systems including Agr. It is a 
water-soluble monomer of 33 kDa with pore-forming and pro-inflammatory 
properties.65 Upon binding to a membrane receptor, Hla forms heptameric pores, 
thereby destroying a variety of host cells, including epithelial cells, erythrocytes, 
fibroblasts, lymphocytes, monocytes and macrophages, but not neutrophils.104 This 
cytolytic activity of Hla is dependent on the interaction with the ADAM10 (disintegrin 
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and metalloproteinase domain containing) receptor; in fact, ADAM10-deficient mice are 
protected from lethal pneumonia and severe skin infection, by S. aureus. Moreover, α-
toxin leads to neutrophil chemotaxis and has pro-inflammatory effects, including 
induction of the inflammation and generation of highly pro-inflammatory cytokines, IL-
1 and IL-18.53 (Figure 2.4) In addition, α-toxin has been shown to contribute to the 
penetration of the epithelial barrier during skin infection by USA300,106 and has also 
been demonstrated to impact on virulence in many infection models, such as  
pneumonia, where it has a significant effect on morbidity and mortality.107 This strong 
impact on the development of USA300 skin infection,37 can be prevented by passive or 
active immunization,108 with anti-α-toxin antibodies or derivative of α-haemolysin, 
respectively. 
β-toxin/β-haemolysin Hlb is peculiar, because it is a sphingomyelinase of type C that 
damages membranes by enzymatic alteration of their lipid leading to cell lysis. And, in 
many virulent S. aureus strains, a pathogenicity island disrupts the gene encoding 
hlb.2,109 β-toxin does not form pores in the plasma cell membrane, in fact the lysis of 
erythrocytes is only observed after the cells are switched to low temperature, thus 
suggesting that the lytic activity of β-toxin is not as efficient as that of other 
haemolysins, at least towards erythrocytes. Although β-toxin is selectively cytotoxic to 
monocytes, and is inactive against fibroblast, lymphocytes and granulocytes, the 
mechanism leading to cytotoxicity is still poorly understood. Currently, it is unknown if 
this result is due to a specific targeting of β-haemolysin to monocytes (possibly 
mediated by a specific receptor) or to a higher sensitivity of these cells to the toxin.110 
2.2.2.2 Leukocidins. 
Leukocidins or leukotoxins, bicomponent (hetero-oligomeric) pore-forming, can lyse 
cells of the myeloid lineage, namely monocytes, macrophages and neutrophils, which is 
considered important for S. aureus immune evasion. These leukotoxins consist of one 
class S and one class F subunit proteins of 32-35 kDa, whose genes are either core 
genome-or phage-encoded. The class S and F subunit proteins are non-toxic on their 
own, but upon oligomerization, they form a β-barreled pore-structure. Five class F 
subunits (HlgB, LukF-PV, LukD, LukF`-PV and LukG) and six class S subunits (HlgA, 
HlgC, Luks-PV, LukE, LukM and LukH) have been described (see Table 2.2.2.2)104 
LukDE and LukGH, are expressed by the majority of CA-MRSA strains, and both 
contribute to the virulence of S. aureus in murine sepsis and renal abscess models. 
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LukGH exhibits potent cytolytic activity towards neutrophils acting in synergy with the 
PVL in vitro.104   
γ-haemolysin Hlg , also named leukocidin, can lyse white blood cells as well as other 
cells. It is encoded by two distinct operons, one that encodes a unique HlgA (S protein) 
and another encodes for HlgC (S protein) and HlgB (Table 2.2.2.2). Both proteins (S and 
F) have to be assembled to form membrane-perforating complexes. Active Hlg is 
encoded in the core genome, and exists in two bioactive forms, haemolysin-c (Hlg) and 
haemolysin-c2 (Hlg2). Hlg is present in 99% of S. aureus strains and appears to 
contribute to septic arthritis with weight loss in mice, and to endophthalmitis in 
rabbits.104 
Table 2.2.2.2 Leukotoxins of S. aureus.104 # PMN: polimorphonucleares. 
Leukotoxins Components Localization Prevalence Cell specificity 
 Class F 
subunit 
Class S 
subunit 
   
Haemolysin-c (Hlg) HlgB 
(Hlg1,LukF) 
HlgA (Hlg2) hlg gene cluster; 
genome 
∿99% Erythrocytes from 
humans and other 
mammalian species 
Haemolysing-c2 
(Hlg2)/Leukocidin 
(Luk) 
HlgB (Hlg1, 
LukF) 
HlgC (LukS)   Human and rabbit 
PMN and rabbit 
erythrocytes 
Panton-Valentine 
Leukocidin (PVL) 
LukF-PV LukS-PV pvl locus; phage 0-5% Human and rabbit 
PMN 
LukDE LukD LukE pathogenicity 
island 
30-87% Murine and rabbit 
PMN 
LukFM LukF`-PV LukM phage 0% Bovine PMN 
LukGH (LukAB) LukG (LukB) LukH (LukA) n.d. n.d. Human PMN 
Panton-Valentine leukocidin PVL, two-component leukocidin, belongs to a β-barrel 
forming family of cytolytic toxins, comprising also other leukocidins, γ-haemolysin 
(Hlg) and α-haemolysin (Hla). PVL is encoded by the prophage-encoded adjacent lukS 
and lukF genes, which produce the two toxin parts. LukS and LukF, both are needed for 
the cytolytic activity of the toxin. Since 1932, when Panton and Valentine noted an 
association between PVL production and abscess formation,105 the interest in PVL has 
been increased enormously due to an epidemiological association between the presence 
of the lukSF genes and CA-MRSA.111 Most CA-MRSA strains have both lukSF genes, 
while their frequency in MSSA is much lower, and they are absent from predominant 
hospital acquire (HA)-MRSA clones.  
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PVL is lytic toxin to human neutrophils at concentrations between 0.3-2 μg/ml.105 
Concentrations of PVL reaching or exceeding that range were demonstrated in human 
skin abscesses and in some clinical specimens from different infection types.105 In 
laboratory experiments, the contribution of PVL to the lytic activity towards human 
neutrophils when assayed with CA-MRSA culture filtrates proved strongly dependent on 
the type of growth media used.112 For these reasons, such studies are barely conclusive 
when judging the role of PVL in CA-MRSA virulence.105 (Figure 2.2.2.2) On the other 
hand, animal infection models have yielded conflicting results, which has been 
attributed to differences between models, inoculum sizes, and, very importantly, the 
host species.104,105 Actually, the leukotoxic activity of PVL differs dramatically between 
species: human and rabbit neutrophils are lysed by very low toxin concentrations, 
whereas 1000-fold higher amounts are required for the lysis of mouse or java monkey 
neutrophils.113 Consequently, and the same way as with many other toxins, it is not 
clear whether pro-inflammatory effects are of benefit to the bacteria, as they may cause 
excessive phagocyte infiltration and tissue damage, or whether they serve the human 
innate immune system to recognize infiltration bacteria and launch a defensive 
response. Most probably, both mechanisms contribute to infection out-come and it 
depends on the specific scenario, which has a stronger impact. Finally, it needs to be 
noted that an increasing number of CA-MRSA clones have been found that do not 
contain lukSF genes.98 For example, in Korea114 and the United Kingdom,115 and Li et 
al.,97 have showed in rabbit skin infection studies that these clones are o average not 
less virulent than lukSF containing CA-MRSA clones.  
γ-haemolysin (HlgC/B) and PVL probably target the same cell types. Both toxins are 
similarly potent at lysing granulocytes and human macrophages. Whereas, PVL and ϒ-
haemolysin are extremely potent, leukocidins LukAB/GH and LukED are only active at 
concentrations 100-fold higher. The relative secretion of the different toxins in 
different conditions remains unknown.110 
2.2.2.3 Phenol-soluble modulins. 
Phenol-soluble modulins PSMs are a family of amphipathic α-helical peptides produced 
by staphylococci.94 Many members of the PSMs family have pronounced cytolytic activity 
towards a variety of human cells, including neutrophils and erythrocytes.94 In addition, 
PSMs trigger inflammatory responses by interaction with the formyl peptide receptor 2 
(FPR2).116 The α-type PSMs, ∼20–25 amino acids in length, may have strong cytolytic 
activity, and β-type PSMs are barely cytolytic and with a ∼40–45 amino acid long.94 In 
particular, the PSMα peptides of S. aureus, PSMα1–PSMα4, are encoded in the psmα 
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operon that contains the potent cytolysin PSMα3. This PSMα3 or δ-haemolysin (Hld), is 
a moderately potent yet often strongly expressed. Three different mechanisms have 
been proposed to explain the haemolytic activity of δ-haemolysin, (i) bind to the cell 
surface and aggregate to form transmembrane pores; (ii) bind to the cell surface and 
affect the membrane curvature, thereby destabilizing the plasma membrane; or (iii) at 
high concentration, act as a detergent to solubilize the membrane.110 
PSMs also contribute to staphylococcal biofilm formation by forming fibril-like 
structures, structure biofilms, and cause biofilm detachment, resulting in the 
dissemination of biofilm-associated infection.105 Actually, in S. epidermidis have been 
demonstrated to participate in the maturation of the biofilm structure, specifically intra-
biofilm channels, and at high concentrations, in mediating bacterial detachment from 
the biofilm. Hence and by extension, probably performing the same biofilm regulatory 
functions in S. aureus.110 (Figure 2.2.2) 
CA-MRSA strains produce high amounts of PSMs, whereas production is on average 
lower in typical HA-MRSA strains (USA100 and USA200 strains) where the psm-mec 
gene is located on a chromosomal cassette.117 94 This might, at least in part, be due to 
the facts that (i) Agr virulence regulator exerts an exceptionally strict control over PSMs 
expression,91 and (ii) HA-MRSA strains often show low, while CA-MRSA strains 
commonly have high, Agr activity.117 Briefly, the PSMα peptides have a significant 
impact on CA-MRSA virulence, in experimental skin infection using mice or rabbits and 
bacteremia in mice.37,94 Notably, PSMα peptides, especially PSMα3, are responsible for 
the increased neutrophil killing capacity that distinguishes CA- from HA- MRSA 
strains.118 Recent findings suggest that PSMs are expressed after neutrophil ingestion of 
the bacteria, in the neutrophil phagosome as a result of agr induction, identifying PSMs 
as the main mediator of quorum- (or diffusion-) sensing-induced neutrophil killing, 
after S. aureus ingestion.119 Moreover, the last research are setting towards the 
possibility that production of α-haemolysin could be modulated by PSMs expression, 
suggesting one coordinated action among Hla and PSMs in host tissue during early 
pathogenesis, confirming a major role for α-haemolysin in epithelial injury during S. 
aureus infection.120 
2.2.3 Other toxins and enzymes. 
Others secreted S. aureus proteins, exactly proteases, are enzymes that degrade host 
molecules in a broad fashion, or interfere with host metabolic or signaling cascades, 
leading to tissue destruction, and may also have a more specific impact. The protease 
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aureolysin, cleaves many proteins including insulin B, with a preference of cleaving after 
hydrophobic residues, or  even can have a major impact on the pathogenesis of 
osteomyelitis because of inactivating PSMs. Up-regulated by Agr at the end of 
exponential phase, aureolysin also leads to maturation of another non-specific S. 
aureus exoprotease, such as the glutamyl endopeptidase SspA (o V8 protease), which 
cleaves after glutamate residues. Aureolysin, glutamyl endopeptidase, and the cysteine 
proteases staphopain B SspB, all interfere with complement factors, leading to evasion 
of complement-mediated bacterial killing. The biological function of further S. aureus 
proteases, a series of serine proteases, is not well understood, except for the exfoliative 
toxin serine proteases [see below]. Finally, S. aureus may produce a protease that 
degrades collagen, called collagenase.109  
Figure 2.2.2 Non-lytic functions of haemolysins, bicomponent toxins, and PSMs. (1) α-hly binds 
ADAM10 and relocalizes it to E-cadherin-containing micro-domains. ADAM10 cleaves E-cadherin, 
leading to loss in epithelial barrier function. (2) Exposure of the underlying glycosaminoglycans-rich 
extracellular matrix to LukS-PV signal peptide favors adhesion. (3) psm-mec RNA controls the 
transcription of virulence factors. (4) β-haemolysin binds DNA, forming nucleoproteins nucleating S. 
aureus biofilm. PSMβ acts as surfactant, promoting the formation of intra-biofilm tunnels and 
bacterial dissemination from biofilms. psm-mec enhances biofilm formation (5) in addition, PSMs 
have antibacterial activity. (6) Finally, PSMs in synergy with β-haemolysin participate in phagosome 
lysis and escape into the host cytosol [see below Figure 2.4].  
# α-hly: α-haemolysin; ADAM10: disintegrin and metalloproteinase domain containing.  
Reprint from [110] with permission from Frontiers Group. Copyright © 2007 - 2015 Frontiers Media 
S.A. Creative Commons Attribution License. All Rights Reserved. 
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Some S. aureus secreted host-damaging factors, such as the fibrinogen-binding protein 
Efb and staphylococcal complement inhibitor SCIN (scn), which are potent inhibitors of 
the function of convertase C3, a crucial enzyme in the complement pathway.109  
Staphylokinase (Sak) is enzyme that activates plasminogen to plasmin, which degrades 
fibrin clots, whose biological significance is to diminish the function of the fibrin 
meshwork in keeping a staphylococcal infection localized. It also cleaves the 
complement factor C3b, adding to the broad attack of other staphylococcal proteases 
and further molecules, such as Efb (fibrinogen-binding protein) and SCIN 
(staphylococcal complement inhibitor), on complement function. Aside staphylokinase 
facilitates bacterial penetration through the skin barrier, while it decreases the severity 
of skin infections by leading to drainage.109 
S. aureus further produces two coagulases, staphylocoagulase and von Willebrand 
factor, which contribute to the formation of fibrin clots after binding to prothrombin 
(forming a complex called staphylothrombin) and several other plasma proteins, thereby 
triggering the conversion of fibrinogen to fibrin. This leads to fibrin clots on the surface 
of S. aureus cells, inhibiting phagocytosis, causing abscess formation and adhesion of S. 
aureus to catheters during biofilm-associated infection.109 
Moreover, S. aureus produces other proteins such as lipases and nucleases, whose 
functions in pathogenesis are poorly understood. Possibly, nucleases may decrease the 
antibacterial activity of neutrophil extracellular traps, which consist of DNA released 
from lysed neutrophils.109 
On the other hand, S. aureus also harbors up to 15 enterotoxins (SEs, A, B, Cn, D, E, G, 
H, I, J, K, L, M, N, O), which are defined as superantigens, and able to produce 
gastrointestinal symptoms that include vomiting and diarrhea. For example, SEA, SEB, 
and SEC are the most frequent enterotoxins associated with food poisoning. Although 
many of these toxins have potential superantigen activity, others do not have a clear 
role in human disease, and the mode of action or mechanism at the surface of the 
intestinal mucosa is unclear. SEB can traverse the mucosa via transcytosis121,122 
nevertheless, SEA, which is one of the first causes of food intoxication, apparently 
cannot. Likewise, SEB and SEC are associated with non-menstrual TSS. 
Finally, Staphylococcal scalded skin syndrome (SSSS) is a superficial skin disorder by 
toxigenic S. aureus that produces either exfoliative toxin A (ETA) or B (ETB), encoded by 
the eta and etb genes, respectively. These toxin genes are located either on a 
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phage (eta)123 or on a plasmid (etb). Two additional isoforms of SSSS toxins (exfoliative 
toxins C [ETC] and D [ETD]) were isolated through pathologic observations in animals 
and with genome screen.124 A recent study indicates that the proportion of S. 
aureus carrying eta or etb in overall staphylococcal nasal carriers or clinical isolates is 
low (0 to 2% of isolates),125 which may explain the rarity of the disease and its clustering 
in favorable milieus. 
2.2.4 Superantigens. 
Aforementioned staphylococcal enterotoxins (SEs), and TSST-1 are the paradigm of a 
large family of pyrogenic exotoxins, called superantigens (SAgs) and denominated SET1 
to SET15.126-128 Superantigens are proteins that do not activate the immune system via 
normal contact between antigen-presenting cells and T-lymphocytes. All of them share 
a common architecture, though quite some variation exists in the primary structure of 
many superantigens. They consist of A and B globular domains, β-sheet barrels and α-
helices, rejoined by a discrete linking piece. A genealogy study of superantigens built 
on the base of their sequence homologies, has segregated them into five groups. Group 
I represented only by TSST-1, and group III contains only staphylococcal superantigens 
(SEs H, I, K, L, and P). Groups II and V contain both staphylococcal and streptococcal 
superantigens (staphylococcal SEs B, C, and G and SEs I, K, L, and P, respectively), and 
group IV only streptococcal superantigens. This underlines the likelihood of horizontal 
gene transfer between these two genera, a fact that is becoming increasingly apparent 
with genome comparisons.129,127 
Recall that toxin genes are dispensable elements, not necessary for growth in rich 
media and in the absence of competition, but obviously provide a way for the bacterium 
to escape host immunity. Thereby, superantigens can result in harm of the host immune 
system, however they are not ultimate bacterial weapons, as they only affect to 
restricted subgroup of anergic patients.123,126,129 This survival advantage of provoking 
allergic diseases, including rhinitis, asthma130 and Kawasaki syndrome,131 is true but 
less intuitive. For example, TSST-1 and few SEs (A,B and C), have been involved in the 
etiology of psoriasis and atopic dermatitis,132 where toxin-induced skin modification 
could promote bacterial survival. TSST-1, associated with the toxic shock syndrome, is 
secreted locally by toxigenic strains, and can cross the mucosal membrane, and then 
disseminate throughout the body. An experimental study suggests that TSST-1 could 
activate directly epithelial cells and the innate immune system to promote its 
translocation.121 Actually, the clinical relevance of this multiplicity of toxins is not 
entirely understood. 
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In short, CA-MRSA and CA-MSSA USA300 do not produce the superantigens SEB and 
SEC, but instead produce SEl-Q (and others superantigens including occasionally SEA 
and often SEl-K). Also it produces an apparently a N-terminal one-half deletion variant 
of TSST-1, whose activity is incompletely characterized, and has recently been 
associated with a newly described illness, extreme pyrexia syndrome, in which patients 
rapidly developed fevers in excess and quickly succumbed and died.133 USA300 also 
secretes the recently described superantigen SEl-X, which has been associated with 
necrotizing pneumonia caused by USA300 strains.134 
2.3 Pathogenesis: Genomic and mobile elements. 
Mobile genetic elements (MGEs) can be defined as DNA fragments, which are able to 
encode one or more virulence and/or resistance determinants, including enzymes that 
mediate for their own transfer and integration into another DNA. Thus, they play a central 
role in the adaptation process, and are a means to transfer genetic information (DNA) 
between and within bacterial species. MGEs are called a ‘‘mobilome’’ because they are 
able to display a mobility in the same cell and between cells.135 MGEs can insert through 
vertical gene transfer phenomena various size of DNA sequences, such as phages, 
transposons, pathogenicity islands, plasmids and chromosome cassettes.  
“This extra-chromosomal DNA elements play a crucial role in the plasticity of the 
genome, allowing bacteria to adjust readily to new environments”.136  
2.3.1 Plasmids, transposons and bacteriophages. 
The definition of Plasmids could be, any small-DNA-molecule able to auto-replicate in 
the own genome within a suitable host, and with the ability to transfer high frequency 
both resistance and virulence determinants, from one bacterium to another (even of 
another species) via horizontal gene transfer. For S. aureus have been classified into 
three different classes, (1) class I, composes of small (1.3–4.6 kbp), multicopy (10–55 
copies per cell) plasmids with either cryptic or caring a single (rarely two) resistance 
determinants (pT181, pC194, pE194); (2) class II, are larger (15–46 kbp) and exist in 
lower copy numbers (4–6 per cell), however, this group includes most of the 
penicillinase and aminoglycoside/trimethoprim resistance plasmids (e.g. pSK1); and (3) 
class III consists of most large (30–60 kbp) plasmids caring a determinant of transfer 
(tra) by conjugation and in most of them, a combination of resistance markers; this 
group includes glycoside-resistance plasmids (pGO1 or pCRG1600) and  usually 
possess one or two transposons and many copies of insertion sequences.135 In addition, 
staphylococcal plasmids encode resistance to a variety of organic and inorganic ions, 
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such as cadmium, mercury, arsenate, etc., which are highly toxic for living cells, as well 
as molecules involved in metabolism.136  
Insertion sequences (IS) are transposable elements, responsible for the recombination 
and stabilization of some resistance genes, which carry only that genetic information 
required for transposition, although it does not code for any resistance. Their presence 
is really important in the evolution of bacterial genome by inducing changes in the 
chromosomal genes expression,135 and can even inactivate several genes either by 
direct insertion or by polar effect on nearby genes transcription. For example, IS256 and 
IS257 are mediated by Tn4001 and Tn4003, and form a hybrid pair promoting 
resistance to aminoglycoside (aacA-aphD) and trimethoprim (dfrA), respectively.135,136 
Staphylococcal transposons (Tn) are probably the smallest elements that encode 
resistance genes predominantly. The smaller transposons are usually presented in 
multiple copies in the genome, either inserted into the chromosome or into MGEs, such 
as SCC or plasmids. The larger transposons are present in single copies and encode 
resistance to antibiotics, such as tetracycline, trimethoprim, aminoglycosides, or 
vancomycin.136  
Transposon Tn552 carries bla for penicillinase. Tn554 carries resistance to 
erythromycin, spectinomycin and macrolide–lincosamide-streptogramin B, presented in 
multiple copies, which can be found integrated into SCC (staphylocociccal cassette 
chromosome), plasmids or on the chromosome.137 Tn5801, found as unique 
conjugative transposon in Mu50, carries tetM encoding the resistance to both 
tetracycline and minocycline.138 Transposon Tn4291 carries resistance gene to 
methicillin, on the penicillinase plasmid (pI524).135 Tn1546 encodes the vanA operon, 
(vanA, vanH, vanX, vanS, vanR, vanY and vanZ) to vancomycin resistance, within a 
conjugative plasmid, whose gene expression occurs only in the presence of vancomycin, 
a process mediated by a two-CS-signal transduction encoded by vanS and vanR.136 
VanY and vanZ encode an accessory protein that could play a role in teicoplanin 
resistance.139 Transposon Tn1546, was likely transferred to MRSA from vancomycin-
resistant Enterococcus (VRE) during co-infection.136  
Bacteriophages (phages) or bacterial viruses, perhaps, have the greatest impact on 
staphylococcal diversity and evolution. All phages are classified into one of three 
distinctive groups: lytic, chronic and temperate. Lytic phages (Myoviridae family) have 
been used in phage therapy, as they lyse completely to bacteria during release of 
progeny phages. Bacteria infected with chronic phages, release progeny into the 
extracellular environment without killing the host, which allows bacteria to grow and 
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divide. Temperate phages (Siphoviridae family), the most numerous group, have the 
ability to lyse bacteria after infection, but they typically form a long-term relationship 
with the host cell, whereby the phage DNA integrates into the staphylococcal genome as 
a prophage. Anyhow, phages can impact expression of virulence determinants by 
lysogenic conversion, positive or negative. Following positive lysogenic conversion, 
bacteria express prophage-encoded virulence determinants. Negative lysogenic 
conversion occurs when there is insertional inactivation of genes (e.g., hlb of S. aureus) 
by integration of the phage DNA into the bacterial chromosome. Although there is a 
loss of β-haemolysin during lysogeny, these prophages contain genes encoding 
immune-modulator proteins, such as staphylokinase, staphylococcal inhibitor of 
complement (Scn), and chemotaxis inhibitory protein (Chp). Other S. aureus prophages 
encode virulence molecules such as enterotoxins and PVL.  
Prophages and prophage-encoded molecules also work together with other MGEs within 
staphylococci. They, for example, can create mobility for some staphylococcal 
pathogenicity islands, i.e., helper phage 80a mediates excision and transfer of 
pathogenicity island SaPI1 to other staphylococci. And others, have also the ability to 
transfer antibiotic resistance by transduction of plasmids or plasmid elements 
previously incorporated into chromosomal DNA, i.e., plasmid pS194 with a 
chloramphenicol resistance determinant and pI258.135,136 
 
 
Figure 2.3.1  Acquisition of MGEs by 
S. aureus. (1) Incorporation of 
plasmids or plasmid elements into 
genomic DNA. (2) Plasmids can be 
maintained as free circular DNA. (3) 
Suicide plasmid. (4) Transfer of a 
transposon or an insertion sequence 
between plasmid and genomic DNA. 
(5) Transfer of a transposon or an 
insertion sequence between plasmids 
within the cell. (6) Transfer of a 
transposon or an insertion sequence 
from genomic DNA to another 
plasmid.  
Reprint from [136] with permission 
from Springer. Copyright © 2010 
Copyright Clearance Center, Inc. All 
Rights Reserved. 
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2.3.2 Pathogenicity and genomic Islands. 
Pathogenicity and genomic islands are continuous structures with variety in size 
(approx. 15 kb to 70 kb) that can harbour many virulence or resistance genes. They 
mostly contain heterologous DNA pointing out exogenous acquisition. A common 
feature of these elements is that they are bracketed by direct or inverted repeats and 
carry recombinase genes. These repeats serve as attachment site (att) for integration 
into homologous regions of the bacterial chromosome. The recombinase, which is often 
an integrase, catalyzes integration into the chromosome.2 
Staphylococcal pathogenicity islands (SaPIs) are MGEs of 14–17 kb of which, at least 23 
have been sequenced, and SaPI1 is considered as the prototype.136,135 SaPIs family core 
genes are highly conserved,136 and include two open reading frame (ORF) encoding 
transcriptional regulatory proteins, and a region encoding integrase (int), replication 
initiator with helicase activity (rep), phage interference function (pif) and phage 
terminase small subunit homologue (terS). SaPIs are integrated in one of six different 
specific sites on the chromosome (atts) and each is always in the same orientation. In 
addition to core genes, almost all SaPIs encode integrase, resistance and virulence 
genes, and other superantigen-related diseases, such as food poisoning or host 
adaptation. SaPIs can be mobilized following infection by certain staphylococcal 
bacteriophages or by induction of endogenous prophages,135,136 such as induced 
excision of SaPI1 by phage 80a. Six kinds of superantigens genes (tst-1, seb, sec, selk, 
sell and selq) are harbored by several kinds of SaPI.136 Agr-regulated enterotoxin genes 
(seb and sec) are carried on SaPI3.135  
On the other hand, several hypotheses to explain the origin and evolution of SaPIs have 
been proposed, between them, Yarwood et al. propose the existence of a common 
ancestral genetic element, probably, a prophage for all SaPIs that then generated 
diversity of islands through modular recombination events.140  
Staphylococcal genomic islands are larger segment of DNA (10–200 kb) commonly 
acquired by horizontal gene transfer.136 The families of genomic islands among the 
S.aureus strains whose genomes have been sequenced, are named ʋSAα, ʋSAβ and 
ʋSAϒ, and are flanked by a broken transposase gene (up-) and partial restriction-
modification system type I (down-). Both flanking DNA segments contribute to the 
stability of genomic islands within the S. aureus chromosome.135,136 Upstream, the 
direct-repeat genes are commonly associated with phages and plasmids and encode for 
both integrases and transposases.136  
Introduction: Staphylococcus aureus: Pathogenesis 
 
44 
ʋSaα carries a lipoprotein gene cluster (lpl) and staphylococcal superantigen-like genes 
(ssl). ʋSAβ (also known as SaPIn3/m3) encodes bacteriocin, enterotoxins, hyaluronate 
lyase, and a serine protease gene cluster. The third, ʋSAϒ, contains genes encoding β-
type PSMs and a cluster of ssl genes similar to that present within mSAa.135,136 
2.3.3 The resistance Island SCCmec. 
Staphylococcal cassette chromosomes (SCC) are considered to be a relatively large DNA 
fragments always insert, on the S. aureus chromosome, into the orfX gene that may vary 
between 15-60 kb. The SCC is other of the MGEs able to carry virulence determinants 
and/or antibiotic resistance, this latter for the expression of broad spectrum beta-
lactam resistance encoded by the mecA gene.2,135,136 Thus, SCC are usually classified 
into two groups: SCCmec and non-SCCmec.,135,136 The SCCmec critical genes are the 
recombinases ccrA and ccrB, which can mediate mobilization of the whole element, and 
are responsible for site-specific integration and excision from the chromosome at 
attBscc.141 And the mecA gene, which mediates β-lactam resistance. The rest of 
SCCmec contains various additional determinants and is referred to as J for junkyard.2  
2.3.3.1 Staphylococcal cassette chromosome (SCC) mec. 
All MRSA strains contain SCCmec, which encodes the mecA gene. Resistance of the S. 
aureus strains to β-lactam antibiotics is expressed by the failure of the methicillin and 
the other β-lactam antibiotics to link a specific low-affinity penicillin-binding protein 
(PBP2a) produced by MRSA, 135,136, thus conferring resistance to methicillin and all β-
lactam antibiotics.142 This SCCmec could have been acquired by S. aureus from S. 
sciuri,136 being necessary for its integration and excision on the S. aureus chromosome, 
a specific attachment site (attBscc) at the 30 end of orfX by recombinases (ccr). 135,136,  
Based on the organization of mec (A, B, C1, C2, D and E),135 of which A–C are the most 
common in S. aureus,136 and the 6 different ccr allotypes, the SCCmec elements have 
been classified into 11 types (I-XI) (Table 2.3.3.1).135 Furthermore, SCCmec types can be 
differentiated into subtypes depending on variations in the J regions.136 These elements 
also differ in what other antimicrobial resistance genes are carried on them. 
Summarizing, types I, IV, V, VI, and VII generally do not carry other resistance genes; 
types II, III, and VIII may contain one or more other resistance genes, such as ermA 
(erythromycin), aadD (tobramycin), and tetK (tetracycline);143 and the last SCCmec type 
identified, type XI has been associated to mecC,144 gene a new variant of mecA.145  
Interestingly, these types are also used to help distinguish CA-MRSA and HA-MRSA 
strains. CA-MRSA strains typically carry SCCmecIV, with some carrying types V and VII 
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elements, whereas HA-MRSA typically contain the larger SCCmecI, II, III, VI, or VIII 
elements143 that may encode resistance determinants in addition to mecA. These 
additional resistance determinants are often encoded by plasmids, transposons, or 
insertion sequences incorporated into the J regions of SCCmec. For example, the J1 
region of SCCmecVIII encodes a putative copper-transport ATPase (copA), and the J2 
region has a Tn554 transposon encoding erythromycin (ermA) and 
streptomycin/spectinomycin resistance (aad9) genes.136 
Table 2.3.3.1 Currently identified SCCmec types in S. aureus strains. 
SCC mec 
types 
ccr gene 
complexes 
mec genes complexes strains 
I 1 (A1B1) B (IS431-mecA-DmecR1-IS1272) NCTC10442, COL 
II 2 (A2B2) A (IS431-mecA-mecR1-mecI) N315, Mu50, Mu3, MRSA252, JH1, JH9 
III 3 (A3B3) A (IS431-mecA-mecR1-mecI) 85/2082 
IV 2 B (IS431-mecA-DmecR1-IS1272) CA05, MW2, 8/6-3P, 81/108, 2314, 
cm11, JCSC4469, M03-68, E-MRSA-15, 
JCSC6668, JCSC6670 
V 5 C2 (IS431-mecA-DmecR1-IS431) WIS(WBG8318), TSGH17, PM1, 
VI 4 (A4B4) B (IS431-mecA-DmecR1-IS1272) HDE288 
VII 5 (C1) C1 (IS431-mecA-DmecR1-IS431) JCSC6082 
VIII 4 A (IS431-mecA-mecR1-mecI) C10682, BK20781 
IX 1 C2 (IS431-mecA-DmecR1-IS431) JCSC6943 
X 7 (A1B6) C1 (IS431-mecA-DmecR1-IS431) JCSC6945 
XI 8 (A1B3) E (blaZ-mecALGA251-mecR1LGA251- 
mecILGA251) 
LGA251 
(http://www.sccmec.org/Pages/SCC_TypesEN.html) 
2.3.3.2 Non-mec staphylococcal cassette chromosome (SCC). 
Non-mec SCC and ψSCC (without or no functional recombinase) contain virulence or 
fitness/survival determinants, but not encode methicillin resistance.,135,136 Thus, in this 
case include SCC-like elements, an ACME, a SCC, and a SCCmec insertion site genomic 
sequence, for what has been suggested that these elements should be described as 
pseudo-SCC elements (ψSCC). Obviously, these SCC-like regions are similar to classic 
SCCmec, so that commonly share the three following characteristics, (i) carriage of 
ccrAB and/or ccrC in a ccr gene complex, (ii) integration at ISS in the staphylococcal 
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chromosome, and (iii) the presence of flanking direct repeat sequences containing an 
ISS. For the nomenclature of such elements, it was recommended to add the suffix 
describing the genes’ names or their functions after SCC.135 As an example, we can have 
SCCHg carries mercury resistance operon. It was probably obtained from CoNS by 
integration of a plasmid that carried the resistance determinant, or by direct transfer of 
the SCCmercury element. If there is no gene carrying inferable functions in the SCC, it is 
recommended to add the name of the strain to the described SCC elements. For 
example, the strains MSSA476 (methicillin susceptible S. aureus strain 476), contains a 
mec-like element (SCC476) that encodes fusidic acid resistance. Moreover, some S. 
aureus strains have been describe to produce capsular polysaccharide 1, confering 
resistance to phagocytosis. The genes encoding synthesis of capsular polysaccharide 1 
are located on a special SCC element named SCCcap1, immobile because of it lacking an 
active ccrA homologue and the ccrB homologue contains a no-sense mutation.,135,136 
2.3.4 Arginine catabolic mobile element. 
The arginine catabolic mobile element (ACME), discovered by sequencing the complete 
genome of USA300,146 encodes a complete arginine deiminase pathway that converts L-
arginine  CO2 + ATP + NH3. Three ACME types have been identified, ACME type I (arc 
and the opp gene cluster), ACME type II (arc gene cluster) and ACME type III (opp gen 
cluster). ACME type I and a truncated form of ACME type II have been identified in S. 
aureus, and exactly in USA300 was ACME type I. ACME is adjacent to SCCmec and 
integrated at the same attB site within orfX. Therefore, it is probably that the 
recombinases that mediate excision of SCCmec also mobilize ACME.146 Actually, five 
novel types of ACME-SCCmec-CI (Composite Island) have been reported from MRSA 
strains with distinct genotypes.147  
Nowadays, it seems that the role played by ACME in the success of USA300 starts to be 
known. Although ACME could not be associated with enhanced virulence of USA300, 
Diep et al.,146 suggest that enhances fitness of S. aureus, likely facilitating colonization 
and/or haematogenous dissemination to target organs.146 On the other hand, 
Montgomery et al.,148 found no significant difference between ACME-positive and 
ACME-negative USA300 strains, in a rat model of necrotizing pneumonia and a mouse 
model of skin infection. Anyhow, the presence of ACME enhances colonization of the 
skin by neutralizing the acidic pH of human sweat,136 and improves S. aureus survival 
and growth on human skin, due to ACME-encoded arginine deiminase system. This 
arginine deiminase system achieves via production of ammonia from L-arginine 
catabolism, and by depletion of L-arginine, only substrate for production of NO via 
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nitric oxide synthase isoform (iNOS)-producing macrophages. Additionally, USA300-
ACME carried speG gene which helps to enhance its fitness. Spermidin N-
acetyltransferase encoded by the ACME-speG gene, counters polyamine toxicity. S. 
aureus exhibits a unique sensitivity among bacteria to this polyamines, USA300 is able 
to survive.147 Indeed, the study of Joshi et al., demonstrated this decisive function in 
fitness by speG gene.149 
Figure 2.3. Atlas of the chromosome of S. aureus USA300 compared to others MRSA.  
 
Reprint from The Lancet [146] with permission from Elsevier. Copyright © 2006 Copyright Clearance 
Center, Inc. All Rights Reserved. 
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2.4 Pathogenesis: Evasion from innate immune defence. 
The first line of defense against invading pathogens in humans is innate immune system. 
This complex system consists mainly of three major effector mechanisms: antimicrobial 
peptides and enzymes, complement system, and phagocytes. The importance and 
efficiency of these effector mechanisms is different depending on the site of infection 
and on bacteria characteristics, as well as the own immune system. In the past, 
leukocytes were considered the main source of molecules involved in inflammatory and 
immunological responses, but eventually it has been shown that other cells could be an 
important source of these mediators. Indeed, lung epithelial cells could modulate the 
inflammatory response in the airways and modulate cell recruitment by producing 
cytokines, chemokines, receptors and adhesion molecules. Similarly, mammary gland 
epithelial cells could produce both cytokines and immunomodulating molecules.150  
The invasion of host tissues and organs by S. aureus triggers a response from innate 
immunity system, which is characterized by a quick response against the pathogen. The 
timing of the immune response is strictly dependent on the first indispensable step: the 
recognition of pathogen associated molecular patterns.150 Additionally, S. aureus should 
adhere to host cell to multiply and, sometimes, even invade host cells,151 then the host 
must reply by the immediate release of antimicrobial components and of 
chemoattractants, while it recruits immune cells for a more efficient response. 
Understandably, bacterial pathogens use very efficient strategies to evade host defenses 
in order to colonize and invade human and animal tissues.151 S. aureus virulence factors 
repertoire, has plenty of mechanisms to evade host innate immunity, including 
modifications of structural component and secretion of a large array of specific immune-
modulating proteins that act in concert to counteract innate immune defenses, and create 
a microenvironment to enable even better survival. S. aureus is also able to avoid Toll-
like receptors (TLR) recognition, and furthermore, their adhesins are quite efficient in 
reducing the effectiveness of complement system and phagocytes, and they have the 
capacity to develop resistance mechanism against host defense peptides, similarly to the 
one developed against conventional antimicrobials.150 Regrettably, S. aureus can also 
survive within an intracellular compartment,152 which may be relevant during persistent 
infections, indeed can be found intracellularly in non-professional phagocytes, either in a 
membrane bound compartment or in the host cytosol.110 Table 2.4 reports a list of the 
known factors involved in S. aureus immune evasion classified by target: complement 
system, neutrophils and phagocytosis, host defense peptides, immunoglobulins and 
opsonins.150  
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Table 2.4. Virulence factors to evade innate immune defenses related to complement, 
leukocyte migration phagocytic activity, immunoglobulins and opsonization. # C: complement; 
SAg: superantigen; PMN: polimorphonucleares; ROS: reactive oxygen species; TNFR: tumoral necrosis factor 
receptor. 
EFFECTOR 
MECHANISM 
EVASION FACTOR  FUNCTION 
Virulence factors to evade innate immune defenses related to complement 
Complement 
inactivation 
Capsular polysaccharides CPSs Alter C3 (CPS5 and 8) or C3b (CPS1) deposition 
Staphylokinase Sak Plasminogen activator 
Staphylococcal complement 
inhibitor 
SCIN Inhibits convertase 
Extracellular complement-
binding protein 
Ecb 
Clamping factor A ClfA Platelets adhesion; binds complement regulator 
factor I 
Surgface protein E SdrE Binds C regulator factor H 
Extracellular fibrinogen-
binding protein 
Efb Binds fibrinogen; inhibits C3 and C5 convertase; 
binds C3 
Virulence factors to evade innate immune defenses related to leukocyte migration and phagocytic activity 
Neutrophil 
migration 
Staphylococcal SAg-like 5 SSL5 Specific binding to P-selectin glycoprotein 
ligand-1 blocking PMNS rolling 
Staphylococcal SAg-like 11 SSL11  
Staphylococcal SAg-like 1 SSl10 Binds chemokine receptors 
Chemotaxis inhibitory protein Chp Blocks C5a receptor and formyl peptide 
receptors 
Staphylococcal SAg-like 7 SSl7 Binds to Fc region of IgA and block recognition 
by neutrophils 
Neutrophil lysis ϒ -toxin Hlg Bicomponent leukocidin; haemolysin 
δ-toxin Hld Cytolytic toxin; binds neutrophils and 
monocytes 
Panton Valentine leukocidin PVL Bicomponent pore-forming; kills leukocytes 
Leukocidins A and B 
(alternative names H and G) 
LukAB/HG Bicomponent pore-forming leukotoxin that kills 
PMNs 
Resistance to 
oxidative stress 
Staphyloxanthin  Carotenoid (protects against ROS) 
Catalase and alkylhydroxide 
reductase 
CatA, AhpC Inactive hydrogen peroxide; pivotal for nasal 
colonization 
Thioredoxin and thioredoxin 
reductase 
 Inactive ROS 
Virulence factors to evade innate immune defenses related to immunoglobulins and opsonization 
Degradation of Ig Protein A Spa Binds Fc domain of Ig, vonWillebrand factor and 
TNFR-1; binds C3 and promoters c3-c3b 
conversion 
Staphylokinase Sak Plasminogen activator 
Cloaking of 
opsonins 
Clamping factor A ClfA Platelets adhesion; binds C regulator factor 1 
Clamping factor B ClfB Platelets activation; binds cytokeratin 10 
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To avoid complement system components, gram-positive pathogens employ several 
proteolytic strategies through specific proteases capable of cleaving C5a or degradation 
of complement system proteins. Notable between these, is the serine protease V8153 and 
the metalloprotease aureolysin,154 which degrade key complement system components, 
including the opsonin C3b and the chemoattractant C5a. (Figure 2.4) Alternatively to the 
degradation of the complement-derived chemoattractant C5a, the neutrophil recruitment 
can be blocked by antagonizing the chemoattractant receptors. This is possible by 
antagonizing of formyl-methionyl-leucylphenylalanine (fMLP) peptides, one powerful 
neutrophil chemoattractants that arise from bacterial protein degradation, and can 
activate high-affinity fMLP peptide receptors on neutrophils. How? Chemotaxis inhibitory 
protein (Chp) is secreted by the pathogen and binds specifically to the fMLP peptide (and 
C5a) receptors to impair their sensing function. Likewise, S. aureus releases FLIPr, 
another virulence factor capable of antagonizing the fMLP peptide receptor to impair 
leukocyte responses to the bacterial-derived chemoattractant agonists.155 (Figure 2.4) 
The next steps to avoid the phagocytic activity, gram-positive bacteria are not sensed 
effectively by extracellular Toll-like receptors (TLRs), but intracellular detection is 
important. TLR family recognition S. aureus invasion triggers a complex mechanism 
through the activation of specific receptors for pathogen associated molecular patterns, 
eventually starting innate immunity response. Recently, a novel mechanism for 
staphylococci to escape the host immune system via interference with recognition by 
immune cells has been identified. Actually, the “phagocytized S. aureus”, have been 
shown to evade detection by limiting phagosome acidification or phagosome fusion with 
granules or lysosome, or by escaping the phagosome altogether, as mediated by toxins 
such as leukocidins.155  
In all of this mechanism, Staphylococcal superantigens-like proteins play an important 
role. These proteins family of molecules are able to interfere with multiple components of 
host immunity, including humoral immunity, opsonization, and trafficking of 
leukocytes.150 Other mechanisms of evading intracellular killing include using protein 
mimicry to immune signaling. On the other hand, S. aureus can be observed 
intracellularly in non-professional phagocytes, membrane bound in a compartment or in 
the cytosol. Respect to this last point, the escape into the host cytosol would involve a 
synergism between δ-haemolysin or PSM and β-haemolysin.152 Curiously, in Cystic 
Fibrosis patients, α-haemolysin is involved in phagosomal membrane lysis in CFTR-
deficient cells.156 (Figure 2.4) 
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Howsoever, S. aureus is able to reply the bacteria to phagocytosis, by inducing the 
oxidative burst response, a key host microbicidal process in which oxygen is consumed, 
and toxic ROS are generated. This pathway is catalyzed by two major reactions in the cell. 
To survive the oxidative burst response, gram-positive pathogens have mechanisms to 
either prevent the production of or dispose of harmful oxidants. Invasive gram-positive 
species like S. aureus, encode a bacterial superoxide dismutase (SOD)157 that accelerates 
conversion of O2  H2O2, and  catalase (Kat) is a common mechanism to oxidize 2H2O2  
O2 + 2H2O.  Whereas, reducing pathways such as thioredoxin systems provide electrons 
to small molecules that can react with H2O2, the tripeptide glutathione can reduce H2O2 
directly.155 
Shortly, other relevant concepts related such as the autophagy, which serves for 
degradation of organelles or self-digestion during nutrient limiting conditions 
(starvation), presumably to constitute a cellular survival mechanism. During bacterial 
infections, eventually, the bacteria escape from their intracellular confinement into the 
host cell cytoplasm in an agr-dependent manner (Figure 2.4), and consequently the host 
cell death is induced. Indeed, agr-deficient S. aureus fails to induce autophagy, which 
results in maturation of bacteria containing phagosomes followed by lysosomal 
degradation of the pathogens. As stated, S. aureus-induced autophagy resulted in a 
vacuolization of the host cell cytoplasm (“Swiss cheese phenotype”). And even more, α-
haemolysis is able to permeabilize membranes for Ca2+, an inducer of autophagy.156 The 
phagocytised bacterial pathogens, also can evade lysosomal killing, e.g., by 
disintegration of the organelle membrane in order to translocate into the host cell 
cytoplasm. This translocation into the cytoplasm of host cell, and the growing without an 
immediately ensuing cell death, illustrates that phagosomal escape is not identical with 
cytotoxicity. The virulence factors required for apoptosis by S. aureus induced in 
endothelial cells, also depend on agr and the alternative stress–response SigB (σB), 
independently of SarA. Aside from apoptosis S. aureus is also able to induce pyronecrosis 
(Figure 2.4).  
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ADAM: Metalloprotease and Disintegrin; Arp2/3: Actin-Related Protein 2 And 3; Atl: Autolysin; Cytc, 
Cytochrome C; Eap: Extracellular Adherence Protein; Fak: Focal Adhesion Kinase; Fnbp: Fibronectin-
Binding Protein; Hla: α-haemolysin; Hsp: Heat Shock Protein; Il: Interleukin; Nfκb: Nuclear Factor Κb; 
Nwasp: Neural Wiskott–Aldrich Syndrome Protein; Pax: Paxillin; Sr: Scavenger Receptor; Vcl: Vinculin; 
WTA: Wall Teichoic Acid. 
Figure 2.4.  A map of intracellular fates of S. aureus. (1) 
α5β1 integrins are sequestered by Fnbp-dependent 
fibronectin cross-linking at focal adhesions. (2) Bacteria are 
eventually endocytosed. (3) Assembly of Hla pores on the 
plasma membrane of host cells leads is dependent on 
ADAM10. Hla-pores are permeable for cations. [Ca2+ has been 
reported to induce macroautophagy]. (4a) Bacteria are 
disinfected by phagolysosomes or (4b) survive and grow within 
endosomes or (4c) in the cytoplasm after phagosomal escape. 
(5a) Phagosomal escape can be mediated by Hla, in Cystic 
Fibrosis cells, and (5b) also by a combination of PSMs and 
phospholipases. (6) Cytoplasmic S.aureus peptidoglycan is 
recognized by NOD2. (7) The mode of cell death induced by 
S.aureus is not completely understood. While caspase-
independent cell death exists, Hla is capable of inducing 
extrinsic apoptosis. Up on Hla induced K+ efflux caspase2 has 
recently been shown to lead to mitochondrial outer membrane 
permeabilization. (8) PVL has been reported to permeabilize 
mitochondrial outer membrane thereby releasing cytochrome c 
and thus inducing the apoptosome in a Bax-independent 
pathway of intrinsic apoptosis. Caspase 9 subsequently 
activates executioner caspases. (9) Cathepsin release from 
permeabilized phagosomes activates the inflammasome. 
Activated caspase1 leads to Il1β maturation and inflammatory 
pyro-necrotic cell death. (10) Toxin-permeabilized endocytic 
vesicles are targeted by autophagy. During autophagy isolation 
membrane engulfs leaky endosomes or cytoplasmically located 
bacteria. Within these autophagosomes bacterial replicate and 
eventually escape the organelle ultimately lead into host cell 
death. Reprint from [156] with permission from Frontiers Group. 
Copyright © 2007 - 2015 Frontiers Media S.A. Creative 
Commons Attribution License. All Rights Reserved. 
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“The spread of highly virulent CA-MRSA is a major concern. Increased prevalence of 
leukotoxins, such as PVL, and increased expression of membrane-damaging factors, such 
as α-haemolysin and PSMs, have been observed in these strains”.110
 
 
Over decades, haemolysis and leukotoxicity have been highlighted as the major role of 
these virulence factors, and increasingly it is clear that the membrane-damaging toxins 
and peptides could have other functions besides killing host cells. Certainly, in vitro 
studies, suggest that these virulence factors are secreted in response to different 
environmental signals or at different stages during colonization or infection, and that this 
differential diffusion of the toxins and peptides within tissues could lead to different 
functions.110 Study of the interaction between these virulence factors and host cells in 
more physiological models should provide us novel important findings.  
 
 
3 Antibiotic Resistance. 
S. aureus is a magnificent example of evolving pathogen, this organism has been shown 
an effective adaptation to the changing conditions of the surrounding medium, and 
therefore, from the point of view of the pathogenicity and the evolution to antimicrobial 
resistance, is regarded as the evolutionary paradigm progression. S. aureus has been able 
to develop resistance to virtually all antibiotic classes available for clinical use. These 
encompass cell wall inhibitors such as β-lactams and glycopeptides; ribosomal inhibitors 
that include macrolide-lincosamide-streptogramin B (MLSB resistance), aminoglycosides, 
tetracyclines, and the new oxazolidinones; the RNA polymerase inhibitor rifampicin; the 
DNA gyrase blocking quinolones; the antimetabolite trimethoprim-sulfamethoxazole; and 
the newer lipopeptides and lipoglycopeptides.2 The main resistance mechanisms are 
summarized in Table 3. Some are discussed subsequently. 
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Table 3. Antimicrobial resistance genes and mechanism in S.aureus. 
ANTIBIOTIC RESISTANCE 
GENE(S) 
GENE PRODUCT(S) MECHANISM(S) OF RESISTANCE RESISTANCE TO LOCALIZATION 
Inhibitor(s) of cell wall synthesis 
β-lactams blaZ β-lactamase Enzymatic hydrolysis of β-lactam ring. Inactivation. Penicillins Plasmid: Transposon 
mecA, mecC144 PBP2a  PBP2 modified with reduce affinity. Modified Target. Penicillins, cephalosporins, 
monobactams, carbapenems 
Chromosome: SCCmec 
Glycopeptides Mutations in 
vraRS, rpoB? 
Altered peptidoglycan Trapping of vancomycin in the cell wall. Cell wall 
thickness: VISA. 
Vancomycin Chromosome 
vanA, vanH? D-Alanine-D-Lactate Reduce affinity. Modified target: VRSA Vancomycin Plasmid: Transposon 
Lipoglycopeptides vanA, vanZ? D-Alanine-D-Lactate Unknown Oritavancin Plasmid: Transposon 
Lipopeptides Mutation in 
mpfR, dltA.  
Multifactorial Change in the cell membrane charge. Decrease drug 
binding. 
Daptomicin Chromosome 
Bacitracina158 braDE, vraDE ABC transporters BraS/R-two-CS (Bacitracin resistance associated) 
responds to low bacitracin concentrations.  
Bacitracin Chromosome 
Fosfomycin159 fosA, fosB, fosX Glyoxilases Ring opening of the epoxide motif. Inactivation Fosfomycin Chromosome and 
Plasmid 
Inhibitor(s) Proteins Synthesis 
Aminoglycosides ant(4´)-Ia 
 
O-Adenyltransferases  (ANT) 
 
Catalyzes ATP-dependent adenylation of hydroxyl 
group  
 
Tobramycin, amikacyn Plasmid. Plasmid: 
Transposon 
aph(3´)-IIIa 
 
O-Phosphotransferases  (APH) 
 
Catalyzes ATP-dependent phosphorylation of a 
hydroxyl group 
 
Kanamycin, neomycin, 
amikacyn, gentamicin,  
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aac(6´)-
Ie+aph(2´´) 
 
N-Acetyltransferases  (AAC) 
 
Catalyzes acetyl CoA-dependent acetylation of an amino 
group 
 
Gentamycin, tobramycin, 
amikacyn 
Macrolide-
lincosamide-
streptogramin 
msrA, msrB MsrABC pump Active efflux Macrolides, streptogramin B 
(MSb) 
Plasmid or 
chromosome 
lnu Nucleotidyltransferase Inactivation Lincosamines 
vgb Phosphorilases Inactivation.  Macrolides, streptogramin B 
(MSb) 
ermA, ermB, 
ermC, (ermT or 
ermY).  
Erythromycin methylase Methylation of ribosome. Reduce binding to the 23s 
ribosomal. 
 
Macrolides, lincosamines, 
streptogramins (MLSb) 
Plasmid or 
chromosome 
Quinoprustin 
/Dalfopristin 
vat Acetyl transferases Enzymatic modification of dalfopristin Streptogramin A Plasmid 
vga ATP-binding cassette (ABC) 
transporters  
Active efflux. 
Oxazolinones rrn 23sRNA Mutations in domain V of 23S rRNA component of the 
50S ribosome. Interferes with ribosomal binding. 
Linezolid Chromosome 
cfr 23S rRNA methylase Methylation of ribosome. Modified target. Linezolid, chloramphenicol, 
streptogramins, 
lincosamides 
Plasmid 
Tetracyclines tetK, tetL Efflux pump Active efflux. Tetracyclines Plasmid or 
chromosome 
tetM, tetO Ribosome protecting protein Protection of drug target Tetracyclines, minocyclines 
Fusidic Acid160 Mutation in 
fusA, fusE 
Elongation factor EF-G (fusA) 
and RNApol RplF (fusE) 
Reduce affinity. Modified target. Fusidic ac. Chromosome 
fusB, fusC, fusD  Protection of drug target Plasmid 
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Chloramphenicol cat Chloramphenicol-acetyl 
transferase 
Inactivation Chloramphenicol Plasmid or 
chromosome 
fexA Efflux pump Active efflux of phenicoles. Florphenicol, 
chloramphenicol 
Chromosome 
Mupirocin161 Mutation in ileS Isoleucyl tRNA synthetase Low resistance (MuL) Reduce affinity. Modified 
target. 
Mupirocin Chromosome 
mupA, mupB162 High resistance (MuH) Plasmid 
Inhibitor(s) of metabolites 
Sulfonamides Mutations in 
dpsA,  
Dihidro-pholate synthetase 
(DHPS) 
DHPS with reduce affinity. Modified target. 
Overproduction of PABA (p-aminobenzoic ac) 
Sulfonamides 
(sulfamethoxazole, etc) 
Chromosome. 
Plasmid? 
Trimethoprim/ 
sulfamethoxazole 
Mutations in 
dfrA 
Dihidro-pholate reductase 
(DHFR) 
DHFR with reduce affinity. Modified target. Trimethoprim Chromosome, Plasmid 
Inhibitor(s) of nucleic acids function or synthesis 
Quinolones163 Mutations in 
grlA (parC), 
grlB  (parE) 
parC and parE, components of 
topoisomerase IV 
Mutations in the quinolones-resistance-determining-
region QRDR, reducing affinity of enzyme-DNA complex 
for quinolones. Modified target. 
Stepwise resistance. 
 
 
1st generation of quinolones 
(nalidixic ac, etc) 
2nd generation, 
fluorquinolones (norfloxacin, 
ciprofloxacin, etc) 
Chromosome 
Mutations in 
gyrA, gyrB 
gyrA, gyrB  component of 
gyrase 
norA, norB, norC Efflux pump Active efflux of hydrophilic quinolones. Quinolones, fluorquinolones Chromosome 
Rifampicin Mutations in 
rpoB 
β-subunit of RNA  polymerase RNA polymerase with reduced affinity Rifampicin, vancomycin? Chromosome 
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3.1 β-Lactams. 
β-lactams are inhibitors of bacterial growth. They act by irreversible inhibiting of 
penicillin-binding proteins (PBPs) via preventing the final cross-linking (transpeptidation) 
step in the synthesis of the peptidoglycan, and thus, they disrupt the cell-wall synthesis. 
Penicillin and other β-lactams are steric analogs of the cell wall precursors D-alanine- D-
alanine terminal. They compete with it for binding to the active site of the membrane-
bound transpeptidase and act as mechanism-based inhibitors of PBP coined for these 
enzymes.2 
In S. aureus, three different mechanisms of resistance has been identified, (i) enzymatic 
inactivation by β-lactamases or penicillinases, (ii) alteration on PBPs, and (iii) tolerance 
phenomena which affect to all β-lactams too.1 Tolerant microorganisms have reduced 
autolytic activity, and in the case of staphylococci, the experiments indicate that this is 
due to an excess of an autolysin inhibitor. Hence, tolerance is manifested as an increased 
resistance to the lethal, rather than the inhibitory, action of β-lactams.164  
3.1.1 Resistance to Penicillin. 
The most common resistance mechanism of S. aureus to β-lactams is penicillinase 
production, encoded by the blaZ gene, usually carried on a plasmid. The gene is 
inducible and proceeded by the blaR1 and blaI regulatory determinants. Penicillinase is 
a secreted enzyme that hydrolyses penicillin and other penicillinase-susceptible 
compounds into inactive penicilloic acid (Figure 3.1.a). Penicillinase-producing S. 
aureus emerged rapidly after penicillin was introduced as a therapeutic agent in the 
mid-1940s. It is prevalent both, in the hospital and in the community, where it 
represents >95% of the isolates.2,165 
3.1.2 Mechanism of Methicillin Resistance. 
The first penicillinase-stable β-lactams such as semisynthetic methicillin, nafcillin or 
cephalosporins became available in the late 1950s. Ironically, the first MRSA was 
described at about the same time. The prevalence of MRSA progressively increased 
thereafter, and nowadays MRSA constitutes 25–50% of clinical isolates in the North 
America, Europe and Asia.165  
Higher-level β-lactam resistance (MRSA) results from the acquisition of the mecA gene, 
which encodes the penicillin-binding protein 2a (PBP2a) whose genes is controlled by 
the MecR-MecI-MecA regulatory systems,165 which responds to β-lactam antibiotics in a 
fashion similar to that of the regulation of blaZ. PBPs are membrane-bound enzymes 
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that catalyze the transpeptidation reaction that is necessary for cross-linkage of 
peptidoglycan chains. Their activity is similar to that of serine proteases, from which 
they appear to have evolved. PBP2a substitutes for the other PBPs and, because of its 
low affinity for all β-lactam antibiotics, enable staphylococci to survive exposure to high 
concentrations of these agents. Thus, resistance to methicillin confers resistance to all 
β-lactam agents, including cephalosporins.141 (Figure 3.1.b) 
Figure 3.1 (a) Induction of staphylococcal β-lactamase synthesis in the presence of the β-lactam 
antibiotic penicillin. (i) The BlaI binds to the operator region, repressing RNA transcription from both 
blaZ and blaR1-blaI. In the absence of penicillin, β-lactamase is expressed at low levels. (ii) Binding of 
penicillin to the transmembrane sensor-transducer BlaR1 stimulates BlaR1 autocatalytic activation. 
(iii)–(iv). Active BlaR1 either directly or indirectly (via a second protein, BlaR2) cleaves BlaI into inactive 
fragments, allowing transcription of both blaZ and blaR1-blaI. (v)–(vii) β-lactamase extracellular (v), 
hydrolyzes the β-lactam ring of penicillin (vi), thereby rendering it inactive (vii). (b) Mechanism of S. 
aureus resistance to methicillin. Synthesis of PBP2a proceeds in a fashion similar to that described for 
β-lactamase. β-lactam antibiotic induces MecR1 synthesis. MecR1 inactivates MecI, allowing synthesis 
of PBP2a. MecI and BlaI have co-regulatory effects on the expression of PBP2a and β-lactamase.  
Reprint from [141] with permission from American Society for Clinical Investigation. Copyright © 2003 
Copyright Clearance Center, Inc. All Rights Reserved. 
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Provision of this adequate substrate to PBP2a requires the functionality of numerous 
accessory genes implicated in the normal wall building,165 some of which, femABCD  
essential factors for the expression and fmhB, are responsible for adding the glycine 
residues critical for the PBP2A function.1 Any alteration in these elements decreases the 
expression of methicillin resistance, even though PBP2a is present. Another fragility of 
PBP2a is that it carries only a transpeptidase domain and misses a transglycosidase 
activity. Thus, for successful assembly of the peptidoglycan, PBP2a needs to hijack the 
transglycosidase domain of normal staphylococcal PBP, namely PBP2.166 This is a salient 
example of heterologous protein cooperation in antibiotic resistance, but also 
represents the ’Achilles’ heel of the system. According to that, successful treatment of 
experimental endocarditis from MRSA achieved with an array of older and newer β-
lactams with good PBP2a affinity could be explained. This approach is a driving force for 
the development of new anti-MRSA compounds, or the re-using of older β-lacatms.2 
As noted, the mecA gene is invariably part of a larger unique MGE, SCCmec, which may 
also contain additional genes for antimicrobial resistance and insertion sequences, as 
well as genes of uncertain function.141 These elements include, transposons such as 
Tn554, which carries resistance genes for spectinomycin and erythromycin, or 
integrated plasmids such as pUB110, which encodes tobramycin and kanamycin 
resistance among others.167  
The different situation about the full-resistance to β-lactams, classified different types 
of strains: (i) higher-producing to β-lactamases, (ii) borderline oxacillin resistant 
mecA(+) strains, BORSA showing heterogeneous resistance, (iii) intermediate level of 
resistance to methicillin due to production of modified (PBP1, PBP2) or normal (PBP4) 
PBPs, achieving a reduced affinity for beta-lactams, and mecA (-), called MODSA,168 (iv) 
cefoxitin/oxacillin susceptibles mecA (+) OS-MRSA,169 and (v) the own MRSA. 
3.2 Glycopeptides. 
In susceptible strains, glycopeptides inhibit cell wall through hydrogen bond interactions 
with the terminal D-alanyl-D-alanine moieties of the N-acetyl-muramic acid/N-acetyl-
glucosamine (NAM/NAG)-peptides, and block both transpeptidation and 
transglycosylation. As a general rule, current glycopeptides are less effectives than β-
lactams against MSSA. Thus, they should not be used as first-line treatment against β-
lactam–susceptible organisms. However, vancomycin is still a "gold standard" against 
severe MRSA infections, until proof is found of newer anti-MRSA drugs, such as 
daptomycin, linezolid and anti-MRSA β-lactams. 
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The first strains of S. aureus with reduced susceptibility to vancomycin were reported at 
1997 in Japan.170 Strains considered to have reduced susceptibility include (i) 
vancomycin-resistant S. aureus (VRSA), characterized by minimum inhibitory 
concentration (MIC) >16 μg/ml, (ii) vancomycin intermediate S. aureus (VISA), 
characterized by MIC = 4–8 μg/ml, and (iii) heterogeneous vancomycin-intermediate S. 
aureus (hVISA), defined as the presence of isolated populations of VISA at the rate of 1 
organism per 105–106 organisms susceptible to vancomycin.14 Both phenotypes have 
been already reported in clinical isolates and might show different clinical and 
epidemiologic relevance. 
3.2.1 Intermediate Resistance to Glycopeptides: GISA / hGISA. 
This first isolate detected to have reduced susceptibility to vancomycin (MIC = 8μg/ml, 
detected by standard broth dilution methods) was called Mu50.170 At that time, the 
Clinical and Laboratory Standards Institute (CLSI, formerly National Committee on 
Clinical Laboratory Standards [NCCLS]) defined for staphylococci: "MIC of vancomycin < 
4μg/ml as susceptible, MIC = 8-16 μg/ml as intermediate, and MIC > 32 μg/ml 
as resistant". Therefore, the Mu50 isolate was defined as a vancomycin (or glycopeptide) 
intermediate S. aureus (GISA). The same author reported a second S. aureus, called Mu3, 
where the vancomycin MIC for this isolate was 4 μg/ml, formally considered as 
susceptible. However, Mu3 contained VISA subpopulations (≤10−6 colony-forming unit 
[CFU]) that grew in the presence of 5 to 9 μg/ml of vancomycin and were not detected 
with standard drug-susceptibility testing. The term heteroresistant (hGISA) was coined 
to define the Mu3 phenotype. Since then, a number of cases of VISA (GISA) and hVISA 
(hGISA) were described worldwide, and were associated with vancomycin treatment 
failures both in animal experiments and in human cases.171   
The VISA (GISA) may cause glycopeptide treatment failure, because of its low level of 
resistance, and sometimes its heterogeneous phenotype makes it hard to detect in the 
laboratory. The brain-heart-infusion (BHI) screen agar with 4 μg/ml vancomycin and 
casein (BHI-V4), together a 0.5 McFarland inoculum keep on being the best sensitivity 
and specificity combination (90% sensitive and 95% specific with a 0.5 McFarland 
inoculum and 100% sensitive and 68% specific with a 2.0 McFarland inoculum), easy to 
perform, which should be useful for clinical detection of hVISA. BHI-V3 (3 μg/ml of 
vancomycin) and BHI-V4 agars provide more precise identification of hVISA and VISA, 
respectively, and they may be reasonable alternatives to gold standard PAP/AUC 
(Population Analysis Profile / Area Curve).172 
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All these GISA showed a thickened cell-wall that contained an increased number of free 
uncrosslinked D-Alanine-D-Alanine terminals, which was thought to act as a shill-lure 
and trap glycopeptide molecules before they reach their target (Figure 3.2.a).141 Recent 
genomic analyses indicate that mutations in a two-CS, vraSR, graSR and tcaRAB, could 
be involved.173 However, other studies over clinical VISA isolates implicated to the 
walkR, vraSR, and rpoB genes. Watanabe et al., 174 showed that most of the VISA strains  
carried mutations in the RNA polymerase gene rpoB. Regardless, in most, but not all 
cases, the relevant mutated genes appear to be directly or indirectly involved with the 
biosynthesis/metabolism of the staphylococcal cell wall, specifically two-CS that control 
the transcription of genes in cell wall synthesis. 
3.2.2 Full Resistance to Glycopeptides: GRSA. 
In 2002, the first vancomycin-resistant S. aureus (VRSA) strain (with a vancomycin MIC 
≥ 32 μg/ml) was reported in the United States. Clearly using vancomycin against such 
isolates would be impossible.175 The strains carried plasmid-borne copies of the 
transposon Tn1546, which was acquired from vancomycin-resistant Enterococcus 
faecalis (VREF). The mechanism of resistance identified in Tn1546 was shown to involve 
alteration of this dipeptide residue from D-Alanine-D-Alanine to D-Alanine-D-Lactate, 
a dipeptide with substantially lower affinity for the antibiotic,174 which in the presence 
of vancomycin, allowing to continue the peptidoglycan assembly (Figure 3.2.b). Hence, 
resistance in VRSA occurs via specific modifications of the peptidoglycan cell wall target 
and is mediated by the VanA operon. This VanA operon is carried on the mobile genetic 
element Tn1546 in Enterococcus and can be transferred to a recipient S. aureus strain 
by transconjugation. Notably, all characterized USA VRSA strains belong to the S. aureus 
CC5 phylogenetic lineage.176 Most strains appeared in a unique epidemiological 
scenario in diabetic wounds of patients that were infected by both vancomycin-resistant 
enterococci and VRSA.  
3.2.3 High Vancomycin MIC susceptibility. 
Besides of hVISA and VISA, one high number of changing patterns of vancomycin MICs 
have been significantly reported regarding the S. aureus population. This has been 
partly driven by studies demonstrating poorer outcomes of vancomycin treatment for 
MRSA infections, even when these MICs are within the susceptible range. This changing 
pattern has been referred to as ‘MIC creep’. The data suggest that the phenomenon of 
elevated vancomycin MICs, now appears to be common to all geographical regions. 
Consequently, vancomycin ‘MIC creep’ will likely further cause concerns as time 
progresses, and the absence of high-level resistance to vancomycin is not noteworthy. 
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Regardless, ‘MIC creep’ may be still overcome, with appropriate and adequate drug 
dosing regimens, wherever possible.177 
Figure 3.2 Mechanisms of S. aureus resistance to vancomycin. (a) These VISA strains synthesize 
additional quantities of peptidoglycan with an increased number of D-Ala-D-Ala residues that bind 
vancomycin, preventing the molecule from getting to its bacterial target. (b) VRSA strains are 
resistant to vancomycin because of the acquisition of the vanA operon from Enterococcus, which 
synthesizes one new dipeptide with a dramatically reduced affinity for vancomycin.  
Reprint from [141] with permission from American Society for Clinical Investigation. Copyright © 2003 
Copyright Clearance Center, Inc. All Rights Reserved 
(a) 
 
(b)  
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3.3 Linezolid and new oxazolidinones. 
The oxazolidinone linezolid is another essentially bacteriostatic antibiotic, inhibitor of the 
elongation of protein synthesis and only active against gram-positive bacteria. It was 
approved in the USA for complicated skin and soft tissues infection and nosocomial 
pneumonia from susceptible organisms, including MRSA. Linezolid inhibits, as 
clindamycin, the secretion of TSST-1 and other toxins, thus should be considered against 
toxin-associated infections including CA-MRSA hemorrhagic pneumonia.178 The 
published guidelines for the treatment of MRSA consider linezolid an alternative first-line 
agent for MRSA pneumonia.  
Linezolid resistance has been reported episodically in clinical settings. It is primarily the 
result of mutations in the 23S rRNA gene.179 Staphylococci harbors 6-7 copies of rRNA 
genes, so that mutations in only one of them do not yield high-level resistance at once. 
MICs increments are progressive, and MICs of such mutants are usually 4 to 8 μg/ml 
compared with a baseline of 2 μg/ml. However, plasmid-mediated high-level resistance 
was recently detected in one clinical isolate of S. aureus and one of S. epidermidis (MIC, 8 
and >257 μg/ml, respectively).180 The resistance gene involved, cfr, encodes a 23S rRNA 
methylase that confers cross resistance to other drugs that bind at the same site, 
including chloramphenicol, lincosamides (i.e., clindamycin), and streptogramin A. Though 
as yet anecdotal, this plasmid-mediated resistance to linezolid is potentially 
transmissible to other organisms, and might become a clinical problem.181 
Tedizolid phosphate, a prodrug of the active agent tedizolid or torezolid, has been 
recently approved by the FDA (Food and drug administration) for indication in the 
treatment of acute bacterial skin and skin structure infections. Tedizolid, a next 
generation oxazolidinone, is one of a very few prospective agents with a spectrum of 
activity including both, MRSA and vancomycin resistant Enterococcus (VRE). Similar in 
many ways to linezolid, tedizolid possesses several potential advantages over linezolid, 
by the moment, in the case of linezolid resistance mediated by cfr, tedizolid potency 
remains nearly unaffected.182 
3.4 New Tetracyclines: Tigecycline. 
Tigecycline is a modified minocycline, from the tetracycline family, also a bacteriostatic 
and protein synthesis inhibitor antibiotic, which acts by binding to the 30S ribosomal 
subunit of bacteria and thereby blocking entry of aminoacyl-tRNA  into the A site of the 
ribosome during translation. It is almost universally active against gram-negative and 
gram-positive pathogens, with the notorious exception of Pseudomonas aeruginosa and 
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a few other gram-negative organisms that can extrude the drug via efflux pumps.183 It 
was approved in the United States and Europe for the treatment of complicated skin and 
soft tissues infection. However, the recent MRSA guidelines do not include tigecycline, 
because the FDA’s september 2010 Safety Statement described one increased overall 
mortality among patients with serious infections treated with tigecycline (4%) vs 
comparator therapy (3%), although it is recommended as a second- or third-line agent 
for MRSA infections when alternative agents cannot be used. Besides, because of its low 
plasma drug concentrations, its bacteriostatic activity and higher mortality rates, 
tigecycline should not be used in patients with MRSA bacteremia, therefore it has not 
been included in the recent IDSA-MRSA treatment guidelines.181 
The resistance has only been described in Klebsiella pneumoniae by mutations in acrR. 
efflux pump AcrAB is regulated by its local transcriptional repressor AcrR, and a global 
transcriptional activator RamA. High-level expression of acrAB can result from mutation 
in acrR and up-regulation on ramA.184 Moreover, tigecycline overcomes current S. aureus 
tetracycline-resistance mechanisms, including ribosome protection and active efflux, and 
thus is effective against all tetracycline-resistant isolates. 
3.5 Other Antibiotic Resistance. 
3.5.1 Macrolide-Lincosamine-Streptogramin B Antibiotics. 
The macrolide-lincosamide-streptogramin B (MLSB) family, bind to the bacterial 
ribosome and block protein synthesis. Resistance proceeds by any of the three classic 
mechanisms: (i) modification of the bacterial drug target by methylation or mutation (as 
detail below), (ii) modification-inactivation of the drug itself by phosphorilases (vat and 
vgb genes),1 and (iii) decreasing intracellular accumulation of the drug controlled by the 
Msr(A) pump, which is coded by the msr(A) or msr(B) gene,185 conferring resistance to 
macrolides and type B streptogramins (MSb phenotype). Ribosome modification and 
drug efflux are the most frequent resistance mechanisms in S. aureus.2  
Ribosome modification, is mediated by the erm gene (erythromycin methylase), being 
the most common ermA and ermC for S. aureus, and conferring MLSb phenotype. 
The erm genes are preferentially located on MGEs such as transposons (e.g., 
Tn554 and ermA) or plasmids (e.g., pE194 and ermC). The expression of erm is 
inducible,186 that means, the erm product is synthesized only in the presence of 
inductive drugs (macrolides). Mutations that result in constitutive erm expression 
(consititutive-cMLSb phenotype), confer global resistance MLSB.187  
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Quinupristin-dalfopristin (Q/D), a combination of streptogramin B and A respectively, 
active against MLSB-resistant staphylococci, has showed an excellent in vitro activity 
against S. aureus, including MRSA, VISA and VRSA, being an alternative to vancomycin 
for the treatment of MRSA infections. Although Q/D resistance among S. aureus clinical 
isolates is rare, one case was reported in China, caused by a combination of ermA–
ermB–ermC–msrA–msrB–vatC–vgaA genes.188 
3.5.2 Quinolones. 
Quinolones, are an important class in the anti-infective armamentarium that originated 
in the 1960s as a byproduct from the synthesis of antimalarial quinines. Known 
quinolone-resistance mechanisms result from chromosomal mutations. Plasmid-
mediated resistance has been described in gram-negative pathogens and is associated 
with the qnr gene, which protects the quinolone targets. A qnr-like gene has been 
described in Enterococcus faecalis, and could confer resistance to S. aureus,189 however 
such a mechanism has not been described in clinical isolates yet. 
Quinolone resistance proceeds by two types of mechanisms, including overexpression 
of the efflux pump NorA,190 and structural mutations in the quinolone targets 
topoisomerase IV (grlA and grlB) and gyrase (gyrA and gyrB) genes.191 Resistance is 
acquired stepwise. A first grlA mutation, (10−7 - 10−8 frequency) , produces a moderate 
increase in MIC (e.g., from 0.5 to 2 μg/ml of ciprofloxacin) and is still considered 
susceptible. However, this first mutation paves the way to a second mutation in 
the gyrA gene, which combined with the grlA mutation results in high-level resistance. 
Therefore, prevention of first-level quinolone resistance by ensuring appropriate drug 
levels in the tissues is important.2 Recently, a new mutation of GyrB has been involved 
in high-level resistance to third-generation quinolones.192  
The prevalence rate of quinolone resistance in health care-acquired -MRSA has been 
around 90% for a long time and is close to 40% in CA-MRSA, which makes older and 
newer quinolones mostly inappropriate against MRSA.2 
3.5.3 Lipoglycopeptides and Lipopeptides. 
Lipoglycopeptides:  dalbavancin, oritavancin and telavancin, are semisynthetic 
derivatives of glycopeptides. Like vancomycin, they bind to the D-Alanine-D-Alanine 
inhibiting both transpeptidation and transglycosylation.2 Oritavancin also inhibits RNA 
synthesis. Their lipophilic nature allows the molecules to interact with the plasma 
membrane, which leads to dispersion of membrane potential and rapid bacterial killing. 
Isolates producing peptidoglycan precursors terminating in D-Lactate may exhibit 
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resistance to oritavancin if all precursors terminating in D-Alanine are eliminated, and 
the expression of the vanZ gene of the vanA gene cluster also results in resistance to 
oritavancin (MIC > 8 μg/ml) via an unknown mechanism. Anyhow, the selection of 
dalbavancin resistance among staphylococci is slower than that with vancomycin. 
Dalbavancin and telavancin are active against VISA and oritavancin is active against both 
VISA and VRSA.193 
Daptomycin is a lipopeptide and an amphophilic molecule that requires calcium to 
solubilize as octamer-micelles in liquid phases,194 necessary to interact with the plasma 
membrane and destabilize its electric potential.195   It is proposed as a replacement for 
vancomycin against MRSA, especially in right-sided infective endocarditis.2 The 
mechanisms of resistance to daptomycin might involve more than one mechanism, 
including (i) increased cell membrane fluidity, (ii) significantly reduced susceptibility to 
cationic host defense peptides of platelet and leukocyte, and (i) altered expression of 
two key determinants of net positive surface charge, either during exponential or 
stationary growth phases. DltA gain-in-function, reflected by a significant increase in 
teichoic acid D-alanylated content, and MprF gain-in-function, reflected by a 
heightened elaboration of lysinylated phosphatidylglycerol. Taken together, S. aureus 
appears to involve multi-factorial and strain-specific adaptive mechanisms for 
resistance to daptomycin.  This issue is especially relevant to MRSA strains in the 
context of invasive endovascular infections.196 
 
4 Characteristics of CA-MRSA. 
The emergence of CA-MRSA as an important pathogen has occurred over the past 15–20 
years.197,198 The first cases described, 1997-1999, were associated with necrotizing 
pneumonia or pulmonary abscesses and sepsis100 with a resolution rapidly fatal. The 
strain responsible was USA400 (also known as the MW2 strain).199 Subsequently, clonal 
outbreaks of skin and soft-tissue infections caused by CA-MRSA were also reported.100 
This time, the strain responsible was USA300.200 These CA-MRSA, both ST8, appear to 
have enhanced virulence, enhance capacity to colonize multiple body sites and to survive 
on environmental surfaces,98,146 as well as one important characteristic, their 
transmissibility due to their small SCCmecIV. Although cases of pyomyositis, purpura 
fulminans with toxic shock syndrome, and Waterhouse-Friderichsen syndrome,100 were 
described, their fatality is due to necrotizing fasciitis and necrotizing pneumonia, 
associated especially to USA300.  
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Pointing out, CA-MRSA is different from health care-acquired (HCA)-MRSA, from both 
epidemiologic and molecular points of view, as well as for clinical syndromes.201 Health 
care-acquired -MRSA is associated with risk factors that included recent hospitalization 
or surgery, living in a nursing-home, or carrying an indwelling catheter or device, 
producing mostly hospital-related pneumonia and bacteremia. Otherwise, CA-MRSA is 
not associated with any risk factors, and produces primarily skin and soft tissue 
infections, recently necrotizing fasciitis and bone and joint infections and sometimes 
rapidly fatal necrotizing pneumonia.202 In addition, health care-acquired-MRSA is 
multiresistant and highly clonal, whereas CA-MRSA is pauciresistant and seemingly more 
polyclonal,111 except for USA300 clone.203 Thus, health care-acquired-MRSA and CA-
MRSA are not alike. Practically, MRSA in patients at risk is likely to be of the multiresistant 
hospital type, whereas MRSA in patients without risks is likely to be more susceptible but 
more invasive. 
4.1 Genetics of methicillin resistance in S. aureus and CA-MRSA clones. 
Aforementioned in a previous chapter, the main characteristic of CA-MRSA is the 
acquisition of a MGE SCCmec of smallest size,204 usually SCCmecIV (sometimes 
SCCmecV), and especially the strains that cause virulent infections. The capacity to 
acquire novel elements have been and is essential to the success of these clones, so 
much as to its transmissibility, as well as to its adaptation or evolution, which has also 
permitted them to hold over time (Figure 5.1). 
"The evolution of virulence in S. aureus clones and lineages is frequently only analyzed in 
terms of acquisition or loss of virulence-associated genes. However, significant changes 
in virulence may arise from minute changes in the genome and all of these changes 
contribute to the evolution of highly virulent CA-MRSA. The peculiar in all CA-MRSA, is 
the higher expression of PSMs and α-haemolysin (Hla) compared to HA-MRSA strains, 117 
likely or at least in part due to the high activity in CA-MRSA of Agr, which controls 
expression of most S. aureus toxins and has a strong impact on CA-MRSA virulence".205 
4.2 CA-MRSA transmissibility and fitness. 
CA-MRSA isolates carry SCCmec elements of type IV or V, which may be associated with 
lower fitness costs105 due to smaller size, so that they may also show increased 
transmissibility and colonization characteristics. Although, the "in vitro206 vs in vivo"202 
studies have been dissimilar in this aspect about the fitness. Actually, the fact that all 
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CA-MRSA strains detected so far harbour one type of the novel, short SCCmec type IV or 
V, indicates that they played a crucial role in the evolution of CA-MRSA. 
On the other hand, although there is only limited data, this potentially increased 
colonization capacity present in CA-MRSA is related to the presence of the ACME, exactly 
ACME-speG gene, which encodes a spermidin acetyltransferase gene that transfers 
resistance to spermidin and other polyamines molecules.147 Thus, the synthesis of this 
speG, could serve to explain augmented colonization capacity in USA300, since the 
exceptional sensitivity towards polyamines is only abolished in ACME-containing strains. 
Briefly, SpeG detoxifies polyamines and may, thus enhance survival of USA300 on the 
human skin.105 
4.3 CA-MRSA virulence. 
Many studies about the virulence of CA-MRSA, where MSSA infections vs MRSA infections 
are compared, have been published. To date, there is no compelling evidence that MRSA, 
in general, is more virulent than MSSA. Although the issue remains unresolved, invasive 
MRSA infection is associated with greater costs, limited treatment options100 and worse 
Figure. 4.1. Evolution of CA-MRSA. The acquisition of SCCmec Type IV (or V) by virulent strains 
appears to have been a common first step in the evolution of CA-MRSA strains. In some strains, 
USA300, additional steps were required. These additional steps may have involved adaptations of gene 
expression. Uptake of SCCmec type IV by a virulent ST8 strain resulted in a virulent MRSA strain 
(USA500), whose fitness was further improved by uptake of ACME. Acquisition of PVL-encoding genes 
appears to have increased virulence at least in some infection types.  
Reprint from with [105] permission from Elsevier. Copyright © 2013 Copyright Clearance Center, Inc. All 
Rights Reserved. 
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long-term outcomes after MRSA bacteremia vs those after MSSA bacteremia.207 The major 
virulence of CA-MRSA is a fact. These strains exhibit high capacity to circumvent the first 
line of defence of the human body against staphylococcal infections, even the killing by 
human neutrophils. Hence, it is exactly the accountable for the ability of CA-MRSA strains 
to infect healthy people.102  
In general S. aureus is not commonly known for producing a plethora of toxins, some of 
which are found virtually in all S. aureus, while others are linked to MGEs and restricted to 
a subset of strains. Among these toxins, some are involved in evasion of neutrophil 
killing, which was at least one of the predominant factors assumed to be associated with 
that enhanced virulence. In short, staphylococcal leukocidins, a specific toxin repertoire 
or an enhanced production of toxins appeared as a likely basis for the enhanced 
virulence characteristics of CA-MRSA.105 
 α-haemolysin (Hla) is a cytolysin that has demonstrated a big impact on virulence in 
many infection models. Hla contributes to the penetration of the epithelial barrier during 
skin infection by USA300,106 and it could contribute to the observed systemic severity by 
CA-MRSA. Thus, α-haemolysin is a critical virulence factor provable in numerous animal 
infection models, for example, brain abscesses, skin and soft tissue infections, and has a 
significant effect on morbidity and mortality in CA-pneumonia.107  
The PSMs peptides have a significant impact on CA-MRSA virulence, due to being 
responsible for the increased neutrophil killing capacity that distinguishes CA-MRSA from 
HA-MRSA strains.94 
And the leukocidin PVL, a virulence factor whose role is more controversial. Because, 
depending on specific infection types or scenarios (animal model) and even of strains, 
could significantly contribute to the severity of the disease caused by CA-MRSA.105 
Actually, its effect keeps on being studied in different experimental models,96,97, 114 
because an increasing number of CA-MRSA clones, not containing lukSF genes are found 
equally virulent.98 On the other hand, the contribution of lytic activity in this PVL toxin 
towards human neutrophils is studied in laboratory experiments.112 Therefore, perhaps 
initially overestimated their virulence. 
CA-MRSA, especially USA300, has been shown to overexpress a number of core-genome–
encoded virulence factors, such as α-haemolysin (Hla) and PSMs. PVL and Hla seem to be 
required for early lung involvement via haematogenous spread. α-haemolysin, but not 
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PVL, significantly impact severe sepsis-related mortality. PVL is the predominant factor 
determining late-stage bone abscesses.208 
Reprint from [161] with permission from American Society for Microbiology. Copyright © 2010 
Copyright Clearance Center, Inc. All Rights Reserved. 
 
 
 
Table 4. Plasmid and characteristics MGEs of S. aureus USA300. 
 Size (bp) Characteristics genes Function 
Mobile genetic elements 
SCCmec type IV - mecA Methicillin resistance 
ACME type I - arc cluster + opp3 cluster Arginine desaminase + oligopeptide permease system 
SaPIs - seq2, sek2 Pyrogenic toxin superantigens 
ϕSA2USA - lukS-PV, lukF-PV PVL 
ϕSA3USA - sak, chp Fibrin-specific-blood-dot dissolving enzyme, chemotaxis 
inhibitory factor 
Plasmids 
pUSA01 3125 - Cryptic 
pUSA02 4439 tetK Resistance to tetracycline 
pUSA03 37136 ermC, ileS Resistance to macrolides, lincosamides, streptogramins 
B an mupirocin 
 
Figure 4. Hypothetical virulence factors in USA300 and other CA-MRSA strains.  
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Since 1900s we have known about mass spectrometry and, since a lack of suitable 
ionization techniques for high mass biomolecules, proteins remained inaccessible to MS 
analysis for decades. Due to the introduction of soft ionization techniques, such as 
Matrix Assisted Laser Desorption Ionization (MALDI) and Electrospray Ionization (ESI), 
mass spectrometry at the end of the 1980s209,210 and protein analysis by mass 
spectrometry underwent a rapid phase of development. Nowadays, has become a widely 
established technique for analyzing chemical structures in low quantities to trace levels. 
In parallel, an increasing number of full genome sequences for a variety of organisms are 
now available and numerous protein databases were constructed from this information. 
Well-annotated, high-quality protein databases built the ground on which high-output of 
protein identification with mass spectrometry can be performed. Another major approach 
has been the combination, or the modular arrangement of different types of mass 
analyzers (MALDI- or ESI), which has resulted in a wide variety of different mass 
spectrometric instrumentation (e.g., MALDI-TOF, ESI-Q-TOF, ESI-ion trap, MALDI-
TOF/TOF, etc.). Although they always required additional sample preparation techniques, 
all of these mass spectrometry techniques allowed the determination of the primary 
structure of a protein. Now, modern mass spectrometers are combined with high 
sensitivity, to improve mass accuracy, mass resolution, and rapid analysis as well as 
getting sophisticated data handling in a system-dependent manner. In addition to these 
technical aspects in mass spectrometry, greatly improved sample separation and 
preparation techniques have also lead to enhanced sensitivity. Currently, the 
multienzyme digestion (MED) filter-assisted sample preparation strategy (FASP) approach 
appears to be especially useful for the analysis of samples available only in minute 
amounts, significantly increasing the number of identified proteins and their sequence 
coverage. The MED-FASP offers efficient exploration of previously unused sample 
material, increasing depth of proteomic analyses and sequence coverage.211 
Quantitative proteomics yields comprehensive data on protein expression levels enabling 
the detailed characterization of biological processes, by comparison of various 
physiological states or different biological entities (such as different bacterial strains or 
samples from healthy and diseased organisms), on a proteome-wide scale. Mass 
spectrometry-based label-free quantification (LFQ) can be achieved by spectral 
counting212 or by determination of peptide signal intensities.213 However, the reliable 
quantification via these approaches requires a highly reproducible chromatographic 
sample separation, which has been resolved with the pre-treatment of the samples by 
nano-LC (Liquid Chromatography). Although it is known that LFQ techniques suffer from 
the fact that peptide signal intensities are not strictly proportional to the peptide 
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concentration owing to ion suppression effects,214 LFQ is a great alternative a label-
techniques such as ITRAQ for these proteogenomic studies. The applicability of label-free 
approaches was shown in different proteomic studies215 and even in the challenging field 
of biomarker discovery.216 
Furthermore, bioinformatics software’s such as, MaxQuant software suite, developed for 
data acquired by high-resolution instrumentation, which permits the identification of 
proteins and analysis later, linked to the large "online" bioinformatics tools. Thus, 
nowadays, an exhaustive-wide and in depth proteogenomic analysis, is possible. 
The proteogenomic studies give us information of each protein within its own 
functionality and its adaptation in different environments or contexts. 
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In the 1940s, S. aureus developed fast resistance to the first known antibiotic, penicillin, 
by acquiring the gene for penicillinase. After penicillinase-resistance, methicillin was 
introduced into use, and resistant strains were found about one year later.98 These first 
MRSA strains spread sustainably on a global level in the next decades, leading to several 
epidemic outbreaks.217 Since the detection of the first MRSA strain in 1959, different 
MRSA clones have emerged.218 At that time, almost all MRSA clones detected worldwide 
belong to only five clonal complexes (CCs): 5, 8, 22, 30 and 45 among them, the archaic 
MRSA clone [strain COL, sequence type (ST) 250] harbored the SCCmec element of type 1 
and belonged to CC8. Since then, important MRSA clones emerged and thus one 
worldwide expansion of common clones. For example, in the 1980s, the MRSA pandemic 
belonging to the same CC8, but had a new SCCmec types (II and III) including the Iberian 
(EMRSA-5, ST247) clone, a descendant of COL, or the Brazilian/Hungarian (EMRSA-1, 
ST239) clone. A further major MRSA clones was the New York/Japan clone (ST5, USA100) 
relevant in the last decade, nowadays shifted by the ‘pediatric’ clone (ST5), both of which 
belong to CC5,119 being SCCmec-II the first and SCCmec-IV the second. 
In September 2000, in the USA two MRSA strains belonged to different pulsed-field types 
were isolated, USA300 and USA400 (represented by the isolate MW2), and they were the 
predominant cause of community acquired infections. Since then, USA300 has been 
implicated in epidemiologically unassociated outbreaks of skin and soft tissue infections 
in healthy individuals in USA, Canada, and Europe.199,200,219-221  
In Spain, MRSA strains comprise approximately 30% of the S. aureus isolated during 
00s,222 one resistance rates maintained over the years. Until 1995, the Iberian clone 
predominated in hospital outbreaks and, in recent decades, the strains of the Iberian 
clone have been replaced by others, such that, nowadays, the ST125-MRSA-IV clone 
represents approximately 50% of those MRSA strains isolated in Spain.223,224 In recent 
years, the epidemiology of MRSA infections has undergone a series of changes towards 
one "homogeneity" of clones, in the same way as in other countries, and concurrently the 
resistance. In the first decade, Spain, had high rates of HA-MRSA and the incidence of 
CA-MRSA seem to be low, and the few cases of PVL-positive CA-MRSA isolates have 
frequently been associated with immigrants from South America, mainly from 
Ecuador.225-229 However, considering also the small number of studies published from a 
few institutions, mostly Hospitals, and descriptions of sporadic cases and outbreaks, 
could have been the reason the divergence in the first spanish studies, limited to a lower 
population and zone. 
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The study carried out by Cercenado et al.,230 analyzing the present situation of CA-MRSA 
in Spain, and its evolution over the last 9 years, shows one more exact map about the 
real situation in our country. This study identified the main clonal lineages of CA-MRSA, 
and its population structure by analyzing all MRSA isolates received at the Spanish 
National Reference Centre for Staphylococci (SNRCS) from 2004 to 2012, confirming a 
recent increase in the rates of CA-MRSA in Spain. This situation found by Cercenado et al, 
was also found in our studies, and though it was in contrast to that described in the USA, 
where a single USA300 epidemic clone is the cause of the majority of CA-MRSA 
infections, it was very similar to what happens in Europe. On the other hand, although 
the prevalence of the USA300 clone in these spanish studies was low, this was according 
to real situation, since this clone did not appear until 2008 and was uniformly distributed 
approximately by 2010. 
Obviously, the urgency of USA300 clone in Spain is a cause of concern since it shows 
multiresistance and is highly virulent, is well adapted to the community, and has a high 
capacity for dissemination, which is helped by international travellers. 
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This study has enormous potential from a clinical point of view for improving clinical 
practices. The main objectives of this thesis have been split, original manuscript and 
scientific letters published (annexed). 
 
The rapid development of resistance to most antibiotics marketed, despite the 
development of new antibiotics, makes the global knowledge about the whole mechanism 
of action of these antibiotics in bacteria, a need. 
Thus, in this original manuscript, the following objectives will be developed: 
1. To know a global "picture" of the response of CA-MRSA USA300 to antibiotic pressure 
of subinhibitory concentrations of main antibiotics to clinical practice, and  
2. To understand the adaptation of CA-MRSA USA300 clone when it is exposed to these 
subinhibitory concentrations.  
3. To investigate the specific cellular response of CA-MRSA  USA300 clone under 
subinhibitory concentrations of four antibiotics in clinical use: linezolid, vancomycin, 
oxacillin and tigecycline, and  
4. To evaluate the effect of these subinhibitory concentrations. 
 
 
AIMS of letters:  
1. To know the clonal distribution in our community. 
2. To compare the displacement of the clones over a short time 2005-2009. 
3. To compare the susceptibility to antibiotics in that time. 
The importance of maintaining constant epidemiologic control, and the need for the 
implementation of new initiatives to prevent their dissemination, are made essential. 
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Synopsis 
 
 
 
This study gives an overview of the expressed proteome of a hypervirulent, community 
acquired and resistant Staphylococcus aureus isolate, S. aureus USA300 strain, and its 
response to antibiotic pressure. Unlike previous genome-wide transcriptome studies, 
which monitored changes on mRNA level, we show qualitative analysis of USA300 cell at 
the protein level that directly reflects physiologically relevant adaptations. We focused on 
several groups of main proteins regulatory system, response to stress (include 
mechanism of resistance) and virulence. Here we provide evidence of the S. aureus 
USA300 cells adaptation to different antibiotics, and the possible therapeutic effect on 
the S. aureus USA300 strain of subinhibitory concentrations of several clinical used 
antibiotics. This study shows how the bacteria adapts to overcome low-level antibiotic 
stress and what proteins are involved. 
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Summary 
Antimicrobial resistance of the human pathogen Staphylococcus aureus is an ongoing 
problem in the healthcare sector. Community-acquired methicillin-resistant S. aureus, 
USA300 strain, has the ability to infect healthy individuals because of its high virulence. 
By using tandem mass spectrometry, we investigated the expressed proteome of USA300 
in response to two subinhibitory concentrations of linezolid, tigecycline, oxacillin and 
vancomycin, and compared it to a control condition without antibiotic. Analysis of the 
respective USA300 cell extracts identified over 40% of USA300 predicted proteome in 
total. 
Analysis of expression patterns of virulence and pathogenesis proteins showed that 
protein synthesis inhibitors had the most effect during the conditions used and cell-wall 
synthesis inhibitors had less effect. The treatment with protein synthesis inhibitors, 
linezolid and tigecycline, increased the expression of ribosomal protein RplC. Tigecycline 
showed a dose-dependent bactericidal activity, exhibited by a strong decrease in 
proteins expression, particularly of α-haemolysin Hla. Oxacillin and vancomycin inhibit 
cell-wall synthesis. Treatment with oxacillin led to an extensive lysis of the bacterial cells. 
Nevertheless, oxacillin increased the expression of virulence factors such as phenol-
soluble-modulins (PSMs) and Panton-Valentine Leukocidin toxin (PVL), but not Hla. 
Therefore, the USA300 strain appeared to have a capacity to adapt itself to subinhibitory 
concentrations of antibiotics, by regulating its metabolism, redirecting the energy, and 
biofilm formation. 
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Material & Methods 
Bacterial strains and reagents. 
The pvl(+) CA-MRSA S. aureus strain USA300 (SCCmecIV-ST8)200 was kindly provided by 
Dr. DeLeo (National Institutes of Health, Hamilton) and genotyped as able to release the 
PVL toxin.146 The strain was grown in tryptic-soy broth. Linezolid, tigecycline, oxacillin 
and vancomycin were all obtained from Sigma Chemicals Co. (St. Louis, MO). Antibiotic 
dilutions were made fresh prior to each experiment. S. aureus strains ATCC 29213 and 
ATCC 25923 served as controls for MIC determinations. 
Determination of MICs. 
Antibiotic MICs were determined for each isolate using the broth microdilution method 
recommended by Clinical Laboratory Standards Institute (CLSI) in Mueller–Hinton II 
medium (bioMérieux, Marcy l’Etoile, France),14 and by E-test® following the 
manufacturer’s instructions (bioMérieux). The medium was inoculated with 5x105 
colony-forming units per milliliter (CFU/ml) (equivalent to 0.5 McFarland) and incubated 
for 18-20 h and until 24 h for vancomycin, at 37 °C without shaking. Experiments were 
done in triplicate and the results are given in Supplementary Table S1. The E-test® 
method was used for determining vancomycin MICs, because it is considered to be more 
reliable in predicting treatment response, and also showed higher correlation with 
population analyses profile-area under the curve (PAP-AUC).231-233 
Culture conditions for proteomic analysis. 
To prepare stock cultures, a single colony of S. aureus USA300 was inoculated into 5 ml 
of sterile tryptic-soy broth and incubated overnight at 37 °C with rotary aeration (200 
rpm). 100 μl of the overnight culture was used to inoculate fresh TSB (dilution 1:100, 
volume ratio 5:1, OD600 = 0.04 + 0.005), and incubated for 4 h at 37 °C with shaking 
(250 rpm). The growth was monitored spectrophotometrically until OD600 = 0.75 + 0.05 
(early stationary phase). At this point, concentrations of 0.25 and 0.5 of MICs of each 
antibiotic were added to 2 ml of culture tubes (final volume and same conditions, volume 
ratio 5:1). The concentrations used were: 0.25 and 0.5 μg/ml for linezolid, 0.12 and 0.25 
μg/ml for tigecycline, 8 and 16 μg/ml for oxacillin, 0.5 and 1 μg/ml for vancomycin, 
respectively. Cultures with or without antibiotics were re-incubated for 4 h at 37 °C with 
shaking (200 rpm) until OD600 reached at 2 + 0.1 (stationary phase). Subsequently, an 
aliquot of each culture was plated on blood agar to determine CFU/ml. Experiments were 
performed in triplicate (Supplementary Figure S1.A). 
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Bacteria were harvested by centrifugation at 2 000 g for 10 min at 4 °C. The pellet was 
washed 3 times with phosphate-buffer saline (PBS) pH 7.4, at 1 000 g for 5 min at 4 °C, 
and subsequently resuspended in 10mM Tris-HCl pH 8.5 with 10% Sodium-dodecyl-
sulphate (Tris-HCl-SDS). An equal volume of 0.1 mm glass beads (Biospec Products Inc., 
Bartlesville, OK) was added to the pelleted cells. The cells were lysed mechanically by 
bead beating for 40 s in a Ribolyser (Bio101 Savant, Vista, CA) at a speed of 6.4 m/s. The 
cell extracts were clarified by centrifugation (15 000 g for 10 min) at 4 °C. Both the lysate 
from pellet and the supernatant from soluble culture, were filtered through pore size 
0,22 μm (Millipore, Billerica, MA). Both protein extracts were next concentrated by using 
a 3K Nanosep® Filter (Pall Life Sciences, MI, USA), the yield was assessed with a Direct 
DetectTM Spectrometer (Millipore, Billerica, MA), and stored at -80 °C until further 
processing.  
SDS-PAGE and in-gel trypsin digestion. 
Total protein extracts (20 mg) were added to an application buffer mixture, containing 10 
mM dithiothreitol, following the manufacturer’s instructions (NuPAGE®Sample Reducing 
Agilent Invitrogen), and heated for 7 min at 96 °C. Thereafter the proteins were 
fractionated by SDS-PAGE using a 4–12% gradient, MiniGels NuPAGE® Novex® (Invitrogen) 
for 35 min at 200 V. SDS-PAGE gels were Coomassie stained using a Colloidal Blue 
Staining kit (NuPAGE Invitrogen). After staining, each gel lane was subjected to in-gel 
reduction, alkylation, and tryptic digestion according to protocol used at the Proteomic 
Unit of University of Bergen (PROBE). In brief, proteins were reduced using 10 mM 
dithiothreitol for 45 min at 96 °C and alkylated with 55 mM iodoacetamide for 30 min at 
room temperature in the dark. The reduced and alkylated peptides were digested with 
sequence grade, modified trypsin (Promega, Madison, WI) at enzyme to protein ratio of 
1:50 (w/w) for 16 h at 37 °C in 50 mM NH4HCO3, pH 8.0. The reaction was quenched 
through acidification with 1% trifluoroacetic acid (Fluka, Buchs, Switzerland). The 
resulting peptide mixture was desalted on reverse phase C18 stop and go extraction 
tips,234 and diluted in 0.1% trifluoroacetic acid prior to nano-LC-ESI-MS/MS analysis. 
(Supplementary figure S1.B). 
Mass Spectrometry. 
All experiments were performed on a Dionex Ultimate 3000 nano-LC system (Dionex, 
Sunnyvale, CA) connected to linear quadrupole ion trap-Orbitrap-Elite (LTQ-Orbitrap) 
mass spectrometer (Thermo Electron, Bremen, Germany) equipped with a 
nanoelectrospray ion source. For liquid chromatography separation, we used an Acclaim 
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PepMap 100 capillary column (C18, 2 μm, 100 Å) (Dionex), 15 cm x 75µm inner diameter 
nanoViper column (Dr. Maisch GmbH, Ammerbuch-Entringen, Germany). The flow rate 
used was 280 nl /min, and the solvent gradient was 8–40% B over 31.5 min and then 40–
90% B over 3 min. Elution of very hydrophobic peptides and conditioning of the column 
were performed during 5 minutes isocratic elution with 90% B and 12 minutes isocratic 
elution with 5% B respectively. Solvent A was aqueous 2% acetonitrile in 0.1% formic acid, 
and solvent B was aqueous 90% acetonitrile in 0.1% formic acid.  
The eluting peptides were ionized in the electrospray and analyzed by the LTQ-Orbitrap 
Velos Elite. The mass spectrometer was operated in the data-dependent-acquisition 
mode to automatically switch between full scan MS and MS/MS acquisition. Instrument 
control was through Tune 2.7 and Xcalibur 2.2. Survey of full-scan MS spectra (from m/z 
300 to 2 000) were acquired in the Orbitrap with resolution of R = 240 000 at m/z 400 
(after accumulation to a target of 1 000 000 charges in the LTQ with maximum allowed 
ion accumulation time of 300 ms). The 7 most intense eluting peptides above a ion 
threshold value of 1000 counts, and charge states 2 or higher, were sequentially isolated 
to a target value of 1E4 and fragmented in the high-pressure linear ion trap by low-
energy CID (collision-induced-dissociation) with normalized collision energy of 35 % and 
wideband-activation enabled. The maximum allowed accumulation time for CID was 150 
ms, the isolation width maintained at 2 Da, activation q = 0.25, and activation time of 10 
ms. The resulting fragment ions were scanned out in the low-pressure ion trap at normal 
scan rate, and recorded with the secondary electron multipliers. One MS/MS spectrum of 
a precursor mass was allowed before dynamic exclusion for 10 s. Lock-mass internal 
calibration was not enabled. 
Sequence database searching. 
All acquired data were processed and analyzed using MaxQuant software (version 
1.4.1.2)235 and MS/MS peak lists from individual 60 RAW files were generated. 
Andromeda engine performed protein identification by searching the data separately 
against S. aureus USA300 protein database, downloaded from UniProt knowledgebase on 
2nd May 2014. The database contained incomplete protein records of 4 S. aureus USA300 
strains; two strains of CA-MRSA (USA300/FPR and USA300/TCH1516) and two strains 
CA-methicillin sensible (USA300/TCH959 and USA300/ISMMS1). Common contaminants, 
such as keratin, bovine serum albumin and trypsin were also added to the database. The 
search parameters used were as follows: enzyme specificity, trypsin/with no proline 
restriction; maximum missed cleavages, 2; carbamidomethyl (Cys) as fixed modification; 
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N-acetyl (protein), oxidation (Met), Glu (pyro-Gln), and Gln (pyro-Glu) as variable 
modifications; first search precursor ion mass tolerance, + 20 ppm for mass calibration, 
while a tolerance of 6 ppm was used for the main search after calibration; and MS/MS 
mass tolerance, 0.5 Da. For protein identification and validation the following parameters 
were used: 1% peptide and protein false discovery rate (FDR), minimal peptide length was 
7 amino acids, and minimal number of unique peptides per protein equalled 1. Proteins 
were validated statistically based on the score of their individual peptides. All MS/MS 
identifications of peptides present in entries with reversed sequences, proteins only 
identified by site and contaminants were discarded. Proteins identified confidently in at 
least two out of three biological replicates for antibiotics assays, and three out of six 
biological replicates for untreated control, were included in the subsequent analysis.  
Label-free quantification. 
Label-free quantification based on the peak area was performed in MaxQuant. Processing 
evidence files, visualization, and statistical analysis were performed by Perseus (v.1.4.1.3 
and v. 1.5.1.6) (Max Plank Institute, Germany).235 The intensity derived from label-free 
quantification (LFQ) for each protein was transformed by log2 and next normalized. Data 
normalization (N) was performed by dividing LFQ intensity of every detected protein (row) 
by LFQ intensities mean of its own biological replicate (column): 
                              
                        
. 
The quantitative data were reported with the t-test differences between each antibiotic 
condition and the untreated-control. Estimation of FDR236= 0.05 and S0 = 0 (S0 is a 
small positive constant ensuring that the variance is independent of protein expression) 
was used for q values for both raw and normalized-transformed LFQ intensities236, which 
were imputed in replicated runs using a Gaussian distribution with a width of 0.3 and 
downshift of 1.8 as the imputation parameters.237 The differentially expressed proteins 
were filtered by the following cut-off: p-value for t-test was lower than 0.05 and the fold 
changes expressed like t-test difference. For normalized data without transforming by 
log2 (N-LFQ), the fold change was calculated as ratio of normalized LFQ (N-LFQ) 
intensities means by, the treated samples against untreated control 
Bioinformatics Analysis. 
To determine the subcellular localization of the proteins, as well as their biological 
process, molecular function, and other annotations, we used the UniProt 
access/identification of both CA-MRSA strains, USA300/FPR and USA300/TCH1916, 
without redundant proteins. All identified proteins were analyzed by using the DAVID 
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web (Database for Annotation, Visualization and Integrated Discovery) algorithm to 
evaluate the pathway enrichment. A group enrichment score, which is a ranking of the 
biological significance of gene groups based on overall EASE (Expression Analysis 
Systematic Explorer) scores238 of all enriched annotation terms, was calculated by using 
the default parameters.239 The p value threshold for pathway enrichment was set to 0.1, 
and medium classification stringency was chosen. The fold change was establish as the 
difference higher/lower than + 1.0, calculated as the subtracting among enrichment 
scores (antibiotic – control) for each cluster.  
To know the context of network interacting, predict protein-protein interactions,240 we 
used STRING 9.1 (Search Tool for the Retrieval of Interacting Genes/Proteins) and 
Medusa 1.5241 to show the graphic analysis. NCBI Protein BLAST was used to complete 
and search the information about the uncharacterized proteins. 
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Results & Discussion 
To study proteins involved in pathogenesis under different subinhibitory antibiotic 
concentrations, we established a workflow to treat the cultures in the early stationary 
growth-phase, and harvest them in the stationary growth-phase. We determined the 
respective subinhibitory concentrations, as half and quarter MICs of each antibiotic 
(Supplementary Table S1). The subinhibitory concentrations, subsequently used in the 
proteomic experiment, reduced the viability of the S. aureus USA300 strain for 2 of the 4 
antibiotics. This was most pronounced with 0.5 MIC of tigecycline and oxacillin (1-2 log10 
reduction). All of the antibiotics resulted in a reduction of the total protein outcomes in 
the extracts (Supplementary Table S2). 
Overview of the proteomic identifications 
The proteomic experiment included S. aureus USA300 cells grown in the presence of two 
sub-concentrations of each antibiotic, and a control cultured without any antibiotic. The 
respective trypsinated cell extracts were subjected to tandem mass spectrometry 
analysis, and the acquired mass spectra were searched against S. aureus USA300 protein 
database with the MaxQuant/Andromeda software. The peptide matches allowed the 
identification of 1 284 proteins, all extracts considered (excel file). The number of protein 
identifications corresponded to approximately 40 % of the 2 600 proteins encoded in the 
S. aureus USA300 genome annotated by Diep.146 Nine-hundred-and-eighty proteins were 
present in at least two biological replicas, and therefore considered as valid proteins. The 
number of identified proteins in each type of extract varied between 418 and 774 
proteins, and the identified protein repertoires were compared by Venn diagrams (Figure 
1). Tigecycline consistently resulted in a lower number of identified proteins in both sub-
concentrations. This effect could be explained by a dose-dependent bactericidal activity 
of tigecycline against S. aureus.242  
To characterize the effects of the different antibiotic conditions, we first retrieved the 
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cellular localization for the identified proteins from the UniProt database (Table 1). 
Treatment with linezolid and vancomycin preserved the cellular localization distribution 
of proteins with respect to the control. In samples treated with 0.5 MICs of oxacillin or 
tigecycline, the numbers of identified membrane proteins were decreased more than 40 
%, especially proteins involved in transport processes, whereas extracellular proteins 
were increased more than 40 %. Extracellular proteins,30 cell surface proteins or proteins 
associated with the membrane,100,243 are often associated with pathogenesis, 
colonization or antibiotic resistance. Therefore, a loss of transporters could point to a 
loss of viability of cell wall function, and the great number of extracellular proteins could 
be associated with an increase in virulence factors and / or a stress response. Second, 
we performed qualitative analysis by DAVID software program, to predict associated 
biological processes and metabolic pathway enrichments. As expected, 0.5 MICs gave 
the most pronounced differences, while 0.25 MICs produced only minor changes, 
compared to the control. Hence according to the literature, the antibiotic pressure led to 
a redirection of the cell metabolism by regulation of the energy, amino acid or purine / 
pyrimidine metabolism pathways, to overcome the influence of the antibiotics244 
(Supplementary Table S3). In addition, changes in the metabolic pathways observed for 
0.5 MIC of linezolid was concordant with the study of Bernando et al.,245 and the down-
regulation of metabolic pathways observed for tigecycline could be associated with 
bactericidal activity242,246 (Supplementary Table S3). On the other hand, linezolid showed 
a dose-dependent increase in a number of ABC transporters, which could be related to 
an early stage of developing resistance.247,248 Whilst, oxacillin increased the number of 
stress response proteins and pathogenesis proteins.247 (Supplementary Table S4). 
Indeed, the treated S. aureus USA300 cells had a substantial number of proteins involved 
in response to stress (Supplementary Figure S2). Therefore, there were considerable 
changes in the protein profiles in response to 0.5 MICs of the antibiotics. The effects 
were particularly pronounced for tigecycline and oxacillin. 
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Figure 1. Proteome comparison in response to antibiotic treatments. Venn Diagrams showing shared 
and exclusive proteins among control samples and both subinhibitory concentrations (0.25 MIC and 0.5 
MIC) of  linezolid, tigecycline, oxacillin and vancomycin. 
 
 
Table 1. Cellular localization distribution of identified proteins in USA300 proteome, under  absence 
(control) or presence of subinhibitory concentrations of antibiotics. 
 
CELLULAR 
LOCALIZATION 
 ANTIBIOTIC  
Control Linezolid Tigecycline Oxacillin Vancomycin Total 
 0.25 
μg/ml 
0.5 
μg/ml 
0.12 
μg/ml 
0.25 
μg/ml 
8 
μg/ml 
16 
μg/ml 
0.5 
μg/ml 
1 
μg/ml 
 
CELL WALL 8 6 6 5 4 6 6 7 7 10 
MEMBRANE 56 49 53 25 21 40 27 45 51 67 
EXTRACELLULAR 30 31 32 23 33 36 35 30 30 42 
CYTOPLASM 247 241 245 169 189 239 216 219 258 291 
UNKNOWED 433 388 395 196 219 407 332 334 418 570 
           
Total proteins 774 715 731 418 466 728 616 635 764 980 
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Quantitative analysis of differentially expressed proteins in response to 0.5 MICs 
To ascertain that the identified proteins originating from extracts of S. aureus USA300 
cells showed good correlation, the LFQ intensities of identified proteins were used to 
calculate Pearson correlation coefficient R, determined by Perseus software 
(Supplementary figure S3). The scatter plots showed good correlations, comparing each 
antibiotic condition with the control (Figure 2, a - d), or by comparing the two different 
antibiotic concentrations. The culture supernatants had relatively few identified proteins, 
except for oxacillin, which resulted in a much higher number of proteins in the 
supernatant than the other antibiotics (Figure 2, e - f). The LFQ intensities of identified 
proteins in the culture supernatants of the two concentrations of oxacillin, correlated well 
but poorly to the control. These “extra” proteins found in the oxacillin supernatants, were 
mainly identified as typical intracellular proteins, inferring extensive bacterial lysis of S. 
aureus USA300 cells.249  
For the comparative analysis of S. aureus USA300 specific response to each antibiotic, we 
only considered proteins differentially expressed in samples treated with 0.5 MICs. To 
analyze these differentially expressed proteins, we took into consideration the 
experiment design and the detection limitations. The differentially expressed proteins 
not identified under some condition, antibiotic or control, with a normalized LFQ 
intensities (N-LFQ intensity) less than 0.20 (LFQ intensity < 106), we decided not to 
consider them. Therefore, among differentially expressed proteins in control, 26, 205, 
117 and 21 were not observed with linezolid, tigecycline, oxacillin and vancomycin 
treatments, respectively, whereas 19, 32, 39 and 17 proteins were differentially 
expressed with linezolid, tigecycline, oxacillin and vancomycin, respectively, which were 
not observed in the control. For the differentially expressed proteins in treated and 
untreated-control S aureus USA300 cells, the statistical analysis revealed 4, 37, 24 and 3 
proteins showing significant statistical differences for linezolid, tigecycline, oxacillin and 
vancomycin, respectively (Figure 3). We only investigated in depth proteins predicted to 
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Figure 2. Individual Plots correlation by Pearson coefficient R. Scatter plots showing each Pearson 
coefficient R, and the correlation between LFQ intensities means ( LFQi) of, (a-d) proteins identified in 
the pellet fraction under 0.5MICs (y axis), plotted against proteins identified in the control (x axis), and 
(e-f) proteins identified in supernatant fraction under 0.5 MIC of oxacillin (y axis), plotted against 
proteins identified in control and 0.25MIC of oxacillin, respectively (x axis). LFQ intensities means were 
calculated as the average among the six, for the control and three, for antibiotics, replicates.  
BLUE = proteins from pellet; BLACK = shared proteins between both fractions; RED = proteins from 
supernatant; GREEN = proteins are not within control.  
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be involved in mechanism of action, pathogenesis and response to stress, including 
mechanism of resistance. Hence, we could analyze regulatory systems or proteins that 
regulate virulence factors in S. aureus USA300, e.g., repressor CodY250 or Clp protease 
family,86 and proteins involved in pathogenesis such as phenol-soluble-modulins 
(PsmA), α-haemolysin (Hla/Hly) and PVL (LukF-PV / LukS-PV). Phenol-soluble-modulins, 
Hla/Hly and PVL are the main virulence toxins characteristic of hypervirulent S. aureus 
USA300.251 We can also analyze proteins predicted to be involved in mechanism of 
resistance to vancomycin (RpoB, RpoC),252 β-lactam family (BlaZ, PBP2a/MecA) or 
aminoglycosides (AphA(3')III). The differentially expressed proteins in control but not 
observed with antibiotics are summarized in Table 2, the differentially expressed 
proteins under antibiotic conditions in Table 3, and the statistical analysis is summarized 
in Supplementary Table 5 and is shown by volcano plots (Figure 3). 
Figure 3. Volcano Plots. Volcano Plots generated by Perseus (v.1.5.1.6) showing the most significant 
differences for proteins differentially expressed under 0.5MIC-conditions of, (a) linezolid, (b) tigecycline, 
(c) oxacillin, and (d) vancomycin, respect to untreated-control-USA300.  
Volcano Plots display both high statistical significance, p-value < 0.05 (y-axis), and large magnitude 
fold changes, antibiotic vs control (x-axis). The dashed black-line shows where p-value =0.05 
expressed as -log t-test p-value (log10 p-value) = 1.30103, with points above the line p < 0.05 and 
pints below the line having p > 0.05. The filled square plot is such that points having a fold-changes 
less/more than 4x (4 < x < 0.25) expressed as ratio antibiotic / control and according to t-test 
difference [antibiotic – control]. The filled diamond plot is such that points having statistical 
significance.  
Aph3'A: aminoglycoside 3'-phosphotransferase; Aur: zinc metalloproteinase aureolysin; BlaZ: beta-lactamase; ClpP: ATP-
dependent Clp protease proteolytic subunit; Eap: extracellular adherence protein; EsaA: virulence protein; EzrA: septation 
ring formation regulator; Ffh: signal recognition particle protein; FtsZ: cell division protein; HemG: protoporphyrinogen 
oxidase; Hld: delta-haemolysin; Hly: alfa-haemolysin; IsaB: immunodominant antigen B; RpsA: 30S ribosomal protein S1; 
LukF-PV: Panton-Valentine leukocidin subunit F; LukS-PV: Panton-Valentine leukocidin subunit S; MecA: pencillin binding 
protein 2a (PBP 2a); PheT: phenylalanine--tRNA ligase beta subunit; ProRS: Proline-tRNA ligase; PurD: 
phosphoribosylamine-glycine ligase; PurL: phosphoribosylformylglycinamidine synthase 2; RplC: 50S ribosomal protein 
L3; RplE: 50S ribosomal protein L5; RpoB: DNA-directed RNA polymerase subunit beta; RpoC: DNA-directed RNA 
polymerase subunit beta; RpsE: 30S ribosomal protein S5; RpsJ: 30S ribosomal protein S10; SarA: Staphylococcal accessory 
regulator A; SdrE: serine-aspartate repeat-containing protein E; Seq: enterotoxin Q; SodA: superoxide dismutase A; SplC: 
serine protease C; SplE: serine protease E; SplF: serine protease F; Ssb: single-stranded DNA-binding protein; SspB: C47 
family staphopain B; SspC: I57 family staphostatin B; TsaD: tRNA N6-adenosine threonylcarbamoyltransferase. 
Statistical significance proteins. Underline protein name. 
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Mechanism of action 
The protein synthesis inhibitors, linezolid and tigecycline, showed a significant increase 
in the expression of RplC (50S L3) (Figure 3a – b, Supplementary Table S5) assembly 
initiator protein involved in the initiation first step, which has also been implicated in 
resistance to linezolid.253 Tigecycline further showed a significant increase in the 
expression of other proteins involved in protein synthesis, such as proline-tRNA-ligase 
ProS and RNA-methyl-transferase (Figure 3b, Supplementary Table S5). This more 
significant increase with tigecycline was concurrent with the lower expression of 
ribosomal proteins, e.g., RplP (Table 2). The cell wall inhibitors, oxacillin and 
vancomycin, did not show significant statistical differences in the proteins expression 
involved in cell wall processes (Figure 3c - d, Supplementary Table S5). Nevertheless, 
oxacillin decreased the expression of FtsZ and its negative regulator EzrA (Figure 3c, 
Supplementary Table S5), predicted to be involved in cell division, and proteins such as 
DltD or MurF (Table 2), involved in cell wall biogenesis / degradation, as well as the 
organelle-organization crucial in chromosome dynamics Smc,254 were not observed 
(Table 2). This was expected considering  that linezolid and tigecycline have effect on 
proteins synthesis, and oxacillin on cell wall synthesis. 
Virulence 
We observed that approximately 1 % of differentially expressed proteins in the control 
with a N-LFQ intensity more than 0.5, were not observed with linezolid or tigecycline 
treatments (Table 2), and the statistical analysis showed a decreased differential 
expression of virulence, especially with linezolid and tigecycline (Figures 3a - b 
respectively, Supplementary Table S5). In samples treated with linezolid, serine proteases 
SplC and Ear protein were not observed, while another serine protease SplE, enterotoxin 
Seq and haemolysin Hld were significantly less expressed. In samples treated with 
tigecycline, Hld, Ear protein, virulence proteins EsaA and EsxA, and serine protease SplA 
were not observed, while SplC and SplE were significantly less expressed. The main 
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virulence factors Hla/Hly and LukS-PV (PVL)255 also showed a lower expression with 
tigecycline, besides other minor virulence factors (Aur, IsaB, SspB). In samples treated 
with oxacillin, only EsaA and SspC significantly, and minor virulence factors (IsaB, SspB) 
showed a lower expression (Figure 3c, Supplementary Table S5). By contrast, an highest 
expression of enterotoxin Sek was observed in samples treated with tigecycline and 
oxacillin (Table 3). In addition, in samples treated with oxacillin, the main virulence 
factor of S. aureus USA300 LukF-PV (PVL)30 was significantly more expressed (Figure 3c, 
Supplementary Table S5), likewise leukocidin LukDE (N-LFQ intensity < 0.20) and SCIN 
(Table 3) were more highly expressed. In summary, the protein synthesis inhibitors, 
linezolid and tigecycline, were superior inhibitors of virulence proteins, and the uniques 
with a effect on serine proteases, toxins and haemolysins, which play a relevant role in 
the pathogenesis of S. aureus. 
Response to stress 
Biofilm formation. We observed that most of proteins predicted to be involved, direct or 
indirect mode, in biofilm formation were highly expressed under antibiotics conditions. 
In fact, FnbA was highly expressed in response to linezolid and tigecycline (Table 3); 
FnbB, coagulase Coa (Table 3) and SdrD (N-LFQ intensity = 0.30) in response to 
tigecycline; ClfA was highly expressed in response to tigecycline and oxacillin (Table 3), 
and Eap showed a higher expression with oxacillin (Figure 3c, Supplementary Table S5). 
Unexpectedly, one of virulence factor for S. aureus USA300 also involved in biofilm 
formation, PsmA1, was more highly expressed only in response to oxacillin (Table 3). In 
contrast, linezolid was the unique antibiotic that significantly decreased the SdrE 
expression (Figure 3a, Supplementary Table S5). Therefore, the increment in the number 
of proteins involved in response to stress by biofilm formation was superior for 
tigecycline and oxacillin, according to increased of the antibiotic pressure carried out for 
these antibiotics.  
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Mechanism of resistance. The proteins involved in the mechanism of resistance to β-
lactam antibiotics were higher expressed as response to oxacillin pressure as expected, 
though also as response to linezolid and vancomycin pressure. Oxacillin and linezolid 
increased the expression of BlaZ (Figure 3a - c, Supplementary Table S5), linezolid and 
vancomycin increased the Pbp2a/MecA expression (Figure 3a - d, Supplementary Table 
S5), and with linezolid, even Ppb3 was highest expressed (N-LFQ intensity = 0.24). Both 
proteins, MecA and Pbp3, are involved in the resistance to all β-lactam antibiotics, thus 
it might indicate that linezolid confer an increased resistance to this antibiotic family, at 
least with this sub-concentration. The resistance to glycopeptides was only increased 
with oxacillin by the higher expression of RpoB256 (Figure 3 c, Supplementary Table S5). 
The resistance to aminoglycosides was only reduced with tigecycline by the significantly 
lower expression of AphA (3´)III (Figure 3b, Supplementary Table S5). 
Endopeptidases Clp family. This heterogeneous Clp family, highly conserved among 
eubacteria, has a dual role, as it both eliminates stress-damaged proteins, as well as 
ensures the timely degradation of major stress regulators.86 In our study, endopeptidases 
Clp were differentially expressed according to antibiotic and subinhibitory concentration, 
especially ClpP. Endopeptidase ClpP was significantly more expressed with tigecycline 
and more expressed with oxacillin (Figure 3b – c, Supplementary Table S5) whereas in 
samples treated with linezolid and vancomycin (Supplementary Table S5) was not 
changed, likely according with the cell density and antibiotic pressure. Hence, we support 
that Clp endopeptidases play a key role in regulatory network in response to stress and 
pathogenesis, and furthermore, ClpP could also have a key role in the S. aureus USA300 
regulation, by interacting with regulatory systems, for the coordinated response against 
antibiotic pressure.  
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Table 2. Differentially expressed proteins in untreated-control USA300, which were not observed in 0.5MIC-treated USA300. Proteins summarized to be 
associated with mechanism of action of antibiotics, response to stress or pathogenesis. Normalized LFQ intensities, not transformed by log2, represented 
as the mean among the six (untreated) or three replicates (treated), and more than 0.2. (see excel file SI002 for more information).  
Num 
id Protein Name Control 
ANTIBIOTIC 
Biological 
Category 
Group 
Linezolid Tigecycline Oxacillin Vancomycin 
0.5 µg/ml 0.25 µg/ml 16 µg/ml 1 µg/ml 
1076 Serine protease SplC (EC 3.4.21.-) 20.33   0.16 1.29 15.40 2 
1078 Serine protease SplA (EC 3.4.21.-) 3.15 0.29   1.07 2.15 2 
873 Probable dual-specificity RNA methyltransferase RlmN (EC 2.1.1.192)  1.71 1.48     1.30 3 
1257 30S ribosomal protein S16 RpsP 1.09 0.77   0.79 0.66 3 
1101 Serine-protein kinase RsbW (EC 2.7.11.1) (Anti-sigma-B factor) 1.01 0.91   1.28 1.09 3 
796 HTH-type transcriptional regulator SarR (Staphylococcal accessory regulator R) 0.92 0.97   1.25 0.79 3 
1197 50S ribosomal protein L16 RplP 0.71 1.00   0.65 1.05 3 
1195 Redox-sensing transcriptional repressor Rex 0.59 0.69   0.39 0.74 3 
1000 RNA polymerase sigma factor SigA RpoD 0.51 0.62   0.56 0.67 3 
314 UvrABC system protein A (UvrA protein) (Excinuclease ABC subunit A) 0.36 0.36     0.42 3 
61 Probable DNA-directed RNA polymerase subunit delta (RNAP delta factor) RpoE 0.33 0.33   0.30 0.25 3 
632 Fur family transcriptional regulator 0.26     0.07 0.28 3 
313 UvrABC system protein B (Protein UvrB) (Excinuclease ABC subunit B) 0.22 0.23     0.30 3 
781 Peptidoglycan pentaglycine interpeptide biosynthesis protein FemB (EC 2.3.2.16)  0.70 0.56  0.64 0.86 6 
1107 UDP-N-acetylmuramoyl-tripeptide--D-alanyl-D-alanine ligase (EC 6.3.2.10) MurF 0.39 0.45     0.56 6 
520 D-alanine--poly(phosphoribitol) ligase subunit 2 (EC 6.1.1.13) (D-alanyl carrier protein) DltC 0.35 0.31     0.55 6 
619 Methicillin resistance factor FemB 0.31 0.31 0.25   0.77 6 
1185 Beta-lactamase regulatory protein (Fragment) BlaR 0.28 1.73   0.43 0.40 6 
1105 Alanine racemase (EC 5.1.1.1) Alr 0.21 0.19   0.23   6 
1397 Delta-hemolysin Hld 47.83 7.07   36.95 31.06 7 
701 Probable thiol peroxidase (EC 1.11.1.-) Tpx 0.79 0.64   1.10 0.62 7 
1047 Putative thioredoxin 0.75 0.41   0.29 0.59 7 
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24 Bacterioferritin comigratory protein (EC 1.11.1.-) Bcp 0.57 0.43   0.39 0.45 7 
69 General stress protein 20U (EC 1.16.3.1), Dps family stress protein 0.52 0.39   1.64 0.54 7 
1088 Possible leukocidin subunit 0.37 0.34 0.78   0.63 7 
145 Transcriptional regulatory protein WalR 0.32 0.23   0.14 0.34 7 
65 S-ribosylhomocysteine lyase (EC 4.4.1.21) Autoinducer-2 production protein LuxS 0.31 0.33     0.44 7 
284 Histidine protein kinase SaeS (EC 2.7.13.3)  0.28 0.29     0.49 7 
167 Superoxide dismutase [Mn/Fe] 2 (EC 1.15.1.1) SodM 0.27 0.21   0.46 0.09 7 
1360 Putative septation protein SpoVG 0.26 0.32   0.58 0.19 7 
629 Staphylococcal respiratory response protein SrrA 0.25 0.21   0.24 0.27 7 
363 I57 family staphostatin B SspC 0.23     0.04 0.22 7 
591 Glutathione peroxidase Bsa 0.23     0.68 0.45 7 
887 Chromosome partition protein Smc 0.23 0.22 0.19   0.19 7 
1079 Uncharacterized protein. Probabey beta-lactamase. 15.36 0.61   4.51 12.50   
402 Virulence protein EsaA 8.27 6.02   0.70 5.43   
751 Uncharacterized protein (1) 2.12 6.79   0.30    
509 Ear protein 1.26     1.19 3.05   
14 UPF0342 protein SAUSA300_1795. UPF0342 protein USA300HOU_1838 (2) 1.17     0.87 0.63   
401 ESAT-6 family virulence protein EsxA 0.84 0.13   1.51 0.70  
1004 Endoribonuclease YbeY (EC 3.1.-.-) 0.49 0.08     0.07   
521 D-alanine-activating enzyme/D-alanine-D-alanyl. D-alanine transfer protein DltD 0.48 0.41     0.52   
571 Fibrinogen-binding protein 0.34 1.27 0.68   0.36   
865 Fibrinogen-binding protein FbpA 0.24 0.15   0.42 0.17   
(1) Probably regulatory protein involved in competence development and sporulation [Replication, recombination and repair; Signal transduction mechanisms] Cytoplasmic  
(Probability = 0.75). 
(2) Putative exported protein, surface protein, putative toxin, beta-grasp domain protein. The protein domain family has been found in a wide range of extracellular matrix 
proteins truncated MHC class II analog protein, partial. 
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Table 3. Highly expressed proteins only under 0.5MICs of each antibiotic. Normalized LFQ intensities, not transformed by log2, represented as the mean 
among the three replicates, and higher than 0.75. (see excel file SI003 for more information). 
Num 
Id Protein Name 
ANTIBIOTIC 
Biological 
Category 
Group KEGG_PATHWAY 
Linezolid Tigecycline Oxacillin Vancomycin 
0.5 µg/ml 0.25 µg/ml 16 µg/ml 1 µg/ml 
472 CHAP domain family. Possible LysM domain protein 1.45 0.38 
  
1   
527 Chitinase-related protein (EC 3.2.1.14) 
 
3.29 
  
1 
Amino sugar and nucleotide 
sugar metabolism 
1164 
Ornithine carbamoyltransferase (OTCase) (EC 2.1.3.3) ArcB 
ArgF 
 
1.83 
  
2 Arginine and proline metabolism 
123 Fibronectin-binding protein B FnbB 
 
3.93 
  
6   
124 Fibronectin-binding protein A FnbA 0.79 1.46 
  
6   
488 Clumping factor A ClfA 
 
1.59 0.13 
 
6   
503 Staphylococcal enterotoxin K Sek 
 
0.91 0.72 
 
7   
741 Staphylococcal complement inhibitor (SCIN) Scn 
  
2.71 
 
7   
379 Staphylocoagulase (EC 3.4.23.48) Coa 
 
0.85 
  
    
413 Putative surface protein 
 
6.80 
  
    
421 Phenol-soluble modulin alpha 1 peptide PsmA1 
  
8.33 
 
    
604 UPF0154 protein SAUSA300_1240, USA300HOU_1280 (1) 0.79 
  
0.85     
(1) Putative exported protein. Cytoplasmic Membrane (Probability = 0.955). Only identified in supernatants. 
 
 
Manuscript: Results and Discussion 
 
111 
Comparative analysis of S. aureus USA300 strain in response to each antibiotic. 
Linezolid 
Linezolid showed a dose-dependent effect reflecting bacteriostatic activity, which also 
led to higher cell density (UFC /ml) (Supplementary Table S2). This higher cell density 
could explain that the expression of AgrC257 (excel file) was only observed under 
linezolid and control conditions. Thus, this AgrC expression could also support the lower 
biofilm formation observed in response to linezolid pressure, compared with tigecycline 
and oxacillin, because AgrC is the receptor of the global regulatory system agr-locus that 
allows bacteria to adjust gene expression258 in response to cell density, interconnecting 
metabolism and virulence gene expression.41,44 Linezolid at 0.25 MIC did not bring about 
major changes in the protein expression, however 0.5 MIC inhibited the synthesis of 
proteins at initiation step. Therefore, aforementioned virulence factors involved in 
pathogenesis, such as enterotoxins, serine proteases and haemolysins were decreased, 
and even the expression of main virulence factors PVL and especially Hla/Hly255 were a 
little less expressed under higher 0.5MIC (Supplementary Table S5).  
Tigecycline 
Tigecycline also inhibited the synthesis of proteins at initiation and elongation steps. One 
of the key factors that distinguished tigecycline from the other conditions was a strong 
down-regulation of protein expression, which resulted in a reduction of observed 
proteins between 55 - 40 % (0.25 - 0.5 MIC, respectively). This affected mainly those 
proteins expressed by low LFQ intensities in the control (N-LFQ intensity < 0.10), such as 
nucleoproteins or transporters. Notably with 0.5 MIC treatment, this reduction affected to 
two-component system such as SarR, critical components of the transcription such as 
RpoD/SigA, or endoribonuclease such as YbeY (Table 2). Unexpectedly, RsbW anti-
sigma-factor (Table 2) and likely RsbU-sigma-factor by extension (control N-LFQ 
intensity = 0.17) were also not observed. This inactivation of the sigmaB could explain 
that proteins involved in response to changes in cellular redox state (e.g., Rex), 
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homeostasis (e.g., Tpx) or SOS system, were neither observed (Table 2). In addition to 
this microbial response to stress, SigmaB operon has also an indirect impact on the agr 
‘quorum sensing’ system,74 demonstrating its role in virulence as a response to stress.75 
Hence, this fact could have also contributed in the lower expression of Hla/Hly and PVL 
(Figure 3b), together with other factors, such as the reduced expression of RNApol/RpoE 
(Table 2), which also plays an important role in Hla/Hly and PVL regulation.259 On the 
other hand, these findings also support the possibility that tigecycline can have a 
bactericidal activity as suggested.246 This bactericidal activity can be demonstrated by 
lysis and kill of S. aureus USA300 cells due to, i) not detection of several two-component 
and regulatory system, ii) lower expression of proteins involved in cell wall cycle, iii) the 
increased expression of proteins involved in the biofilm formation, which helps bacteria 
to escape antibiotic-induced killing;260 and iv) the significant decrease in cell density 
(CFU / ml)246 (Supplementary Table S2). Therefore, subinhibitory concentrations of 
tigecycline could be beneficial for treatment of infections by S. aureus USA300, due to the 
lower expression of main virulence factors, Hla/Hly and PVL255, and its probable 
bactericidal activity. 
Oxacillin 
The key factor of oxacillin was that both subinhibitory concentrations had an effect on 
cell wall, which could have achieved the observed cell wall lysis on S. aureus USA300 
cells, as a result of the antibacterial activity of the both oxacillin sub-concentrations. 
However, the reduction over 15 % with 0.5 MIC, in respect to treatment with 0.25 MIC, on 
the S. aureus USA300 proteome showed a stronger effect of this 0.5 MIC, including a 
great effect on cell wall processes. Contrary to the expected, the reduced expression of 
proteins, with 0.5 MIC, were harmful to ribosomal proteins, helicases or nucleases such 
as YbeY (Table 2), and even aforementioned ABC transporters. We also observed that 
there were not a higher expression of proteins involved in resistance to β-lactams (e.g., 
MecA or PBPs). This was interpreted as a not selection to high level resistance to β-
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lactams (homotypic resistance, HoR),261,262 despite the fact that, the increased TCA 
activity and production of acetyl-CoA (Supplementary Table S4) would support the 
selection of heterogeneous expression resistance (HeR) towards the high level 
expression (HoR), to promote survival in the presence of β-lactam antibiotics.261-263 
Since the understanding of this selection remains to be completed, we cannot know if 
these results could be due to the sub-MICs killing the HoR populations, or it could even 
be related with the overexpression of ClpP protease263 (Figure 3c). Anyhow, under 
oxacillin conditions, the biofilm formation was more assisted due to higher expression 
of PSM105 and other proteins involved in biofilm formation. It further increased LukF-
PVL30 significantly. Both facts would advise against its use for infections by PVL producer 
strains. 
Vancomycin 
In samples treated with vancomycin, we observed very few changes and most of them 
common to the other antibiotics. The vancomycin sub-concentrations showed poor 
antibacterial activity, and only the higher dose showed some effect on the cell wall 
synthesis. In samples treated with 0.5MIC, SepF was barely expressed (N-LFQ intensity = 
0.12) and D-Ala pathway was also slightly down-regulated (Supplementary Table S4), 
only for this condition. This down-regulation could have led the bacteria towards an 
increased of peptidoglycan biosynthesis, and consequently increasing the synthesis of 
proteins. These observations could support the significantly increased of HemG only for 
this 0.5MIC (Figure 3d, Supplementary Table S5). The vancomycin sub-concentrations 
had not effect on the virulence factors. 
Non-specific response to antibiotic pressure.  
Some of the observed changes in protein expression appear to be more a non-specific 
responses due to the disruption of the environment of S. aureus USA300 by the 
subinhibitory antibiotic concentrations. Concerning proteins differentially expressed in 
at least 3 of the 4 highest sub-concentrations (0.5 MIC) of the antibiotics, we found 13 
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proteins highly expressed and 96 proteins not expressed. Among the highly expressed 
proteins under antibiotic conditions (Table 4), approximately 40 % have been 
documented to be related with virulence or response to stress, including colonization 
and biofilm formation. For example, PstS has been involved in a reversible adaptation to 
antibiotic stress to survive in the presence of β-lactams,264 and by extension, in our 
study to other antibiotics. In addition, IsdA protein and ClfB are involved in the cell 
adhesion and biofilm formation,265 and are overexpressed under restricted environments 
of iron266 and calcium265 respectively. Hence, the common bacterial response against 
antibiotic pressure was the higher increase of response to stress and biofilm-
formation,265,267 according to the literature. The differentially expressed proteins in 
control not observed under antibiotic conditions, close to 80 % and only 3 % had N-LFQ 
intensities less than 0.20 and more than 0.5, respectively (data not shown). The 
haemolysin HlgA was the unique virulence protein highly expressed in control (N-LFQ 
intensity = 14.32) that was not observed with linezolid, tigecycline and oxacillin. 
Aforementioned AgrC (control N-LFQ intensity = 0.20) was not observed with 
tigecycline, oxacillin and vancomycin treatments, probably owing to lower cell density 
(CFU / ml) observed due to bactericidal activity of these antibiotics (Supplementary Table 
S2). Another EssB/C system (control N-LFQ intensities = 0.23 / 0.17) involved in the 
establishment of infection in the host and dispensable for laboratory growth,268 were not 
detected with any treatment, as expected. 
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Table 4. Differentially expressed proteins only under 0.5MICs of all or three antibiotics. Normalized LFQ intensities, not transformed by log2,  represented 
as the mean among the three replicates. (see excel file SI003 for more information). 
Num 
Ids Protein Name 
ANTIBIOTIC 
Biological 
Category 
Group KEGG_PATHWAY 
Linezolid Tigecyclin Oxacillin Vancomycin 
0.5 μg/ml 0.25 μg/ml 16 μg/ml 1 μg/ml 
338 3-oxoacyl-[acyl-carrier-protein] synthase 3 (EC 2.3.1.180) FabH 0.24 0.28 0.16 0.26 1 
Fatty acid 
biosynthesis 
728 Nicotinamidase (EC 3.5.1.19) 0.09 
 
0.20 0.19 1 
 
132 
tRNA uridine 5-carboxymethylaminomethyl modification enzyme MnmG 
(Glucose-inhibited division protein A) 
0.21 0.67 0.54 0.20 3 
 
1013 Chaperone protein DnaJ 0.11 0.36 0.21 0.15 3 
 
1351 DNA topoisomerase 1 (EC 5.99.1.2) TopA 
 
0.20 0.15 0.15 3 
 
808 D-lactate dehydrogenase (EC 1.1.1.28) Ddh 
 
2.58 0.58 0.18 4 
Pyruvate 
metabolism 
919 
Phosphate-binding protein PstS (PBP);Phosphate ABC superfamily ATP binding 
cassette transporter, binding protein 
0.64 2.51 0.29 
 
5 
ABC transporters. 
Two-component 
system 
303 
Transferrin receptor. Iron (Fe+3) ABC superfamily ATP binding cassette 
transporter, binding protein 
0.10 0.29 0.26 
 
5 ABC transporters 
1163 Clumping factor B ClfB 1.20 3.50 0.43 
 
6 
 
560 
Iron-regulated surface determinant protein A (Fur-regulated protein A) 
(Staphylococcal transferrin-binding protein A) IsdA 
0.57 0.99 1.82 
 
7 
 
1173 
Putative surface anchored protein. LPXTG family cell wall surface anchor protein 
SasF 
1.63 1.25 0.54 
   
743 Staphylokinase Sak 3.66 4.74 1.59 
   
1182 Uncharacterized protein (1) 2.62 2.02 1.02 
   
(1) Putative immunity protein/bacteriocin. Only identified in supernatants. 
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Conclusions 
S. aureus has a marked ability to adapt to different environments by modulation its 
central metabolism according to changing conditions, in vitro and in vivo. The adaptive 
biological response to able to survive, is led by regulatory systems, such as the quorum-
sensing. Nevertheless, to understand the differential protein expression as response to 
antibiotic pressure of S. aureus USA300 strain, it would be necessary a specific regulatory 
network. We think that, the Clp protein family could contribute to antibiotic adaptation, 
and probably can interplay pathogenicity and response to antibiotic pressure. This 
response of S. aureus USA300 strain, to antibiotic pressure of subinhibitory 
concentrations, was led towards greater expression of proteins involved in biofilm 
formation, especially with tigecycline and oxacillin treatments. 
The higher dose were superior and showed an effect on the proteins involved in each 
mechanism of action. The protein synthesis inhibitors, linezolid and tigecycline, inhibited 
the expression of several virulence factors involved in pathogenesis, such as serine 
proteases and haemolysins. The 0.5 MIC of linezolid further significantly decreased the 
expression of enterotoxin Seq and sialoprotein SdrE, which can be an advantage for 
clinical treatment of CA-MRSA infections such as osteomyelitis, bacteremia and even 
endocarditis. Tigecycline was superior against S. aureus USA300 using both subinhibitory 
concentrations, and showed a decreased expression of the main virulence factor of S. 
aureus Hla, as well as of PVL. Tigecycline was also considered to show a bactericidal 
activity. The sub-concentrations of oxacillin were efficient against S. aureus USA300, 
though the higher expression of virulence factor involved in the pathogenesis such as 
PSMs and Luk-F (PVL), more than the possible selection of homotypic-resistant MRSA, 
would reject its clinical used. The vancomycin had not effect over the virulence factors 
and was the less efficient. Hence, this study provides for the proteomic changes in a CA-
MRSA USA300 strain and an insight in cellular response to different sub-concentrations 
of several antibiotics. All these findings might ultimately be useful for further study in a 
clinical-setting. 
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Table S1. Minimal Inhibitory Concentration (MICs) of antibiotics tested against USA 300. 
Figure S1. Schematic diagram of sample preparation (A) culture and (B) digestion, for 
proteomics analysis by LFQ. Table S2. CFU/ml and amount of protein (means) of sub-
MICs tested against USA 300. Cultures were incubated until optical density OD600 reached 
at 2 + 0.1 (stationary phase) and the aliquots were plated on blood-agar. The proteins 
extracts were previously concentrated and 20 μg of protein were loaded and fractionated 
by SDS-PAGE. Table S3. Pathway enrichment study by DAVID with a score more than 2.5. 
Annotation coverage of 45%. Up- or down- regulation of metabolic pathways was defined 
by score enrichment values from DAVID web for each pathway cluster using the score 
value for the antibiotic condition minus the score value of the control (antibiotic – 
control). Differences between  + 1 was considered not significant. Table S4. Biological 
Process distribution of identified proteins (absolute values). Definition of Biological 
Category group in the left.  The GO annotations coverage was 75%. Figure S2. Stress 
Profile Scatter Plot.. Profile scatter-plot for differentially expressed proteins involved in 
pathogenesis and response to stress identified for 0.5MICs. LFQ intensities normalized 
without transforming, represented as the mean among the three (treated samples) and six 
biological replicates (control). n= number of identified proteins,   LFQ i = LFQ intensities 
means. Figure S3. Plots correlation by Pearson coefficient R. MultiScatter Plot showing the 
correlation between LFQ intensities means of identifiend proteins for each subinhibitory 
concentration of every antibiotic, plotted against LFQ intensities means of identifiend 
proteins for the control, and their corresponding Pearson correlation R, for (a) pellet cells, 
and (b) supernatant cells. BLUE = proteins from pellet; BLACK = shared proteins between 
both fractions; RED = proteins from supernatant; GREEN = proteins are not within control. 
P = pellet; S = supernatant; Ctrl = CONTROL; LNZ= linezolid; TIG= tigecycline; OXA= 
oxacilline; VAN= vancomycin. Figure S4. HeatMap and detail of the most relevant 
differences between treated-USA300 and control-USA300. The HeatMap was generated 
by Perseus software, it shows the LFQ intensities means of the untreated-control USA300 
and the treated USA300 (columns), and the proteins names (rows) clustered following the 
instructions from Perseus..The row cluster was defined as < 20. The row color bar show 
the untreated-control USA300´s cluster. The used parameters were the euclidean 
distance linkage as mean, one preprocess with k-means and number the cluster 300 
(parameters by default) to the imputed LFQ intensities and without the preprocess to no 
imputed LFQ intensities. LFQ intensities means calculate as the average among six 
(control) or three replicates (antibiotic). Ctrl= control; LNZ= linezolid; TIG= tigecycline; 
OXA= oxacilline; VAN= vancomycin. Bars of LFQ intensities and GREY = undetectable 
protein. Table S5. Statistical significance and fold change of differentially expressed 
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proteins for 0.5 MICs. Proteins summarized to be associated with mechanism of action of 
antibiotics or pathogenesis Statistical analysis performed by Perseus v.1.4.1.3. Fold-
change 2 (Antibiotic / Control) calculated as [(Antibiotic mean / Control mean)] for each 
protein individually, and 1 log t-test p-value = (log10 p-value)*(-1). absolute value = 
1.30103. (See excel file SI004 for more information).  
 
Excel file SI_001. This file includes a list of the 1284 identified proteins and their LFQ 
intensities, as well as the Protein ID, total number of unique peptides, sequence coverage, 
posterior error probability (PEP) score from MaxQuant. Excel file SI_002. Proteins uniquely 
expressed in untreated USA300 but not observed in treated-control-USA300. LFQ 
intensities normalized without transforming, represented as the mean among the six 
biological replicates. Excel file SI_003. Proteins uniquely expressed in treated USA300 but 
not observed in untreated-control-USA300. LFQ intensities normalized without 
transforming, represented as the mean among the three biological replicates. Excel file 
SI_004. Statistical significance proteins. Statistical analysis performed by Perseus v.1.4.1.3  
where log t-test p-value = (log10 p-value)*(-1), absolute value = 1.30103 and the fold-
change as t-test difference (antibiotic – control). 
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FIGURES 
Figure S1. Schematic diagram of sample preparation (A) culture and (B) digestion, for proteomics 
analysis by LFQ. TSB= Tripticase-soy broth. LNZ= linezolid; TIG= tigecycline; OXA= oxacilline; VAN= 
vancomycin.  
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Figure S2. Stress Profile Scatter Plot under 0.5MICs. 
   LFQ i = LFQ intensities means. 
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Figure S3. Plots correlation by Pearson coefficient R.  
 
 
 
 
BLUE = proteins from pellet; BLACK = shared proteins between both fractions; RED = proteins from 
supernatant; GREEN = proteins are not within control.  
P = pellet; S = supernatant; Ctrl = CONTROL; LNZ= linezolid; TIG= tigecycline; OXA= oxacilline; VAN= 
vancomycin  
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Figure S4. Heat Map and detail of  the most significants changes with respect to untreated-control-USA300. 
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TABLES 
MATERIAL AND METHODS  
Table S1. MICs  of antibiotics tested against USA 300. 
 
 
*MICs used to this study except the vancomicyn where the MICs by E-test was used. 
 
 
 
RESULTS AND DISCUSSION 
Table S2. CFU/ml and amount of protein (means) of sub-MICs tested against USA 300.  
      Amount (gr) of protein (mean) 
 
Concentration 
(μl/ml) 
CFU/ml  
(mean) 400 μl of pellet 1 ml of supernatant 
Linezolid 
0.25 1.54E+11  1 3.6 
0.5 1.58E+11  0.65 1.87 
Tigecycline 
0.125 8.68E+09  0.5 2.6 
0.25 6.77E+09  0.44 1.9 
Oxacillin 
16 2.57E+10  1.1 1.9 
32 7.77E+09  1.1 1.8 
Vancomycin 
0.5 2.77E+11  1.2 2.2 
1 1.05E+10  0.74 2.75 
Control 
 
3.52E+11  1.2 2.25 
 
 
 
  MIC (mg/L) in MH-I I  medium 
  Microdilution* E-test 
 Linezolid 1 1 
 Tigeciclyn 0.5 0.5 
 Oxacillin  32 16 
 Vancomycin 0.5 2* 
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Table S3. Pathway enrichment study by DAVID with an annotation coverage of 45%.  
 
 
ANTIBIOTIC 
Pathway Cluster 
Linezolid Tigecycline Oxacillin Vancomycin 
0.25 
μg/ml 
0.5 
μg/ml 
0.12 
μg/ml 
0.25 
μg/ml 
8 
μg/ml 
16 
μg/ml 
0.5 
μg/ml 
1 
μg/ml 
Ribosome             
 
  
Purine metabolism             
 
  
Aminoacyl-tRNA biosynthesis 
  
        
  Pyrimidine metabolism 
 
              
Glycolysis / Gluconeogenesis 
 
  
 
  
 
  
  Citrate cycle (TCA cycle) 
 
      
 
  
  Pyruvate metabolism / Propanoate metabolism 
 
  
 
  
 
  
  Peptidoglycan biosynthesis 
 
  
 
  
 
  
  Amino sugar and nucleotide sugar metabolism         
 
      
Oxidative Phosphorylation 
 
      
    Fatty acid biosynthesis 
 
      
 
  
  Nucleotide excision repair     ND ND 
 
ND   
 D-Alanine metabolism 
 
  
 
      
 
  
  
              
ND = Enrichment score No determined 
 
 
 
+3 +1.5 +1 -regulation / Down-  -1 -1.5 -3 -6 
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Table S4. Biological Process distribution of identified proteins (absolute values). 
Biological 
Category 
group  
BIOLOGICAL PROCESS  Control  
Linezolid  Tigecycline  Oxacilllin  Vancomycin  
Total 0.25 
μg/ml  
0.5 
μg/ml  
0.12 
μg/ml  
0.25 
μg/ml  
8 μg/ml  16 
μg/ml  
0.5 
μg/ml  
1 μg/ml  
1  
METABOLISM  
CARBOHIDRATES  41  40  40  28  31  41  38  39  39  46  
LIPID-FATTY AC MP  17  18  17  9  11  15  17  14  18  21  
CATABOLIC MP  2  3  3  1  2  2  2  3  2  4  
BIOSYNTHETIC MP  8  6  6  5  4  8  6  6  8  10  
MP  31  28  28  14  13  31  23  26  31  41  
PRIMARY MP  10  7  8  5  5  7  7  9  9  11  
2  
AMINO ACIDS & DERIVATIVES MP  44  42 39  18  24  38  31  36  48  56  
PROTEINS MP  49  45  43 28  33  43  45  38  44  56  
3  
NUCLEOTIDE, NUCLEOSIDE AND NUCLEIC ACID MP  56  52  56  30  36  57  46  44  63  71  
DNA MP  17  16  17  11  11  22  14  12  21  27  
REPLICATION  13  11  15  10  8  16  10  11  17  20  
TRANSCRIPTION  25  21  22  14  10  23  22  20  27  37  
TRANSLATION  80  78  82  64  70  77  69  77  79  84  
4  
OXIDO-REDUTION  26  21  27  12  15  22  19  18  28  33  
GENERATION OF PRECUSOR METABOLITES &ENERGY  22  22  22  19  18  21  18  22  22  22  
OTHERS (Vit, CoEnz, Cofactor & others)  23  22  20  10  15  30  23  20  25  32  
5  TRANSPORT  
Metal IonTransport  12  12 16  7  7  10  8  11  9  17  
Others  25  20 21  5  6  15  11  19  22  30  
6  
CELL-CELLULAR 
MP  
CELL ORGANIZATION & BIOGENESIS  32  29  32  21  19  29  25  26  28  33  
CELL CYCLE, CELL ADHESION & CELL DIVISION  8  3  7  5  8  6 5  4  6  14  
7  
CELL DEATH, CELL KILLING & REPRODUCTION  11  10  10  8  8  12 11  10  12  14  
SIGNAL TRANSDUCTION  8  7  7  3  3  7  7  6  10  10  
CELLULAR PROCESS  6  6  6  1  1  5  3  3  6  6  
CELLULAR HOMEOSTASIS  8  8  8  3  3  9  8  7  8  9  
CELLULAR COMPONENT ORGANIZATION  1  1  1  1  1  1  0  1  1  1  
RESPONSE  
TO STRESS  9  10  8  7  7  13  12  8  10  13  
TO BIOTIC STIMULUS  0  0  0  0  0  1  1  0  0  1  
PATHOGENESIS  8  8  8  6  9  10  12  8  8  12  
-  UNKNOWN  182  169  162  73  88  157  123  137  163  249  
TOTAL 774 715 731 418 466 728 616 635 764 980 
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Table S5. Statistical significance and fold change of differentially expressed proteins for 0.5 MICs. 
Num 
Ids Protein Name 
ANTIBIOTIC 
Biological 
Category 
Group KEGG_PATHWAY 
linezolid tigecyclin oxacillin vancomycin 
(1) 
log t-
test p-
value2 
Fold-
change3 (1) 
log t-
test p-
value2 
Fold-
change3 (1) 
log t-
test p-
value2 
Fold-
change3 (1) 
log t-
test p-
value2 
Fold-
change3 
(1) Statistically Significant Proteins 
320 
ATP-dependent Clp protease proteolytic subunit (EC 3.4.21.92) 
Endopeptidase ClpP 
 
0.03 2.41 + 1.96 4.63 
 
2.41 2.87 
 
0.01 0.78 2   
363 I57 family staphostatin B SspC 
 
NaN NaN 
 
NaN NaN + 2.13 0.16 
 
0.15 0.98 2   
1074 Serine protease SplE (EC 3.4.21.-) + 1.84 0.39 + 2.68 0.05 
 
0.05 0.43 
 
0.20 0.62 2   
1076 Serine protease SplC (EC 3.4.21.-) 
 
NaN NaN + 2.61 0.01 
 
1.18 0.06 
 
0.05 0.76 2   
1096 tRNA N6-adenosine threonylcarbamoyltransferase (EC 2.3.1.-) TsaD 
 
NaN NaN + 2.52 1.75 
 
NaN NaN 
 
0.89 1.41 2   
1256 Signal recognition particle protein (Fifty-four homolog) Ffh 
 
2.15 1.58 + 3.88 6.03 
 
0.20 1.56 
 
0.40 1.06 2 
Protein export. Bacterial 
secretion system 
206 Single-stranded DNA-binding protein Ssb 
 
0.31 1.00 
 
NaN NaN + 3.92 4.11 
 
0.16 0.49 3 
DNA replication. Mismatch 
repair. Homologous 
recombination 
229 RNA methyltransferase, TrmH family, group 3 
 
1.21 1.06 + 2.04 2.79 
 
0.79 3.31 
 
1.31 1.45 3   
534 Phosphoribosylformylglycinamidine synthase 2 (EC 6.3.5.3) PurL 
 
0.26 0.68 + 4.93 0.07 
 
0.60 0.73 
 
0.14 0.82 3 Purine metabolism 
538 Phosphoribosylamine--glycine ligase (EC 6.3.4.13) PurD 
 
0.02 0.87 + 3.34 0.12 
 
1.84 0.39 
 
0.02 0.97 3 Purine metabolism 
564 Phenylalanine-tRNA ligase / tRNA synthetase beta subunit (EC 6.1.1.20) PheT 
 
0.14 0.90 
 
0.35 1.72 + 3.93 4.76 
 
0.29 1.06 3 
Aminoacyl-tRNA 
biosynthesis 
632 Transcriptional regulator, Fur family 
 
NaN NaN 
 
NaN NaN + 1.93 0.26 
 
0.20 1.04 3   
901 Proline--tRNA ligase (EC 6.1.1.15) (Prolyl-tRNA synthetase) ProRS 
 
1.30 1.23 + 4.03 3.91 
 
0.35 1.66 
 
0.69 2.21 3 
Aminoacyl-tRNA 
biosynthesis 
972 30S ribosomal protein S1 RpsA 
 
0.64 0.54 + 3.23 0.36 
 
1.42 0.34 
 
0.28 0.66 3 Ribosome 
1204 50S ribosomal protein L3 RplC + 3.15 10.99 + 4.09 26.97 
 
0.48 11.77 
 
0.13 1.40 3 Ribosome 
2 Protoporphyrinogen oxidase (EC 1.3.3.4) HemG 
 
NaN NaN 
 
NaN NaN 
 
NaN NaN + 4.38 1.96 4 
Porphyrin and chlorophyll 
metabolism 
253 Ser-Asp rich fibrinogen/bone sialoprotein-binding protein SdrE + 3.18 0.04 
 
0.50 0.62 
 
0.11 0.54 
 
0.55 0.33 6   
Manuscript: Supplementary Information 
 
133 
504 Staphylococcal enterotoxin Q Seq + 1.10 1.03 
 
0.25 1.84 
 
0.08 0.88 
 
0.07 1.39 7   
622 Panton-Valentine leukocidin, LukF-PV 
 
0.08 0.96 
 
0.04 0.59 + 1.98 1.94 
 
0.40 0.58 7   
337 Possible extracellular adherence protein Eap 
 
0.08 1.34 
 
0.21 0.95 + 1.67 2.07 
 
0.42 0.53     
402 Virulence protein EsaA 
 
0.30 0.73 
 
NaN NaN + 3.75 0.08 
 
0.60 0.66     
1187 
3'5'-aminoglycoside phosphotransferase (Aminoglycoside 3'-
phosphotransferase) (EC 2.7.1.95) Aph(3')III 
 
0.71 0.60 + 1.83 0.57 
 
0.78 0.65 
 
1.20 1.93     
Not statistically Significant Proteins 
1166 Zinc metalloproteinase aureolysin (EC 3.4.24.29) Aur 
 
1.13 0.15 
 
1.91 0.08 
 
0.48 0.26 
 
0.63 2.13 2   
1184 Beta-lactamase BlaZ 
 
1.15 4.44 
 
0.82 1.47 
 
2.52 2.76 
 
0.91 1.14 2 
beta-Lactam resistance. 
Two-component system 
236 
DNA-directed RNA polymerase subunit beta (RNAP subunit beta) (EC 2.7.7.6) 
RpoB 
 
0.48 1.39 
 
0.93 2.28 
 
1.48 2.44 
 
0.12 0.88 3 
Purine metabolism. 
Pyrimidine metabolism. RNA 
polymerase 
237 
DNA-directed RNA polymerase subunit beta' (RNAP subunit beta') (EC 
2.7.7.6) RpoC 
 
0.36 1.48 
 
0.72 1.83 
 
1.14 2.22 
 
0.24 1.03 3 
Purine metabolism. 
Pyrimidine metabolism. RNA 
polymerase 
452 Transcriptional regulator SarA (Staphylococcal accessory regulator A) 
 
0.84 2.10 
 
0.35 1.95 
 
1.12 4.89 
 
0.07 1.27 3   
769 30S ribosomal protein S5 RpsE 
 
0.77 2.88 
 
0.19 3.40 
 
0.04 2.04 
 
0.20 1.19 3 Ribosome 
1205 30S ribosomal protein S10 RpsJ 
 
0.68 0.67 
 
0.04 1.61 
 
1.45 0.51 
 
0.47 1.10 3 Ribosome 
149 
MecA (Pbp2a) (Pencillin binding protein 2a (PBP 2a, methicillin resistance 
determinant MecA, transpeptidase); (EC 3.4.16.4) 
 
0.92 2.28 
 
0.18 1.19 
 
0.07 0.97 
 
0.87 2.25 6 beta-Lactam resistance 
364 Cysteine protease (EC 3.4.22.48);C47 family staphopain B SspB 
 
0.31 0.54 
 
1.90 0.05 
 
0.71 0.10 
 
0.25 0.24 7   
574 Alpha-haemolysin Hly 
 
0.56 0.42 
 
2.20 0.07 
 
0.45 0.22 
 
0.16 1.17 7   
623 Panton-Valentine leukocidin, LukS-PV 
 
0.63 0.71 
 
1.03 0.35 
 
0.48 0.48 
 
0.07 1.11 7   
704 Septation ring formation regulator EzrA 
 
0.98 1.26 
 
0.43 0.95 
 
1.58 0.50 
 
0.00 0.89 7   
993 Superoxide dismutase [Mn/Fe] 1 (EC 1.15.1.1) SodA 
 
0.07 1.05 
 
1.29 3.48 
 
1.88 2.15 
 
0.27 0.92 7   
1252 Cell division protein FtsZ 
 
1.55 1.61 
 
0.71 1.31 
 
1.24 0.66 
 
0.10 0.93 7   
1397 Delta-haemolysin Hld 
 
1.03 0.15 
 
NaN NaN 
 
0.12 0.77 
 
0.32 0.65 7   
1167 Immunodominant staphylococcal antigen B IsaB 
 
0.07 0.69 
 
1.73 0.18 
 
2.12 0.14 
 
0.08 0.91     
(1) Statistically significant proteins = + 
(2) log t-test p-value = (log10 p-value)*(-1), absolute value = 1.30103 
(3) Fold-change (Antibiotic / Control) calculated as [(Antibiotic mean / Control mean)] for each protein individually. Values < 0.5 are down-regulated proteins and values > 2 are 
up-regulated proteins. 
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Free PMC article available : http://jcm.asm.org.pva.uib.no/content/46/12/4114 
PMID:18945834 [PubMed - indexed for MEDLINE] PMCID: PMC2593277 
Abstract not available. 
 
 
 
"Staphylococcus aureus strains with resistance to methicillin or oxacillin (MRSA) 
represent one of the main nosocomial pathogens at present. MRSA infections are clearly 
associated with higher mortality and economic cost than those caused by methicillin-
susceptible S. aureus (1). In Spain, the prevalence of methicillin resistance among S. 
aureus isolates has increased since the 1990s and in some cases has now reached levels 
higher than 30% (2). 
A total of 301 S. aureus strains were evaluated (51 mecA negative and 250 mecApositive 
as determined by PCR). S. aureus ATCC 29213 was used as a negative control. Molecular 
typing of the X region of the spa gene was done with the 250mecA-positive isolates (4), 
and these were then grouped into a spa clonal complex (BURST.Ridom StaphType 
software), with 4 types more prevalent than the others (t02, 23.6%; t18, 22%; t67, 17.6%; 
and t12, 16.3%)." 
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J Med Microbiol. 2012 Feb;61(Pt 2):305-7. doi: 10.1099/jmm.0.036889-0. Epub 2011 Oct 6. 
 
 
PMC Article available : http://jmm.sgmjournals.org.pva.uib.no/content/61/2/305 
PMID:21980043 [PubMed - indexed for MEDLINE 
Abstract not available 
 
 
"The aim of the present study was to determine the circulating clones in the north of 
Spain and their antimicrobial susceptibility. A total of 455 MRSA isolates were collected 
in 16 Spanish hospitals over a 4-month period (February–May 2009) and included in this 
analysis. One sample was taken per patient, and the isolates were mainly from the 
respiratory tract and wounds. 
In conclusion, this study highlights the predominance of spa-CC067 and ST-CC5 (spa-
t067 and t002) and of SCCmec IV in north Spain hospitals, the utility of spa-typing in 
short-term epidemiological surveillance, and a high prevalence (91.4 %) of MRSA isolates 
with a ‘borderline’ MIC for VAN (>1 mg l−1), which has been associated with a poor 
response to this antibiotic." 
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Material & methods 
1 Identification of clones of MRSA. Antimicrobial susceptibility.  
1.1 Bacterial strains and reagents. 
MRSA strains were collected in different Spanish hospitals from the north of Spain: 
University Hospital Complex of A Coruña (CHUAC), Ourense (CHOU), Vigo (CHUVI), 
University Clinical Hospital of Santiago de Compostela (CHUS), Hospital of Coast (Burela, 
Lugo), Architect Marcide Hospital (Ferrol, La Coruña), Xeral Calde University Hospital 
(Lugo), Civil Hospital of Basurto (Bilbao), General Yagüe (Burgos), Hospital Complex of 
Leon, Bierzo Hospital (Ponferrada, Leon), Virgen del Camino Hospital (Pamplona), 
Donostia Hospital (San Sebastian), Marques de Valdecilla University Hospital-IFIMAV 
(Santander), Hospital of Soria, Hospìtal of Sierrallana (Torrelavega, Burgos), University 
Clinical Hospital of Valladolid. 
S. aureus strains ATCC 29213 and ATCC 25923 were used as controls for MIC 
determinations, and Mu3 and Mu50 kindly provided by Dr. Rafa Cantón (Ramon y Cajal 
Hospital, Madrid) were used as control for glycopeptide resistance. 
1.2 Determination of MICs. 
All strains were tested by microdilution VITEK-2 with AST-P559/-588 cards (bioMérieux, 
Marcy l’Etoile, France). The sensitivity to ciprofloxacin, cotrimoxazole, clindamycin, 
erythromycin, gentamicin, rifampicin and mupirocin were confirmed by disk diffusion and 
the results were interpreted according to the rules of the Clinical Laboratory Standards 
Institute (CLSI)14. The sensitivity to linezolid and glycopeptides, vancomycin and 
teicoplanin were confirmed by E-test. 
1.3 Molecular characterization. 
1.3.1 DNA extraction.  
A loopful of material from an overnight culture (grown on blood agar plates) was 
suspended in 0.5 ml sterile H2O. The suspension was heated to 95°C for 10 min. After 
centrifugation at 14 000rpm for 5 min, the supernatant was used for PCRs.  
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1.3.2 PCR conditions and sequencing 
The primers used for each PCR and the conditions, initial denaturation, cycles/Tº/time 
and final extension, are summarized in Table 1.3. Reactions were performed in a 25-µl 
volume with buffers and ECOTaq DNA polymerase from Ecogen. PCR products were 
purified with Montage®-PCR Filter Units from Millipore and sequenced with PCR forward 
or reverse primers, with BigDye® Terminator v1.1 Cycle Sequencing Ready Reaction kit 
(Applied Biosystems). DNA sequences were obtained with an ABI PRISM 3100 Avant 
sequencer (Applied Biosystems). The chromatogram files were assembled and edited 
using Chromas Pro.  
1.3.3 Spa typing and classification. 
The variable X region of the spa gene was amplified by PCR with the primers 1095Fow 
and 1517Rev.269 In case the sample did not amplificate, another reverse primer (5'-
GAACAACGTAACGGCTTCATCC-3') was used with the same forward primer and 
conditions. Spa types were determined with specific software (www.seqtools.com) 
developed for this study, using the Ridom nomenclature. The new types we found were 
submitted at the Ridom Spa Server (www.spa.ridom.de). 
Spa-types with similar repeat profiles were clustered into different groups (spa-CC) with 
calculated cost between members of a group  6. Spa-types shorter than 3 repeats were 
excluded from analysis. This was kindly performed by Dag Harmsen using the BURP 
clustering of the Ridom Staph Type software (www.ridom.de/staphtype).  
1.3.4 Multilocus sequence typing (MLST) and classification. 
MLST was performed to one representative strain of each spa type.270 The S. aureus 
MLST scheme uses internal fragments of the following seven house-keeping genes: 
arcC, aroE, glpF, gmk , pta, tpi and yqiL. PCR amplification was carried out using an 
annealing temperature of 55ºC. The same primers were used for amplification and 
sequencing. Sequence types (ST) and MLST-clonal complex (ST-CC) were determined 
with the database accessible via internet (www.mlst.net) where 7 numbers depicting the 
allelic profile defined a ST.  
1.3.5 Methicillin resistance and Panton Valentine leukocidin. 
The detection of PVL virulence genes and simultaneous confirmation of methicillin-
resistant staphylococci were performed with the multiplex PCR271 to all the isolates. It 
was performed containing 0.08 and 0.24 µM for the primers specific for the lukS/F-PV, 
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and mecA genes, respectively. The PCR produced distinct bands, corresponding to their 
molecular sizes (433bp and 310bp for the lukS/F-PV, and mecA genes, respectively).  
1.3.6 SCCmec typing. 
The method described by Lencastre et al.,272,273 was used for the investigation of 
SCCmec type in the mecA-positive isolates.  
1.3.7 Agr locus PCR and sequencing. 
The characterization of agr locus was realized in at least two representative strain of 
each type spa. It characterized the type of agr by means of amplification and later 
sequencing of the agrC.274 The sequencing made with BigDye Terminator v1.1 Cycle 
Sequencing Ready Reaction kit, using an Abi Prism 3100-Avant (Applied Biosystems). 
1.3.8 Aminoglycosides resistance. 
All study strains were tested for the presence of genes encoding key enzymes that 
confer resistance to aminoglycosides. It was conducted by PCR-multiplex for the 
ant(4´)-Ia, aph(3´)-IIIa and aac(6´)-Ie+aph(2´´) genes.275 
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Table 1.3. Primers used for this study & PCR conditions. 
GEN SIZE(pb) PRIMERs (5’3’) PCR conditions 
mecA 310 
mecA1 GTAGAAATGACTGAACGTCCGATAA 
Methicillin resistance and PVL 
 
80ºC 10min 
35x [94ºC 45s + 60ºC 45s + 72ºC 1min 30s] 
72ºC 10 min 
mecA2 CCAATTCCACATTGTTTCGGTCTAA 
pvl 433 
Luk-pvl-1 ATCATTAGGTAAAATGTCTGGACATGATCCA 
Luk-pvl-2 GCATCAAGTGTATTGGATAGCAAAAGC 
Spa-X 30-500 
1095-F AGACGATCCTTCGGTGAGC 
1517-R GCTTTTGCAATGTCATTTACTG 
Aac(6´)-Ie+aph(2´) ~220 
Aac-2022 CCAAGAGCAATAAGGGCATACC 
Aminoglycosides resitance. 
 
94ºC 5 min 
35x [94ºC 20s + 55ºC 60s + 72ºC 50s] 
72º C 10 min 
Aac-2369 CACACTATCATAACCATCACCG 
Ant(4´)-Ia 172 
Ant-605 CTGCTAAATCGGTAGAAGC 
Ant-777 CAGACCAATCAACATGGCACC 
Aph(3´)-III 268 
Aph-329 CTGATCGAAAAATACCGCTGC 
Aph-597 TCATACTCTTCCGAGCAAAGG 
I, J1 region 495 
CIF2 F2  TTCGAGTTGCTGATGAAGAAGG  
SCCmec typing 
 
94ºC 5min 
30x [94ºC 30s +  53ºC 30s + 72ºC 1min] 
72ºC 8min 
CIF2 R2 ATTTACCACAAGGACTACCAGC 
V, ccr complex 449 
ccrC F2 GTACTCGTTACAATGTTTGG 
ccrC R2 ATAATGGCTTCATGCTTACC 
III, J3 region 414 
RIF5 F10 TTCTTAAGTACACGCTGAATCG 
RIF5 R13  ATGGAGATGAATTACAAGGG 
V, J1 region 377 
SCCmec V J1 F  TTCTCCATTCTTGTTCATCC 
SCCmec V J1 R AGAGACTACTGACTTAAGTGG 
I, II, IV, and VI, J3 region  342 
dcs F2 CATCCTATGATAGCTTGGTC 
dcs R1  CTAAATCATAGCCATGACCG 
II and IV, ccr complex 311 
ccrB2 F2 AGTTTCTCAGAATTCGAACG 
ccrB2 R2  CCGATATAGAAWGGGTTAGC 
II, J1 region  284 kdp F1 AATCATCTGCCATTGGTGATGC 
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kdp R1  CGAATGAAGTGAAAGAAAGTGG 
III, J1 region  243 
SCCmec III J1 F CATTTGTGAAACACAGTACG 
SCCmec III J1 R  GTTATTGAGACTCCTAAAGC 
II and III, mec complex 209 
mecI P2  ATCAAGACTTGCATTCAGGC 
mecI P3 GCGGTTTCAATTCACTTGTC  
Internal positive control  162 
mecA P4 TCCAGATTACAACTTCACCAGG  
mecA P7 CCACTTCATATCTTGTAACG 
arcC 456 
arcC-up TTG ATT CAC CAG CGC GTA TTG TC 
Multilocus sequence typing (MLST) 
 
94ºC 10min 
30x [94ºC 30s +  55ºC 30s + 72ºC 30s] 
72ºC 10min 
arcC-dn AGG TAT CTG CTT CAA TCA GCG 
aroE 456 
aroE-up ATC GGA AAT CCT ATT TCA CAT TC 
aroE-dn GGT GTT GTA TTA ATA ACG ATA TC 
glpF 465 
glpF-up CTA GGA ACT GCA ATC TTA ATC C 
glpF-dn TGG TAA AAT CGC ATG TCC AAT TC 
gmk 429 
gmk-up ATC GTT TTA TCG GGA CCA TC 
gmk-dn TCA TTA ACT ACA ACG TAA TCG TA 
pta 474 
pta-up GTT AAA ATC GTA TTA CCT GAA GG 
pta-dn GAC CCT TTT GTT GAA AAG CTT AA 
tpi 402 
tpi-up TCG TTC ATT CTG AAC GTC GTG AA 
tpi-dn TTT GCA CCT TCT AAC AAT TGT AC 
yqiL 516 
yqiL-up TTT GCA CCT TCT AAC AAT TGT AC 
yqiL-dn CGT TGA GGA ATC GAT ACT GGA AC 
agrI 106 
agrI-F CCAGCTATAATTAGTGGTATTAAGTACAGTAAACT 
Agr locus 
 
95ºC 10min 
30x [95ºC  15s + 60ºC 1min + 72ºC 1min] 
72ºC 10minutos 
agrI-R AGGACGCGCTATCAAACATTTT 
agrII 180 
agrII-F CAATAGTAACAATTTTAGTGACCATGATCA 
agrII-R GCAGGATCAGTAGTGTATTTTCTTAAAGTT 
agrIII 80 
agrIII-F CATTATAACAATTTCACACAGCGTGTT 
agrIII-R GCAAGTGCATAAGAAATTGATACATACA 
agrIV 128 
agrIV-F GAGTTCTCAAAAAGATTAGCTCATCATATC 
agrIV-R TAGCTTCATCCGAGTTTATTTGAGAAT 
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Discussions & Conclusions 
Identification and antimicrobial susceptibility of methicillin-resistant 
Staphylococcus aureus (MRSA) clones. 
 2005. In this study, the most prevalent clone was the pandemic New York / Japan 
(t002, ST5-II), which was associated to MLSBc resistance. The percentage of 
Iberian clone (t051, ST241-I) was significantly low, likely in order to favour other 
clones more transmissible, such as the EMRSA-16 (t018, ST36-II). This EMRSA-16 
clone had been previously described in United Kingdom in 90s and reported to be 
the major clone in two hospitals in Vigo during 1997-2005, in fact our findings 
were very similar to published by Potel et al.276 The EMRSA-16 was also associated 
to mupirocin and MLSbc resistance. The Brazilian clone (t037, ST239-II), probably 
imported from Brazil in 90s, which also became one of major clones in hospitals in 
Vigo,276 represented 2 % of isolates and was associate to cotrimoxazole resistance. 
 2009. In this study, the most prevalent clone was the comunitary t067, ST125-
IV,223 followed for the another comunitary clone, the Pediatric clone (t002, ST5-
IV), which has been associate to ermC plasmid. The prevalence of spa type t008, 
SCCmec IV was high, however all of them were PVL-negative, thus the virulent 
USA300 clone or USA-like clones were not detected. More than 80 % of isolates 
belonged to sequencing type - clonal complex ST-CC5, and even though the 
sample size and number of isolates were bigger, there was a great homogeneity of 
clonal distribution. 
 Clonal evolution over the time: (i) the Iberian clone was replaced for other clones, 
such as (ii) EMRSA-16 clone (ST36-II), which became the prevalent clone until 
2005, to be also replaced. (iii) The comunity t067, ST125-IV got to replace this 
pandemic clone and became the major clone in 2009. (iv) The New York/Japan 
(ST5-II), reported in a northern Spanish in 2005, was replaced by pediatric clone 
(ST5-IV). Therefore, (v) CA-MRSA replaced to HA-MRSA, and increased its 
distribution mainly towards the ST-CC5, getting so one more homogeneity in 
clonal distribution. (vi) The spa-clonal complex CC067 and ST-CC5 were kept over 
the time like the most prevalent clonal complex. 
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 Resistance evolution over the time: (i) ciprofloxacin resistance was remained, 
however (ii) tobramycin resistance, mainly associated to ant (4`) gen, decreased 
more than 40 % in 2009 study respect to 2005, and (iii) erythromycin resistance, 
mainly associated to mrs(A) and mrs(B), and clindamycin resistance, associated to 
ermC and ermA, decreased more than 30 and 50%, respectively; (iv) the 
susceptibility to cotrimoxazole decreased, even disappeared, together with the 
extinction of the Brazilian clone; and (v) for the rest of antibiotics, the 
susceptibility was maintained in both studies, including the CMI90 for linezolid and 
vancomycin (1 μg  and 2 μg / ml, respectively). 
 
 
 
 
 
 
In summary, the epidemiology and antibiotic susceptibility of MRSA can switch over the 
time, especially in favour the clones more transmissible and more able to adapt. In the 
last decade, it has been observed a global change in the epidemiology of MRSA,277 
towards a higher distribution and uniformity of CA-MRSA clones, which are more 
transmissible and also more susceptible. Thus, the movement and displacement of 
clones observed in our study, from a multidrug-resistance HA-MRSA in favour of CA-
MRSA,  contributed to the reduction of observed resistance, as well as being consistent 
with to global change. 
Since, the genotype can determine the pathogenicity and antibiotic susceptibility pattern 
of the bacteria, the application of both sequencing techniques can be especially useful 
in epidemiological studies. In fact, the application of MLST is very useful in long-term 
studies and the spa-typing is more useful in short-term studies. 
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Sinopsis 
Este estudio permite un conocimiento global de la adaptación de la cepa hipervirulenta de 
Staphylococcus aureus resistente a meticilina (SARM)  aislado en la comunidad, USA300 
clon, a la presión antibiótica. Además, marca una diferencia con los anteriores estudios de 
transcriptómica sobre el genoma, donde sólo es posible observar cambios en el ARNm, 
pero no a nivel de proteína, dónde realmente se reflejan de forma directa las adaptaciones 
fisiológicamente relevantes.  
El estudio de los efectos de las concentraciones subinhibitorias de linezolid, tigeciclina, 
oxacilina y vancomicina, se ha centrado sólo en proteínas implicadas en la regulación de 
la patogénesis, virulencia, mecanismos de acción asociadas a cada antibiótico, incluyendo 
mecanismos de resistencia, y la respuesta al stress o presión antibiótica. Por lo tanto en 
este estudio proporcionamos como puede ser la adaptación "in vitro" del proteoma de 
USA300 clon, independiente y dependientemente del mecanismo de acción de cada 
antibiótico, y el posible efecto terapéutico de altas concentraciones subinhibitorias de 
varios antibióticos usados clínicamente. 
 
 
 
 
Palabras clave: USA300, MRSA, patogénesis, proteoma, factores de virulencia.  
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Introducción:  
Staphlylococcus aureus es un patógeno humano, Gram-positivo, de gran importancia 
clínica, principalmente debido a su alta incidencia y propagación de la resistencia a los 
antibióticos. S. aureus resistente a meticilina (SARM), es una causa importante de 
infecciones nosocomiales y asociadas a la comunidad en todo el mundo. Las infecciones 
por SARM causan manifestaciones clínicas que van desde infecciones leves de la piel a 
infecciones graves como bacteriemia y neumonía necrotizante. En los últimos años la 
prevalencia de SARM se ha incrementado drásticamente y, SARM es ahora la principal 
causa de infecciones de piel y tejidos blandos.  
La pérdida de la actividad de los antibióticos β-lactámicos frente a las cepas de S. aureus 
productores de PBP2a, mecA(+), ha obligado a la comunidad médica a usar numerosos 
antimicrobianos alternativos. Esto ha provocado un cambio en la terapia empírica de las 
infecciones estafilocócicas, de tal modo que antibióticos no β-lactámicos con actividad 
contra SARM son cada vez más prescritos. En consecuencia, las cepas de SARM que han 
sido típicamente susceptibles a los antibióticos no β-lactámicos (por ejemplo, 
clindamicina, tetraciclinas, trimetoprim-sulfametoxazol) se están volviendo resistentes a 
estos antibióticos.278,279 Vancomicina, aunque ha conseguido mantenerse como el 
antibiótico de elección contra SARM, su uso clínico ha ejercido una presión selectiva 
continua desencadenando la aparición de S. aureus con susceptibilidad intermedia a 
vancomicina (VISA), o concentraciones mínimas inhibitorias (CMI) elevadas, un fenómeno 
conocido como vancomicina "creep CMI",280-282 así como cepas hetero-resistentes (hVISA) 
e incluso resistentes a vancomicina (VRSA).171,283-285 Estas cepas tienen una 
susceptibilidad reducida a los glucopéptidos, y están asociadas con fracaso286 terapéutico 
a vancomicina. 
S. aureus, además, produce una amplia gama de factores de virulencia que juegan un 
papel importante en la patogénesis de la infección estafilocócica, entre ellos α-
hemolisina (Hla), leucocidinas y toxinas. Particularmente, las cepas de SARM adquiridas 
en la comunidad (SARM-AC) están mejor adaptadas a la evasión de la respuesta inmune 
innata, una característica que probablemente contribuye a su mayor virulencia.102 
Además, la infección por SARM-AC se asocia con necrosis intensa in vivo, que muy 
probablemente conduce a una peor difusión de los antibióticos, lo que consecuentemente 
resulta en bajas concentraciones en los sitios de infección. De acuerdo con las recientes 
directrices basadas en varias series de datos in vitro, se recomienda el uso de antibióticos 
que inhiban la expresión de los factores de virulencia para el tratamiento de infecciones 
graves causadas por S. aureus, incluidas las productores de la toxina Panton-Valentine 
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leucocidina (PVL).287 Por otro lado, varios estudios han demostrado que las 
concentraciones subinhibitorias de antibióticos pueden modular la expresión de factores 
de virulencia en S. aureus, y por lo tanto, pueden afectar a la resolución de las infecciones 
estafilocócicas graves. Los resultados de estos estudios sugieren que niveles de sub-CMIs 
de los antibióticos, pueden mejorar la producción de algunos de los factores de virulencia 
mientras disminuyen la síntesis y liberación de los demás, en consecuencia, a través de 
esta `manipulación´ de los factores de virulencia, los antibióticos podrían empeorar o 
atenuar la enfermedad.288 Por lo tanto, la eficacia del tratamiento para las infecciones por 
S. aureus puede depender no sólo de los efectos bacteriostáticos o bactericidas del 
antibiótico, sino también de su capacidad para evitar la liberación de los factores de 
virulencia.178,245,289,290 También debe tenerse en cuenta que, la resistencia y tolerancia a 
antibióticos se cree que evoluciona en entornos con concentraciones subinhibitorias de 
antibióticos, como el entorno natural o cuerpo humano, además de la propia fluctuación 
de la concentración del antibiótico administrado en el tiempo y el espacio.  
En los últimos años, la transcriptómica ha comenzado a ser aplicada al estudio de la 
resistencia antibiótica.291-293 Estos estudios han demostrado que los antibióticos 
provocan respuestas transcripcionales específicas, involucrando muchas vías de 
transducción de señales metabólicas, que apoyan la idea de que la susceptibilidad a los 
antibióticos debe ser examinada desde un punto de vista global. El uso de métodos de 
espectrometría de masa (EM) con tecnología de última generación para perfilar los 
cambios en la expresión de las proteínas bacterianas ha sido un paso natural. Unos pocos 
estudios, proteo-transcriptómicos y de proteómica comparativas (iTRAQ combinan con 
2-DE), han sido empleados para estudiar el mecanismo de resistencia en S. aureus a 
daptomicina y vancomicina, respectivamente.294-296 En general, se observó una pobre 
correlación entre los datos de proteómica y transcriptómica. Los estudios de  proteómica 
comparativa revelaron que proteínas asociadas a la pared celular y formación de 
biopelículas, se expresaban diferencialmente en la adaptación a daptomicina.295 En el 
segundo estudio, rutas metabólicas como biosíntesis y metabolismo de la pared celular, 
se encontraban reguladas positivamente (+) en cepas con susceptibilidad intermedia a 
vancomicina.296 El primer estudio que describe los cambios en todo el proteoma de SARM 
bajo concentraciones subinhibitorias de oxacilina, y utilizando cuantificación sin marcaje 
(LFQ), han sido publicado recientemente por Liu et al.,247 quienes investigaron los 
cambios globales en el perfil proteómico de SARM y S. aureus sensibles a meticilina, bajo 
condiciones de estrés a oxacilina, para entender los mecanismos de resistencia y de 
tolerancia desde un punto de vista sistemático.  
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Objetivos:  
El objetivo de este estudio fue investigar la respuesta celular de la cepa de S. aureus 
USA300, bajo dos concentraciones subinhibitorias de cuatro antibióticos de uso clínico, 
linezolid, tigeciclina, oxacilina y vancomicina, y por lo tanto el efecto de los mismos en el 
perfil proteómico de USA300. Los resultados además nos proporcionaran una visión 
global de la respuesta al estrés, y/o mecanismo de adaptación de SARM-AC USA300 a 
estas concentraciones subinhibitorias, así como las proteínas involucradas. 
Materiales y métodos. 
Cepas bacterianas y reactivos: USA300 clon146,200 (Staphylococcus aureus resistente a 
meticilina adquirido en la comunidad, SARM-AC). Antibióticos: linezolid, tigeciclina, 
vancomicina y oxacilina. 
Determinación de CMIs: Método de microdilución en caldo recomendado por el Clinical 
Laboratory Standards Institute (CLSI)14 en medio Mueller-Hinton II y por E-Test ® 
siguiendo las instrucciones del fabricante (bioMérieux). Los experimentos se realizaron 
por triplicado.  
Preparación de la muestra para el análisis proteómico: Condiciones de cultivo: Una única 
colonia de USA300 se inoculó en 5ml de TSB estéril toda la noche  a 37°C/200 rpm.  
100μl de este cultivo fueron inoculados en 10ml de TSB (Figura 1). El crecimiento se 
monitorizó espectrofotométricamente hasta fase estacionaria temprana. En este punto, se 
añadieron concentraciones de 0,25 y 0,5 CMIs de cada antibiótico. Las concentraciones 
utilizadas fueron: 0,25 y 0,5 μg/ml para linezolid, 0,12 y 0,25 μg/ml para la tigeciclina, 8 
y 16 μg/ml para oxacilina, 0,5 y 1 μg/ml para la vancomicina, respectivamente. Los 
cultivos con o sin antibióticos se volvieron a incubar durante 4 horas/37°C/200 rpm hasta 
fase estacionaria. Posteriormente, las bacterias se sembraron en agar sangre para 
determinar UFC/ml. Los experimentos fueron realizados por triplicado. Las bacterias 
fueron recogidas por centrifugación a 2 000x g/10 min/4°C,  se lavaron 3 veces con PBS a 
1 000x g/5 min/4°C. El sedimento se resuspendió en Tris-HCl-SDS. Las paredes de las 
células se lisaron mecánicamente en un Ribolyser. Lisado y fracción soluble fueron 
clarificados, filtrados y concentrados, y el rendimiento se evaluó con un DetectTM 
Espectrómetro directo. SDS-PAGE y en gel de digestión con tripsina: 20μgr de extracto de 
proteína total fueron posteriormente fraccionados por SDS-PAGE usando un 4-12% Bis-
Tris gradiente. Después de la tinción, cada carril de gel fue dividido en 4 fracciones 
(2.5x10mm), y cada fracción se sometió a reducción en gel- alquilación-digestión con 
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tripsina de acuerdo con el protocolo utilizado en la Unidad de Proteómica de la 
Universidad de Bergen (PROBE). La mezcla de péptidos resultante se desaló en fase 
inversa C18 y se diluyó en 0,1% de Tri-fluor-acético234 antes del análisis nano-LC-ESI-
QTOF-EM/EM. (Figura 1)  
Figura 1. Preparación de las muestras (A) cultivo y (B) digestión. LNZ= linezolid; TIG= tigeciclina; OXA= 
oxacilina; VAN= vancomicina.  
 
 
Espectrometría de masas (EM): Todos los experimentos se realizaron en un sistema de 
nano-3000 LC Dionex final) conectado a un LTQ-Orbitrap espectrómetro de masas. El 
disolvente A fue acetonitrilo acuoso al 2% en ácido fórmico al 0,1%, y el disolvente B fue 
acetonitrilo acuoso al 90% en ácido fórmico al 0,1%.297  
Secuencia de búsqueda de base de datos: Todos los datos obtenidos fueron procesados y 
analizados utilizando MaxQuant (versión 1.4.1.2)235 software desarrollado 
específicamente para datos adquiridos por instrumentación de alta resolución. La 
identificación de proteínas se realizó mediante la búsqueda de los datos por separado 
frente a las proteínas de USA300 desde la base de datos descargada de UniProt. La 
identificación de proteínas y su validación fue realizada con el uso de Identify.exe y los 
siguientes parámetros: FDR:298 0,01 (1%), longitud mínima de péptido fue de 7 
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aminoácidos, y para garantizar una tasa de identificación de alta confianza, y el número 
mínimo de péptidos únicos por proteínas: 1. Entonces las proteínas fueron validadas 
estadísticamente en base a la puntuación de sus péptidos individuales. Utilizando estos 
criterios, todas las identificaciones EM/EM de péptidos presentes en las entradas con 
secuencias invertidas, sólo identificados por sitio y los contaminantes no fueron 
validadas. Proteínas identificadas con confianza en al menos dos de cada tres réplicas 
biológicas para los ensayos de antibióticos y tres de las seis réplicas biológicas para el 
control no tratado se incluyeron en el análisis posterior.  
Cuantificación sin marcaje: La cuantificación basada en el área del pico se realizó en 
MaxQuant. El análisis estadístico y visualización fue realizado usando Perseus 
(v.1.4.1.3).237 Las proteínas expresadas diferencialmente se filtraron por el siguiente 
corte de valor de p para la prueba t < 0.05. El fold change fue calculado como t-test 
diferencia (antibiótico –control) para los datos transformados por log2 y como el ratio 
(antibiótico / control) de los datos sin transformar. 
Análisis Bioinformático: Para determinar la localización subcelular de las proteínas, así 
como su proceso biológico (BP), la función molecular, y otras anotaciones, se utilizó 
UniProt-database. Todas las proteínas identificadas se analizaron mediante el uso de la 
web DAVID239 a través de la cual se calculó el algoritmo para evaluar el enriquecimiento 
de las vías metabólicas. Para mostrar estas proteínas en el contexto de su red 
interactuante, se utilizó STRING 9.1240 para predecir las interacciones proteína-proteína y 
Medusa 1.5241 para mostrar el análisis gráfico. 
Resultados y discusión  
Identificación global de las proteínas de USA300: Se identificaron un total de 1 284 
proteínas, de las cuales 980 estaban presentes en al menos dos réplicas biológicas y por 
lo tanto fueron considerados como proteínas válidas para su posterior análisis. Esto 
representó aproximadamente el 40% de las aproximadamente 2 600 proteínas 
codificadas en el genoma de USA300 anotado por Diep et al.146  
La Figura 2 muestra los correspondientes diagramas de Venn que describen las proteínas 
comunes e identificadas de forma selectiva para cada antibiótico y condición. 
Análisis cualitativo. Distribución de las proteínas identificadas con respecto a la 
localización celular, función biológica y ruta metabólica: Para comparar los cambios entre 
las diferentes condiciones de antibióticos, primero analizamos la localización celular de 
las proteínas identificadas. Linezolid y vancomicina no mostraron cambios significativos 
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con respecto a la distribución de la localización celular. Sin embargo, en las muestras 
tratadas con 0.5sub-CMI de oxacilina y tigeciclina, las proteínas de membrana, 
especialmente proteínas implicadas en procesos de transporte, fueron reducidas en 
número en más de un 30%. Por otra parte, el número de proteínas extracelulares aumentó 
más del 40% para estas mismas condiciones de 0.5sub-CMI de tigeciclina y oxacilina. Esta 
pérdida de proteínas transportadoras de membrana podría estar asociado a una pérdida 
de la viabilidad de la función de la pared celular, y el gran número de proteínas 
extracelulares podría estar asociado con un incremento en los factores de virulencia y / o 
respuesta al estrés, para estas sub-concentraciones. 
Figura 2. Diagrama de Venn. Diagrama de Venn  para la comparación del proteoma entre el control-no 
tratado y las concentraciones subinhibitorias (0.25 MIC y 0.5 MIC) de linezolid, tigeciclina, oxacilina y 
vancomicina. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Para seguir con este análisis cualitativo, utilizamos el programa disponible en la web 
DAVID. Este análisis nos permitió conocer la distribución de estas 980 proteínas respecto 
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a los procesos biológicos (BP) anotados, y a las rutas metabólicas anotadas, con sus 
respectivos "escores de enriquecimiento", para cada condición de antibiótico respecto del 
control. Las proteínas anotadas por estar implicadas en el metabolismo de carbohidratos 
(grupo 1), aminoácidos y derivados de los procesos metabólicos y metabolismo de las 
proteínas (grupo 2), y procesos metabólico de los ácidos nucleicos, nucleótidos y 
nucleósidos (grupo 3), constituyeron el 50% sobre el total (Figura 3) para todas las 
condiciones. 
Figura 3. Distribución de los Procesos Biológicos de las proteínas diferencialmente expresadas 
agrupadas en diferentes grupos. 
 
El análisis de los "scores de enriquecimiento" con respecto a las rutas metabólicas (Figura 
4) difirieron enormemente entre los cuatro antibióticos, por ejemplo, para la 0.25sub-CMI 
de linezolid se observó una regulación negativa (-) de la vía ribosomal, sin embargo con 
la concentración de 0.5sub-CMI esta misma ruta metabólica estaba regulada 
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positivamente (+). Ahora bien, todas las sub-CMIs consiguieron modificar la regulación 
de la ruta del metabolismo ribosomal o metabolismo de purinas/pirimidinas. 
Resumiendo, las concentraciones más altas, pero todavía por debajo de la concentración 
que se considera terapéutica, las bacterias responder de una manera completamente 
diferente para contrarrestar el efecto de la presión antibiótica. Suponemos así, que bajo 
0.25sub-CMIs, USA300 adapta su metabolismo a través de la regulación negativa de las 
principales vías metabólicas. Sin embargo, a dosis más altas y próximas a la CMI de los 
antibióticos, la bacteria parece redireccionar su metabolismo a través de la regulación del 
ciclo acido tricarboxílico, biosíntesis de ácidos grasos o de las vías del metabolismo de 
purinas/pirimidinas, para de este modo poder superar la presión antibiótica, es decir, se 
aumenta la respuesta al estrés.  
Figure 4. Estudio del "score de enriquecimiento" de las rutas metabólicas por DAVID software con 
una cobertura para las anotaciones del 45%. La regulación positiva (up), o negativa (down) de las rutas 
metabólicas se definió como la substracción entre (score-puntuación del enriquecimiento para cada 
condición de antibiótico – score -puntuación del enriquecimiento para el control). Las diferencias por 
encima de ± 1 fueron consideradas significativas. 
 
Como conclusión, nuestros resultados fueron consistentes con la literatura reciente, la 
cual sugiere que los cambios en el metabolismo energético, ciclo acido tricarboxílico y 
metabolismo de purinas/pirimidinas, son respuestas bacterianas comunes frente a la 
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presión antibiotica,244 al mismo tiempo que la respuesta al estrés y la formación de 
biopelículas se incrementan.267  
Análisis cuantitativo del perfil del proteoma de USA300 en respuesta a la concentración 
subinhibitoria de 0.5CMI: Previamente al análisis estadístico y comparativo, se 
comprobaron las correlaciones entre las réplicas biológicas. Estas correlaciones 
representadas como coeficiente de correlación Pearson R, fueron entre 0.8-0.99 para 
todos los extractos de las células (pellet), excepto para las tratados con tigeciclina. Sin 
embargo, para los sobrenadantes del cultivo, este coeficiente R fue mucho menor. Los 
bajos coeficientes de correlación R para tigeciclina podrían ser explicados por una mayor 
actividad de este antibiótico, y la mayor presencia de proteínas intracelulares en los 
sobrenadantes tratados con oxacilina podría ser debido a una extensiva lisis 
bacteriana.249(Datos no mostrados). 
Para este análisis comparativo de la respuesta específica a cada antibiótico, sólo se 
consideraron las proteínas expresadas diferencialmente en las condiciones de 0.5sub-
MICs. Para analizar estas proteínas expresadas diferencialmente, consideramos el diseño 
del experimento y las limitaciones de detección. Por lo tanto, las proteínas expresadas 
diferencialmente pero no identificados bajo alguna condición, antibióticos o control, y 
con unas intensidades normalizadas LFQ (N-LFQ) por debajo de 0.20 (equivalente a LFQ 
< 106), no fueron consideradas. Entre las proteínas expresadas diferencialmente en el 
control, 26, 205, 117 y 21 no fueron observadas con linezolid, tigeciclina, oxacilina y 
vancomicina, respectivamente. También se determinaron 19, 32, 39 y 17 proteínas 
expresadas diferencialmente con linezolid, tigeciclina, oxacilina y vancomicina, 
respectivamente, las cuales no fueron observadas en el control. El análisis estadístico, 
para las proteínas expresadas diferencialmente en ambas condiciones, antibióticos y 
control, reveló 4, 37, 24 y 3 proteínas estadísticamente significativas para linezolid, 
tigeciclina, oxacilina y vancomicina, respectivamente (Figura 3). Entre estas proteínas 
diferencialmente expresadas observamos, como era de esperar, proteínas asignadas por 
estar implicadas en, i) mecanismo de resistencia a, quinolonas (GyrA, GyrB, Parc ParE), 
vancomicina (RpoB, RpoC),252 β-lactámicos (BlaZ, FemA y PBP2`a/MecA) y 
aminoglucósidos (AphA(3')-III); ii) sistemas de regulación, p.ej., de resistencia antibiótica 
(MarR), virulencia, como el represor CodY cuya delección ha sido relacionado con un 
aumento de la virulencia de USA300,250 o ambos, como las proteasas-dependiente de 
ATP Clp asociadas a la resistencia a β-lactámicos y virulencia de USA300;263 iii) respuesta 
al estrés, como superóxido-dismutasa SodA/D; y iv) patogenia y virulencia, como 
inhibidores de la vía del complemente (Sbi, EfB, Chp),299 enterotoxinas (SEC), y las 
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principales toxinas características del hipervirulento SARM-AC, clon USA300: fenol-
soluble-modulinas (PSM-A4), Hla/Hly y PVL (LukF-PV y LukS-PV).300 Las proteínas con 
una mayor expresión diferencial en condiciones de antibióticos se recogen en la Tabla 1, 
y las proteínas expresadas diferencialmente en el control pero no observados con 
antibióticos se resumen en la Tabla 2. 
Figura 3. Volcano Plots. Volcano Plots donde se muestran las diferencias más significativas de las 
proteínas expresadas diferencialmente bajo 0.5MIC de, (a) linezolid, (b) tigeciclina, (c) oxacilina, y (d) 
vancomicina, con respeto al no tratado-control-USA300, relacionadas con el mecanismo de acción y 
patogénesis. 
p-valor estadístico < 0,05 (eje y), y `fold-change´ antibióticos versus control (eje x). La línea 
discontinua muestra donde p-valor = 0,05 expresados como log de t-test p-valor (log 10 p-valor) = 
1,30103. Puntos por encima de la línea se corresponden con p < 0,05 y por debajo de la línea se 
corresponden con p > 0,05. El      se corresponde con los puntos que tienen un `fold change´ más de 
2x (2 <x <0.5), expresado como el ratio, antibióticos / control, y de acuerdo a la diferencia de la prueba 
t [antibiótico - control]. El       se corresponde con los puntos que son estadísticamente significativos. 
Aph3'A: aminoglucósido 3'-fosftransferasa; Aur: zinc metaloproteinasa aureolisina; BlaZ: beta-lactamasa; 
ClpP: ATP-dependiente Clp proteasa subunidad proteolítica; Ffh: señal de reconocimiento de partículas; FtsZ:  
proteína de la división celular; HemG: protoporfirinógeno oxidasa; Hld: delta-haemolisina; Hly: alfa-
haemolisina; IsaB: antígeno inmunodominante B; RpsA: proteína ribosomal 30S S1; LukF-PV: Panton-Valentine 
leucocidina subunidad F; LukS-PV: Panton-Valentine leucocidina subunidad S; MecA: proteína de unión a 
penicilina 2a (PBP 2a); PheT: fenilalanina - ARNt ligasa subunidad beta; ProRS: Proline-tARN ligasa; PurD: 
fosforribosil-amina-glicina ligasa; Purl: fosforibosil-formil-glicin-amidina sintasa 2; RplC: proteína ribosomal 
50S L3; RplE: proteína ribosomal 50S L5; RpoB: ARN polimerasa DNA-dirigida subunidad beta; RpoC: ARN 
polimerasa DNA-dirigida subunidad beta; RpsE: proteína ribosomal 30S S5; RpsJ: proteína ribosomal 30S S10; 
SarA: regulador accesorio estafilocócica A; SdrE: serina-aspartato proteína E; Seq: enterotoxina Q; SodA: 
superóxido dismutasa A; SplC: serinproteasa C; SplE: serinproteasa E; SplF: serinproteasa F; Ssb: proteína de 
unión al ADN monocatenario; SspB: C47 estafopaína familia B; SspC: Familia I57 estafostatina B; TsaD: N6-
adenosina ARNt treonil-carbamoil-transferasa. 
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Tabla 1. Proteínas altamente expresadas sólo bajo 0.5MICs de cada antibiótico. LFQ intensidades 
normalizadas no transformadas por log2, representadas como la media entre las tres réplicas biológicas, 
y mayores de 0.75. 
(1) Putativa proteína exportadora. Membrana Citoplasmática. (Probabilidad = 0.955). Sólo identificada en 
sobrenadantes. 
(2) Putativa proteína de inmuniidad/bacteriocina. Sólo identificada en los sobrenadantes. 
 
 
 
 
 
Tabla 2.  Proteínas diferencialmente expresadas en el control sin ser observadas usando 0.5MICs de 
cada antibiótico. Proteínas asociadas con el mecanismo de acción de los antibióticos o implicadas en la 
patogénesis. LFQ intensidades normalizadas no transformadas por log2, representadas como la media 
entre las seis (control) o las tres (antibióticos) réplicas biológicas, y mayores de 0.20. 
Num 
Ids Protein Name 
ANTIBIOTIO 
Grupo 
Biológico 
Linezolid Tigeciclina Oxacilina Vancomicina 
0.5 µg/ml 0.25 µg/ml 16 µg/ml 1 µg/ml 
472 CHAP dominio-familia. Posible LysM dominio  1.45 0.38 
  
1 
527 
Proteína relacionada con la familia de 
chitinasas (EC 3.2.1.14) 
 
3.29 
  
1 
1164 
Ornitina carbamoiltransferasa (OTCasa) (EC 
2.1.3.3) ArcB ArgF 
 
1.83 
  
2 
123 Proteína fijadora de fibronectina B FnbB 
 
3.93 
  
6 
124 Proteína fijadora de fibronectina B FnbA 0.79 1.46 
  
6 
488 Factor de agregación A ClfA 
 
1.59 0.13 
 
6 
503 Enterotoxina K Sek  
 
0.91 0.72 
 
7 
741 
inhibidor  estafilococal del complemento 
(SCIN) Scn 
  
2.71 
 
7 
379 Estafilocoagulasa (EC 3.4.23.48) Coa 
 
0.85 
  
  
413 Proteína putativa de superficie 
 
6.80 
  
  
421 Fenol-soluble-modulina péptido alfa 1 PsmA1 
  
8.33 
 
  
604 
Proteína UPF0154 SAUSA300_1240, 
USA300HOU_1280 (1) 0.79 
  
0.85   
808 D-lactato dehidrogenasa (EC 1.1.1.28) Ddh  2.58 0.58 0.18 4 
919 Proteína fijadora de fosfato PstS  0.64 2.51 0.29  5 
303 Transferrina, receptor de hierro (Fe+3)  0.10 0.29 0.26  5 
1163 Factor de agragación B ClfB 1.20 3.50 0.43  6 
560 Proteína estafilococcal fijadora de 
transferrina, proteina A IsdA 
0.57 0.99 1.82  7 
1173 PXTG familia, proteína de anclaje de la pared 
celular SasF 
1.63 1.25 0.54   
743 Estafiloquinasa Sak 3.66 4.74 1.59   
1182 Proteína no caracterizada (2) 2.62 2.02 1.02   
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(1) Probablemente una proteína reguladora involucrada en el desarrollo de competencia y esporulación. [Replicación, 
recombinación y reparación, y mecanismo de traducción de señales] Citoplasmática  (Probabilidad = 0.75). 
(2) Putativa proteína de transporte o de superficie, o toxina con beta-dominio. La familia del beta-dominio ha sido 
relacionada con un amplio rango de proteínas de matriz extracelular truncadas análogas a MHC-II. 
Num 
id Nombre de la proteína Control 
ANTIBIÓTICO 
Grupo 
Biológico 
Linezolid Tigeciclina Oxacilina Vancomicina 
0.5 µg/ml 0.25 µg/ml 16 µg/ml 1 µg/ml 
1076 Serinproteasa SplC (EC 3.4.21.-) 20.33   0.16 1.29 15.40 2 
1078 Serinproteasa SplA (EC 3.4.21.-) 3.15 0.29   1.07 2.15 2 
1103 Regulador Factor Sigma B RsbU 0.17 0.27     0.35 2 
61 
Probable ARN polimerasa dirigida por ADN subunidad 
delta (RNAP factor delta) RpoE 0.33 0.33   0.30 0.25 3 
313 
Sistema UvrABC, proteína B (Proteína UvrB) 
(Excinucleasa ABC subunidad B) 0.22 0.23     0.30 3 
314 
Sistema UvrABC, proteína A (UvrA proteína) 
(Excinucleasa ABC subunidad A) 0.36 0.36     0.42 3 
796 
Regulador transcripcional SarR (Accesorio Staphylococcal 
regulador R) 0.92 0.97   1.25 0.79 3 
1000 ARN polimerasa Factor Sigma SigA RpoD 0.51 0.62   0.56 0.67 3 
1101 
Serin-proteína-quinase RsbW (EC 2.7.11.1) (Factor Anti-
sigma-B) ( efector negativo Sigma-B RsbW) 1.01 0.91   1.28 1.09 3 
1175 
Operón de adhesión intercelular (Ica operón), regulador 
transcripcional, TetR familia 0.13 0.09     0.11 3 
1195 Sensor-redox, represor transcripcional Rex 0.59 0.69   0.39 0.74 3 
873 Probable dual RNA metiltransferasa RlmN (EC 2.1.1.192)  1.71 1.48     1.30 3 
1267 Canal de larga-conductancia  mecano-sensible MscL 0.68 0.89   0.15 0.98 5 
520 
D-alanina—poli(fosforibitol) ligasa subunidad 2 (EC 
6.1.1.13) (proteína transportadora de D-alanil) DltC 0.35 0.31     0.55 6 
619 Factor de resistencia a meticilina FemB 0.31 0.31 0.25   0.77 6 
666 Proteína determinante de la forma celular MreC 0.12 0.15     0.14 6 
781 
Proteína de biosíntesis del interpéptido de pentaglicina 
FemB (EC 2.3.2.16)  
0.70 0.56 
 
0.64 0.86 6 
953 Proteína del ciclo celular GpsB (proteína Guiding PBP1-shuttling) 0.13 0.13     0.11 6 
1185 Proteína reguladora de beta-lactamasas (Fragmento) BlaR 0.28 1.73   0.43 0.40 6 
69 Proteína de stress general 20U (EC 1.16.3.1),  familia Dps  0.52 0.39   1.64 0.54 7 
145 Proteína de regulación transcripcional WalR 0.32 0.23   0.14 0.34 7 
363 I57 estafostatina B SspC 0.23     0.04 0.22 7 
629 Proteína  estafilocócica de respuesta respiratoria, SrrA 0.25 0.21   0.24 0.27 7 
887 Proteína  cromosómica de división Smc 0.23 0.22 0.19   0.19 7 
1088 Posible leucocidina, subunidad 0.37 0.34 0.78   0.63 7 
1397 Delta-haemolisina Hld 47.83 7.07   36.95 31.06 7 
14 
Proteína UPF0342 SAUSA300_1795. Proteína UPF0342 
USA300HOU_1838 (1) 1.17     0.87 0.63   
402 Proteína de virulencia EsaA 8.27 6.02   0.70 5.43   
509 Proteína Ear  1.26     1.19 3.05   
521 
D-alanina-activador enzima/D-alanina-D-alanil, proteína 
dltD. Transferidora de D-alanina DltD 0.48 0.41     0.52   
571 Proteína fijadora de fibrinógeno 0.34 1.27 0.68   0.36   
751 Proteína(2) no caracterizada 2.12 6.79   0.30 
 
  
865 Proteína fijadora de fibrinógeno FbpA 0.24 0.15   0.42 0.17   
1004 Endoribonucleasa YbeY (EC 3.1.-.-) 0.49 0.08     0.07   
1079 Proteína no caracterizada. Probable Beta-lactamasa 15.36 0.61   4.51 12.50   
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Linezolid y tigeciclina mostraron un efecto sobre la síntesis de proteínas, observado por 
el aumento estadísticamente significativo de la expresión de RplC (50S L3) (Figura 3a - 
b). Oxacilina mostró un efecto sobre la síntesis de la pared celular, ya que la expresión 
de FtsZ y su regulador negativo EzrA (Figura 3c) estaba disminuida, y proteínas como 
DltD o MurF (Tabla 2) no fueron observadas. 
Los inhibidores de la síntesis de proteínas, linezolid y tigeciclina, fueron mejores 
inhibidores de la expresión de proteínas implicadas en la virulencia, y los únicos 
antibióticos con efecto sobre las serinproteasas, toxinas y hemolisinas (Figura 3, Tabla 
2), las cuales desempeñan un importante papel en la patogénesis de S. aureus. 
Tigeciclina además disminuyó la expresión del principal factor de virulencia de S. aureus 
Hla/Hly y la controvertida toxina PVL255, por disminución de la expresión de la subunidad 
LukS-PV (Figura 3). Por el contrario, oxacilina aumentó significativamente la expresión 
del principal factor de virulencia de USA300, LukF-PV (PVL)291 (Figura 3c), y de forma 
inesperada, PsmA1, otro factor de virulencia implicado además en la formación de 
biopelículas (Tabla 1). Por lo tanto, hubo un incremento en la expresión diferencial de 
proteínas implicadas en la respuesta al estrés incluyendo la formación de biopelículas, la 
cual fue superior con tigeciclina y oxacilina, probablemente debido al aumento de la 
presión llevado a cabo por estos antibióticos (Tabla 1).  
Linezolid incrementó la expresión de MecA (Figure 3a) y PBP3, ambas proteínas están 
implicadas en la resistencia a todos los β-lactámicos, por lo que esto podría indicar que 
linezolid confiere una mayor resistencia a esta familia de antibióticos, al menos con esta 
sub-concentración. Oxacilina incrementó la expresión de RpoB256 (Figura 3c), por lo 
tanto la resistencia a glucopéptidos. Tigeciclina disminuyó la resistencia a los 
aminoglucósidos por la significativa menor expresión de AphA (3 ‘) III (Figura 3b). 
Perfil proteómico de USA300 bajo cada concentración subinhibitorias:  
Linezolid: El efecto de linezolid fue dosis-dependiente, probablemente en relación a las 
condiciones de estrés y densidad celular que actuaron de manera diferente a través de 
proteínas reguladoras como AgrC (agr-locus). La 0.25sub-CMI fue pobremente eficaz, sin 
embargo cuando se utilizó la 0.5sub-CMI la síntesis de proteínas fue inhibida, y la 
expresión de los principales factores de virulencia como PVL y Hla255 fue menor, respecto 
al control y 0.25sub-CMI. La 0.5sub-CMI disminuyó la expresión de otros factores de 
virulencia implicados en la patogénesis, como enterotoxinas, serinproteasas y 
hemolisinas. 
Tigeciclina: Ambas sub-concentraciones de tigeciclina mostraron ser efectivas, e inhibir 
la síntesis de proteínas. La fuerte reducción del proteoma de USA300 afectó 
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principalmente a proteínas ribosomales o sistemas reguladores como AgrA/C, entre 
otros. Como consecuencia, los principales factores de virulencia implicados en la 
patogénesis de USA300, Hla y PVL,255 estaban menos expresados. Además, consideramos 
que tigeciclina podría tener un efecto bactericida246 debido a, i) la disminución en 2 log10 
del recuento de colonias (UFC/ml), ii) la menor expresión de proteínas implicadas en la 
biosíntesis de la pared celular y homeostasis, iii) la mayor expresión de proteínas 
implicadas en la formación de biopelículas, lo que ayuda a la bacteria a escapar de la 
muerte inducida por antibióticos,260 y iv) la menor expresión de sistemas de regulación 
como WalK/R-TCS, o vi) la menor expresión de sistemas de reparación del ADN (sistema 
UvrA/B SOS). 
Oxacilina: Ambas sub-concentraciones provocaron una lisis de la pared celular, lo que 
fue interpretado como sub-concentraciones efectivas frente a USA300. Este efecto fue 
dosis-dependiente. El efecto de 0.5sub-CMI fue superior, incluyendo el aumento 
significativo de la expresión de PVL291 y PSMs, principales factores de virulencia de 
USA300. Sin embargo, no hubo un aumento en la resistencia a β-lactámicos. Esto no 
quiere decir que no pueda existir una adaptación y selección de alto nivel o resistencia 
homotípica (HoR-SARM),261,262 lo que significaría una total no efectividad de la oxacilina, 
puesto que si hubo una mayor actividad del ciclo tricorbaxílico o producción de acetil-
CoA,261,262 ambos hechos vinculados con la supervivencia en presencia de antibióticos β-
lactámicos.261,262 
Vancomicina: Las sub-CIMs de vancomicina fueron poco efectivas. La diana terapéutica 
de la vancomicina mostró pocos cambios, y sólo la dosis más alta de 0.5sub-CMI, mostró 
algún efecto sobre la división celular, aumentando la expresión de SepF. Las sub-CMI de 
vancomicina no tuvieron efecto en los factores de virulencia, ni sobre la respuesta al 
estrés. 
Conclusión  
S. aureus tiene una notable habilidad para adaptarse a diferentes condiciones, ambientes, 
hospedadores, medios de cultivo, etc., con la finalidad de mejorar su capacidad de 
supervivencia. Esta adaptación se realiza mediante la alteración o redireccionamiento de 
su metabolismo central, de acuerdo a las condiciones del medio e incluso fase de 
crecimiento. Esta adaptación es controlada y dirigida por sistemas regulatorios de dos 
componentes, como el "quórum sensing", o también mediante la carga de la superficie 
bacteriana. Todo ello contribuye a esa respuesta de supervivencia frente al estres 
oxidativo y presión antibiótica. Nuestras observaciones, al igual que otros estudios 
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recientes, apoyarían que las proteínas Clp puedan contribuir a esta adaptación a la 
presión antibiótica. El mejor conocimiento de esta interesante maquinaria proteolítica 
haría un mejor entendimiento sobre la patogenicidad de USA300 y mejoraría el 
tratamiento de las infecciones estafilocócicas.  
Esta respuesta a la presión antibiótica se caracterizó por una mayor expresión de 
proteínas involucradas en la formación de biopelículas, especialmente con tigeciclina y 
oxacilina. Las sub-concentraciones más altas (0.5sub-MICs) fueron más efectivas, pero 
sólo los inhibidores de la síntesis proteica, linezolid y tigeciclina inhibieron la virulencia. 
Linezolid fue efectivo, en una manera dosis-dependiente, contra al clon USA300, y 
aunque tuvo pocos efectos sobre los principales factores de virulencia, PVL o Hla/Hly, 
inhibió otros factores de virulencia implicados en la patogénesis, especialmente la 
0.5sub-CMI la cual podría ser eficaz en infecciones sistémicas. La tigeciclina fue efectiva 
utilizando ambas concentraciones subinhibitorias, y los principales factores de virulencia 
implicados en la patogénesis, Hla y PVL, estuvieron menos expresados, así como la 
resistencia a aminoglucósidos. Las sub-CIMs de oxacilina fueron efectivas contra USA300 
en una forma dosis-dependiente, sin embargo, la mayor expresión de los principales 
factores de virulencia implicados en la patogénesis, como PSM y Luk-F (PVL), más que la 
posible selección de subpoblaciones homo-resistentes, desaconsejaría su uso clínico. La 
vancomicina no tuvo efecto sobre los factores de virulencia y en general fue menos 
efectiva. Este estudio principalmente proporciona un mejor conocimiento de la respuesta 
celular de USA300 a diferentes sub-concentraciones de antibióticos de uso clínico. 
 
Abreviaturas: 
-AC: Adquirido en la Comunidad 
CMI: Concentración Mínima Inhibitoria 
ES /MS Espectrofotometría de Masas 
Hla / Hly: α-haemolisina 
LFQ: "Label Free Quantification": Cuantificación sin marcaje 
N- : Normalizado 
PBP: Proteínas Fijadoras de Penicilina 
PBS: Buffer de Fosfato Salino 
PVL: Panton Valentine Leucocidina 
SARM: Staphylococcus aureus Resistente a Meticilina 
SDS: Sodio-Dodecil-Sulfato 
TCS: "Two-Component regulatory System": Sistemas regulatorios de dos componentes 
TSB: Tripticase Soja caldo de cultivo 
UFC: Unidades Formadoras de Colonia 
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«Lo peor no es cometer un error, sino tratar de justificarlo, en vez de 
aprovecharlo como aviso providencial de nuestra ligereza o ignorancia" 
«Se ha dicho hartas veces que el problema de España es un problema 
de cultura. Urge, en efecto, si queremos incorporarnos a los pueblos 
civilizados, cultivar intensamente los yermos de nuestra tierra y de 
nuestro cerebro, salvando para la prosperidad y enaltecimiento patrios, todos 
los ríos que se pierden en el mar y todos los talentos que se pierden en 
la ignorancia». 
«Me reservo el derecho a pensar de acuerdo con mis ideas actuales». 
 
 
"The worst is not making a mistake, is to try justifying it, rather than use it as 
providential notice of our levity or ignorance" 
"It has been said a lot of time that the problem of Spain is a cultural problem. 
Urge, indeed, if we incorporate us to civilized peoples, cultivate intensively the 
wilderness of our land and of our brain, saving for prosperity and patriotic 
exaltation, all rivers are lost at sea and all the talents that are lost in the 
ignorance. " 
"I reserve the right to think according to my current ideas." 
 
 
Santiago Ramón y Cajal 
Nobel Prize of Medicine 1906 
 

  
 
